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Abstract 
In Bihar state, India, the cure rate of antimonial compounds in the treatment of visceral 
leishmaniasis (VL) has declined from over 85% to less than 50%.  This has been 
attributed to prolonged, widespread misuse of antimonials within the Indian private 
healthcare system.  An alternative resistance hypothesis is that exposure to arsenic in 
drinking water in this region has resulted in antimony-resistant Leishmania parasites.  
Leishmania donovani were serially passaged in mice exposed to 
environmentally-relevant levels of arsenic in drinking water.  Arsenic accumulation in 
organs of these mice was proportional to exposure.  After five passages, isolated 
parasites were refractory to SbV in drug sensitivity assays.  Treatment of infected mice 
with SbV confirmed that these parasites retained resistance in vivo, supporting this 
hypothesis. 
A retrospective field study on a cohort of antimony treated VL patients was 
performed in an arsenic contaminated area of Bihar to evaluate the presence of an 
increased risk of treatment failure and death in those exposed to arsenic.  It 
demonstrated a significant increased risk of death from VL in arsenic exposed patients 
but did not indicate a significant relationship between arsenic exposure and antimonial 
treatment failure. 
Collectively these data suggest that it is biochemically possible that arsenic 
contamination may have contributed to the development of antimonial resistance in 
Bihar although issues of underpower and the retrospective nature of our epidemiological 
study made it difficult to conclusively demonstrate this.  Further research in to the 
relationships between arsenic exposure and antimonial treatment failure and death in the 
leishmaniases is warranted. 
1 
 
 
  
Chapter 1- 
Introduction 
2 
 
1.1 Leishmania  
1.1.1 Kinetoplastids 
The order Kinetoplastidia contains eukaryotic parasites that include important human 
pathogens within the Leishmania and Trypanosoma species (Stuart et al., 2008). They are 
uni-flagellated protozoa which are characterised by the presence of mitochondrial DNA 
contained in a unique organelle called the kinetoplast, located near the base of the 
flagellum.  The species Leishmania, Trypanosoma cruzi and Trypanosoma brucei, although 
sharing many similar cellular biology features, cause the distinctly different diseases of the 
leishmaniases (Section 1.1.2), Chagas disease and human African trypanosomiasis (HAT, 
also called African sleeping sickness), respectively.  They all rely on invertebrate 
transmission between human (and in some regions mammalian hosts) in the form of the 
sand fly, tsetse fly and triatomine bug. The diseases affect the poorest of the poor (Boelaert 
et al., 2009) and are associated with poor housing and population displacement.  
The leishmaniases, HAT and Chagas Disease are part of a group of 17 ‘Neglected 
Tropical Diseases’ (NTD), classified by the World Health Organisation (WHO),  that pose 
a significant barrier to socioeconomic development and poverty reduction in low income 
countries. NTDs are endemic in 149 countries and affect more than 1 billion people 
worldwide. In 2012, the kinetoplastid diseases were highlighted in the WHO 
Implementation Road Map1 for intensified disease management intervention as they lack 
simple tools for control and current treatments have unacceptable toxicity profiles as well 
as many regional issues with efficacy. The most dramatic example of this is the necessity 
for continued use of the arsenical based drug melarsoprol, for the treatment of the 
neurological phase of HAT caused by T.rhodesiense, which causes a reactive arsenic 
                                                          
1 http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf 
     
Leishmania 
(L.) Species 
Disease in 
Humans 
Transmission Mammalian 
host 
Vector Geography 
L. major Old world 
CL (oriental 
sore) 
Rural zoonotic Gerbil, sand 
rat 
P.papatasi, 
P.dubosqi, 
P.salehi 
Central and 
West Asia, 
North Africa, 
Sahel of 
Africa, Central 
and West 
Africa 
L. tropica Old world 
CL (oriental 
sore) 
Urban 
anthroponotic 
Humans, rock 
hyraxes 
P. sergenti Central and 
West Asia, 
North Africa 
L. aethiopica Old world 
diffuse CL 
Rural zoonotic Rock hyraxes P. longipes, P. 
pedifer 
Ethiopia, 
Kenya 
L. donovani VL Epidemic 
anthroponotic 
Humans P. argentipes, 
P. orientalis, 
P. martini 
Indian 
subcontinent, 
East Africa 
L. infantum VL 
(infantile) 
Zoonotic, 
peridomestic 
Domestic dog P. ariasi, P. 
perniciosus 
Mediterranean 
basin, Central 
and West Asia 
L. infantum 
(syn Chagasi) 
VL 
(infantile) 
Zoonotic, 
peridomestic 
Domestic dog Lutzomyia 
longipalpis 
Central and 
South America 
L. Mexicana New world 
CL 
(chiclero’s 
ulcer) 
Sylvatic 
zoonotic 
Forest rodents Lutzomyia 
olmeca olmeca 
Central 
America 
L. 
amazonenesis 
New world 
CL 
Sylvatic 
zoonotic 
Forest rodents Lutzomyia 
flaviscutellata 
South America 
L. (Viannia) 
braziliensis  
New world 
CL and MCL 
(espundia) 
Sylvatic 
zoonotic 
Forest rodents Lutzomyia 
wellcomei. 
Lutzomyia 
complexua, 
Lutzomyia 
carrerai 
Central and 
south america 
L. (Viannia) 
peruviana  
New world 
CL (uta) 
Upland 
zoonotic 
Upland 
zoonotic 
Lutzomyia 
peruensis, 
Lutzomyia 
verrucarum 
Peru 
L. (Viannia) 
guyanensis 
New world 
CL, 
metastatic 
(pian-bois) 
Sylvatic 
zoonotic 
Sloth, anteater Lutzomyia 
umbratilis 
South America 
L. (Viannia) 
panamensis 
New world 
CL 
Sylvatic 
zoonotic 
Sloth Lutzomyia 
trapidoi 
Central 
America 
   
Table 1.1 Leishmania species and their sand fly vectors 
Each sand fly tends to transmit one strain of parasite and each parasite tends to lead 
to one disease phenotype. L. = Leishmania P. =Phlebotomus. Adapted from (Bates et 
al., 2007; Lukes et al., 2007).  
A 
C 
B 
D 
Figure 1.1 Human diseases caused by the Leishmania parasite 
Panel A shows the raised pearly edge lesion of cutaneous leishmaniasis (source 
CDC) Panel B depicts destruction of the nasal septum from mucocutaneous 
leishmaniasis (source CDC) Panel C shows profound weight loss and the massive 
hepatosplenomegaly found in advaced visceral leishmanaisis (source WHO ) Panel 
D depicts diffuse depigmented macules of Post Kala Azar Dermal Leishmaniasis 
(Source: author’s own) 
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encephalopathy in up to 10 % of patients that is often fatal (Pépin et al., 1995) (Kennedy, 
2013).  The Implementation Road Map has optimistic goals for 2020 of success in regional 
elimination programmes for the Leishmaniases and Chagas disease and global elimination 
of HAT.  There remain many issues to be overcome for this to be achieved. 
1.1.2 Leishmania epidemiology 
There are 30 species of Leishmania that infect mammals and 21 of these cause human 
disease (Herwaldt, 1999) collectively named the leishmaniases.  Features of the most 
important species with their disease phenotype and vector are summarised in Table 1.1 
(Bates, 2007).  These diseases are cumulatively thought to be responsible for the ninth 
largest infectious disease burden worldwide and together account for the loss of 2.1 million 
Disability Adjusted Life Years (DALYs2) (Stuart et al., 2008). The human diseases caused 
are cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL) and visceral 
leishmaniasis (VL, also called kala azar).  Cutaneous leishmaniasis is a skin sore, caused by 
a range of Leishmania species (Table 1.1), which occurs, either at the site of the bite of the 
sand fly or following metastasis to a distant cutaneous location, and can take the form of a 
papule but more classically is an ulcer with a raised edge (Figure 1.1, panel A) (Chappuis et 
al., 2007). CL lesions often regress spontaneously without treatment but in endemic 
countries CL is a major cause of morbidity and permanent scarring (Llanos-Cuentas et al., 
2008).  Infection with the species L.braziliensis can lead to the dreaded complication of the 
development of mucocutaneous lesions where the parasite spreads to mucosal surfaces of 
the upper airways and can cause dramatic facial disfigurement (Figure 1.1, panel 
B)(Chappuis et al., 2007).  
                                                          
2 Each disease is given a disability weight.  A DALY is calculated from the sum of the years of life lost and 
years lived with disability (Arnesen and Nord, 1999). 
 
Figure 1.2  Status of endemicity of cutaneous leishmaniasis, worldwide, 2012. 
Source: WHO 
Figure 1.3  Status of endemicity of visceral leishmaniasis, worldwide, 2012. 
Source: WHO 
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Figure 1.4  Estimates of incidence of visceral leishmaniasis India 
Incidence is calculated using input from national and international experts, 
underreporting rates and disease figures reported to the government.  Source: 
(Alvar et al., 2012) 
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Visceral leishmaniasis is a progressive systemic illness caused by the species 
L.infantum and L.donovani (Section 1.1.3) (Figure 1.1, panel C) which is fatal without 
treatment. The sequelae, in a proportion of treated patients is the diffuse skin condition post 
kala azar dermal leishmaniasis (PKDL) (Figure 1.1, panel D) (Chappuis et al., 2007).  This 
study focusses mainly on visceral leishmaniasis. 
There are serious issues relating to underreporting of the leishmaniases in certain 
regions (Mondal et al., 2009) but their global incidence was recently estimated at 0.7 to 1.2 
million per annum for CL (including MCL) and 0.2 to 0.4 million per annum for VL (Alvar 
et al., 2012).  Approximately three quarters of CL cases are found in Afghanistan, Algeria, 
Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, Costa Rica and Peru (Figure 1.2). 
Ninety percent of mucocutaneous leishmaniasis cases occur in Bolivia, Brazil and Peru3. 
The annual reported mortality rate for VL is estimated to be 10% with between 20 and 
40,000 deaths per year (Alvar et al., 2012). Ninety percent of VL cases are in 6 countries 
India, Bangladesh, Sudan, South Sudan, Ethiopia and Brazil (Figure 1.3). In India, the area 
on which this study is focussed, the VL incidence is estimated to be up to 282,800 cases per 
annum (Figure 1.4) (Alvar et al., 2012). The level of under-reporting can be up to a factor 
of 4.17 (Singh et al., 2010) (Figure 1.4). 
1.1.3 Leishmania history 
 
The Leishmania parasite is thought to be descended from a protist parasite 
Shuiyousphaeridium spp. that has a fossil record from 1600 million years ago (Mya)(Tuon 
et al., 2008). Kinetoplastidia lack a fossil record dating this far but fossil records of their 
close relatives the euglenids suggest their appearance around 450 Mya with a probable 
primitive water dwelling animal as host.  Flying insects appeared at 300 Mya and the 
                                                          
3 www.who.int/leishmaniasis/en/ 
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relationship between mammal and invertebrate development implies that leishmaniasis was 
established at 50 Mya. The worldwide dissemination of Leishmania likely followed vectors 
and hosts together as sand flies cannot migrate large distances.  The genus most likely 
originated in South America 46 -36 Mya from where it migrated to Asia and then on to 
Africa, India and Europe as indicated by DNA sequencing showing a divergence of the 
visceral strains L.donovani and L.infantum at ~1 Mya, with further divergence of 
infraspecific genetic groups between 0.4 and 0.8 Mya (Lukes et al., 2007). The L. donovani 
complex possibly migrated both ways between East Africa and Asia probably via 
immigration or slaves.  L.infantum, completed the circle 500 years ago through migration 
from Europe, back to South America by European settlers (Singh and Roy, 2009). 
L.chagasi is now synonymous with L.infantum. 
Although there are historical records of CL dating back to 650 BC, when old world 
CL was described on tablets of King Ashurbanipal of Assyria, there were no descriptions of 
VL until 1824 AD from Jessore, Bengal.  The disease, which was named kala azar – Hindi 
for ‘black disease/fever’, spread rapidly by road and rail and had a devastatingly high 
mortality of 30 % within affected populations (Singh and Roy, 2009).  It was initially 
presumed to be a form of quinine-resistant malaria. The identification of the causative 
parasite did not occur until almost simultaneously discovered in the spleen of patients who 
been resident in West Bengal, by William Leishman and Charles Donovan.  It was correctly 
identified as being closely related to the trypanosomes and the given the name Leishmania 
donovani (Ross, 1903).  
1.1.3 Leishmania biology and life cycle 
The life cycle of the Leishmania species is depicted in Figure 1.5. The parasite is 
transmitted, in promastigote form through the bite of an infected sand fly and ingested at 
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the site by rapidly recruited neutrophils.  Infected neutrophils undergo apoptosis and release 
the parasites prior to ingestion by the macrophage. The promastigote differentiates into 
amastigote form in the phagolysosome of the macrophage and the amastigote multiplies by 
binary fission. Further macrophages are infected directly by amastigotes released from lysis 
of heavily infected macrophages (Murray et al., 2005). When a sand fly takes a blood meal 
from an infected host, infected macrophages are taken up and lysed in the sand fly gut.  
Here, the amastigotes differentiate into promastigotes which further differentiate in the 
chitinous foregut into non proliferative metacyclic forms and migrate to the proboscis.  
Infected sand flies are thought to have a ‘blocked’ gut which promotes them to probe the 
skin more frequently and more persistently particularly when metacyclic forms are present, 
thus enhancing transmission of the highly motile metacyclic forms to the mammalian host 
(Rogers and Bates, 2007).  Approximately 1000 promastigotes are transmitted in a bite 
within a proteophosphoglycan (PPG) plug which promotes pathogenicity and increased 
parasite burden within the host (Rogers et al., 2004). 
Table 1.1 summarises the hosts Leishmania inhabit which act as reservoirs for 
transmission from the sand fly to humans in these regions.  The Leishmania parasite can 
also be vertically transmitted from mother to child and parenterally through blood 
transfusion, needle sharing and laboratory accidents (Herwaldt, 1999).  These are 
uncommon modes of transmission. 
1.1.3.1 Leishmania genome 
The first full Leishmania genome to be assembled was that of the CL-causing species 
Leishmania major in 2005 (Ivens et al., 2005). It is a 32.8 megabase haploid genome with 
36 chromosomes. Later comparison between L.major and L.infantum genomes indicated 
that gene deletion and pseudogene formation accounted for the main differences. These 
Figure 1.6  Factors influencing infection and clinical course in visceral 
leishmaniasis 
Proximity to cattle and other VL (kala-azar) cases increases risk of infection 
which can be mediated by use of bednets and good quality housing. Cell 
mediated immunity is thought to be the most influential in progression to 
clinical VL. Figure from (Bern et al., 2010)  
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included key genes involved in host pathogen interactions and intra-macrophage survival 
(Peacock et al., 2007).  The availability of the genome has been, and will continue to be 
valuable, for many insights into biology and pathogenesis (Stuart et al., 2008). 
1.1.4 Visceral leishmaniasis clinical features  
The clinical features of Leishmania infection are related to both parasite and host factors. 
Only 1 in every 5-10 infections with L.donovani and L.infantum develop into clinical VL 
disease.  The reasons behind development of clinical infection are not fully understood but 
risk factors identified include age, ethnic origin, sand fly exposure levels, proximity to a 
previous case, poverty, housing conditions, low red meat intake and low zinc and retinol 
levels (Bern et al., 2010; Bern et al., 2007; Bucheton et al., 2002) (Figure 1.6). The 
observation of familial clustering and high sibling relativity point towards genetic factors 
behind the development of infection.  In Sudan, strong correlations have been identified 
between SLC11A1 (formerly NRAMP1 (natural resistance associated macrophage protein)) 
and susceptibility (Mohamed et al., 2004).  There was no correlation between this protein 
and susceptibility found in recent work from the Leishmania genetics consortium in India. 
It identified a strong correlation with polymorphisms in the HLA-DRB1-HLA-DQA1 HLA 
class II region (Fakiola et al., 2013). Innate immunity and T cell responsiveness is also 
thought to be integral to response to infection (Murray et al., 2005). 
In clinical visceral leishmaniasis the incubation period is weeks to months following 
which patients can follow an acute or chronic course with classic symptoms of fever, 
malaise, anorexia and eventual cachexia.  In India this is accompanied in a proportion of 
cases with skin darkening which gave the condition its name of “kala azar” which means 
“black fever” in Hindi.  Patients display signs of hepatosplenomegaly due to a combination 
of inflammation and a heavy burden of parasitised macrophages. In Africa this is 
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accompanied by pronounced lymph node enlargement, a clinical sign almost absent in 
Indian VL. Laboratory markers are of pancytopenia (anaemia, thrombocytopenia and 
leucopenia with a relative lymphocytosis and monocytosis) a hypergammaglobulinaemia 
and hypoalbuminaemia.  Death is usually from bacterial co-infection due to gradual 
disabling of the immune system with progressive infection (Herwaldt, 1999).  
Relapse of the signs and symptoms of VL can occur, most commonly in the 6 
months following treatment, but in some cases more than 10 years post initial infection 
(unpublished data and personal communication Shyam Sundar).  There is a debate whether 
these late relapses are reinfection or recrudescence but parasites can persist intra-cellularly 
post successful treatment and a VL infection should confer lifelong immunity so reinfection 
is less likely (Murray et al., 2005). 
A proportion of treated cases, 50% in Sudan (Zijlstra et al., 1995) and 10-15% in 
India (Desjeux et al., 2013), go on to develop PKDL (Figure 1.1, Panel D), characterised by 
highly parasitized skin lesions on sun exposed areas. This happens within months in Africa 
but on average not for 1-2 years in India.  Although the lesions are non-painful macular, 
papular or nodular lesions that can spontaneously regress, treatment is advised as PKDL is 
an important reservoir for VL transmission. 
1.1.5 Leishmania immunology 
The interplay between Leishmania and the host immune system is essential for parasite 
survival. The host defences mounted against the leishmania parasite are responsible for 
many of the clinical symptoms and the manipulations of the immune system by the parasite 
are responsible for the immunosuppression and susceptibility to co-infections (Murray et 
al., 2005).  Metacyclic promastigotes evade complement(C)-mediated lysis by changing 
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their cell surface membrane’s lipophosphoglycan (LPG) which prevents the insertion of the 
membrane attack complex (MAC) together with the enhanced synthesis of gp63 which 
inactivates C3b to iC3b.  The presence of iC3b stimulates phagocytosis by macrophages – 
the leishmania cell of choice (Späth et al., 2003). 
Within the macrophage the phagosome fusion with the lysosome is transiently 
delayed by the surface LPG to allow for differentiation from promastigote to amastigote.  
The resulting parasitophorus vacuole has an acidic pH of 5.5 and hydrolytic activity which 
are thought to be survived by the parasite through further cell surface changes (Sacks and 
Sher, 2002).  In an immunocompetent host the triggering of the T cell helper 1 (Th) system 
is responsible for activating the macrophage into a cytocidal state to produce reactive 
nitrogen and oxygen species.  However, the intra- macrophage amastigote arrests the 
JAK/STAT signal pathway by action on SHP1 thus actively inhibiting the production of 
interleukin-12 (IL-12) which stimulates the production of interferon–γ (IFN–γ) and the Th1 
response (McDowell and Sacks, 1999).  In addition to affecting dendritic cell function, 
which is vital for antigen presentation, Leishmania encourage the immunosuppressive Th2 
response, including IL-4, IL-10, IL-13 and Transforming growth factor-β, which dampens 
the Th1 response and deactivates macrophages.  Although a balance favouring a Th2 
response is strongly evident in experimental infections the relationship is less clear cut in 
human VL (Murray et al., 2005). However, even in the presence of T cell dependent 
immune responses producing self-healing or asymptomatic infection, intracellular infection 
is thought to be life-long as residual parasites persist in macrophages.  The importance of a 
T-cell response has been well documented experimentally (Sacks and Anderson, 2004) and 
is clinically demonstrated by the poor prognosis of VL patients co-infected with human 
immunodeficiency virus (HIV) which targets CD4+ T cells (Cota et al., 2013). 
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1.1.6 Leishmania diagnosis and screening 
The gold standard for Leishmania diagnosis is demonstration of Leishman-Donovan (LD) 
bodies following microscopic examination of Giemsa-stained splenic aspirates.  This 
method has an excellent specificity and sensitivity ranges from 93.1-98.7%.  Unfortunately, 
it is invasive and technically challenging and without appropriate precautions can carry the 
risk of fatal haemorrhage (Sundar and Rai, 2002). Bone marrow biopsy can also diagnose 
VL through visualisation of LD bodies but its sensitivity is low: between 52 -85% 
(Srivastava et al., 2011a). 
A serological test, rK39, against a recombinant antigen of a 39 amino acid repeat in 
L.chagasi was initially shown to be effective for diagnosis in an enzyme linked 
immunosorbent assay (ELISA).  Since then many different commercial dipsticks have 
become available. A meta- analysis of sensitivity and specificity in South Asia is 97.1% 
and 95.3%, respectively (Chappuis et al., 2006).  However, for unknown reasons, in East 
Africa, the sensitivity and specificity of rK39 are considerably lower at 79.0% and 85.2%, 
respectively.  The rK39 is the recommended test for diagnosis on the Indian subcontinent. 
The direct agglutination test is a semi quantitative test where dilutions of the 
patient’s blood or serum are mixed with fixed, stained promastigotes in a v-shaped well 
micro plate.  Agglutination is visible to the naked eye if antibodies to the parasite are 
present. This test also has a higher sensitivity and specificity in South Asia versus East 
Africa but its performance is better than the rK39 in Africa with sensitivity and specificity 
of 93.2% and 96.1% respectively. The direct agglutination test is in routine use in Sudan 
(Chappuis et al., 2006).  
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Other techniques such as ELISA, immunoblotting and immunofluorescence 
antibody test (IFAT) are expensive and time consuming and not for routine use in the field. 
The use of urinary antigens as a minimally invasive form of diagnosis shows promise. The 
use of PCR is a growing field in Leishmania diagnostics and field work and has been 
particularly useful in species identification.  The techniques mainly use primers which 
target multicopy genes such as rRNA and kinteoplastid DNA, however as yet no techniques 
are in routine use in the field for VL (Srivastava et al., 2011a). 
The prevalence of sub-clinical infection within endemic communities presents a 
diagnostic challenge.  Studies of most diagnostic tests show higher specificities when the 
control group are healthy rather than a controls living in an area endemic for VL (Chappuis 
et al., 2006).  Interestingly though, a longitudinal study in Bihar and Nepal showed that 
seropositivity and/or rK39 at high titres was associated with an increased risk of developing 
clinical VL (Hasker et al., 2014) and that seroconversion to negative serology does occur 
despite the fact that infection with VL is thought to be permanent (Hasker et al., 2013). 
The toxicity of anti-leishmanial treatments (Section 1.1.7) means that accurate 
diagnosis is essential.  The Foundation for Innovative Diagnostics (FIND) brings together 
professionals from all fields to try and accelerate the development of new diagnostics.  It is 
currently leading work evaluating the PCR technique Loop mediated isothermal 
amplification (LAMP) and is looking at ELISA assays to establish a serological test as a 
test of cure at the end of treatment4. 
                                                          
4 http://www.finddiagnostics.org/programs/hat-ond/leishmaniasis/ 
Figure 1.7 Chemical structures of current anti-leishmanial therapies 
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1.1.7 VL treatment overview 
The chemotherapeutic arsenal against VL is currently limited to four main drugs: 
pentavalent antimonials, amphotericin B compounds, miltefosine and paromomycin (Croft, 
2008; den Boer et al., 2009)(Table 1.2) and (Figure 1.7).  There are significant issues with 
each drug for use in low income countries including efficacy, toxicity, cost and storage. 
Antimonial based compounds are the main subject of this study and will be discussed in 
detail in Section 1.2. 
1.1.7.1 Amphotericin 
Amphotericin B was originally isolated from Streptomyces nodosus and has been used 
since the mid-20th century against fungal infections.   Its mechanism of action is through 
binding to membranous ergosterol, thus forming membranous pores, which allows for loss 
of vital intracellular constituents.  This mechanism unfortunately also leads to marked renal 
and ototoxicity (Ng et al., 2003). In the 1980s researchers were able to capitalise on the 
discovery of liposomes (New et al., 1981) for drug delivery and liposomal amphotericin 
compounds (L-AMB) were developed with a more favourable toxicity profile. 
Amphotericin B deoxycholate was first found to be effective against VL in 1963 but was 
only shown to be an effective first line treatment in South Asia in the 1990s (Mishra et al., 
1994).  Subsequently, differing regimes with L-AMB have shown excellent results in Asia 
with initial cure rates exceeding 95% (Burza et al., 2014a; Sundar et al., 2010).  Although 
L-AMB has a lower efficacy in the VL endemic African countries (91% initial cure rate) 
(Salih et al., 2014), it has an important place in treating vulnerable groups e.g. in pregnancy 
or HIV co-infection (Balasegaram et al., 2012). 
The 6-month cure rate of 96% for single dose liposomal amphotericin (Sundar et 
al., 2010) is particularly attractive for practical and compliance reasons and negotiations are 
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underway for this to be the primary drug in the VL elimination programme (Section 
1.1.8.5).  The main fear of this single dose regime is resistance development.  However, 
although amphotericin resistant parasite strains have been easily selected in vitro in 
promastigotes, (Mbongo et al., 1998) only one case report of amphotericin resistance in a 
clinical isolate (Srivastava et al., 2011b) has been published.   Reassuringly, assessment of 
sensitivity to AMB in successive clinical isolates from an HIV co-infected patient 
following repeated AMB administration showed no change in drug sensitivity (Durand et 
al., 1998).  The efficacy of L-AMB in Africa is lower and it is not recommended as a first 
line treatment (World Health Organization, 2010). 
The cost of L-AMB, as well the need to keep it in a cold chain, is an impediment to 
its widespread use.  However, through preferential pricing organised by the WHO, there 
has recently been a promise from Gilead to provide L-AMB at $18 per vial – more than ten 
times less than the cost of private purchase (World Health Organization, 2010). 
1.1.7.2 Miltefosine 
Although the establishment in 2002 of the alkylphospholipid miltefosine as the first oral 
drug for VL was greeted with great excitement (Sundar et al., 2002), a decade later its cure 
rate at 6 months had fallen from 94% to 90% (Sundar et al., 2012) with 10% more late 
relapses (>6 months) also reported (Rai et al., 2013a).  Miltefosine, originally developed as 
an anti-cancer drug, is thought to inhibit vital cell signalling pathways and is metabolised 
by the phospholipid pathways (Dorlo et al., 2012).  It has a half-life of approximately 7 d, 
giving it high resistance potential.  Interestingly though, minimal correlation has been seen 
between miltefosine treatment failure and parasite susceptibility in current in vitro assays 
(Rai et al., 2013a) leading to speculation about the mechanism of treatment failure. In a 
recent trial, greater than half of patients reported significant gastro-intestinal side effects 
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which is a major issue for compliance in unsupervised treatment regimens (Sundar et al., 
2012). Its teratogenicity is also a major issue. Although initially part of the VL elimination 
programme, in the WHO 2010 report (World Health Organization, 2010), these above 
developments meant that miltefosine was not recommended as a first line treatment in any 
region. 
1.1.7.3 Paromomycin 
Paromomycin is an aminoglycoside antibiotic which inhibits protein synthesis by directly 
binding to ribosomal RNA (Fernandez et al., 2011). It is effective against VL and CL as 
well as having toxicity against other protozoans: amoeba and cryptosporidia. It is very 
attractively priced and an efficacy of 94% as monotherapy and non-inferiority to AMB has 
been demonstrated in India (Sundar et al., 2007).  However, paromomycin is only 
recommended for use in combination therapy due to fears of resistance development 
(Hendrickx et al., 2012) and poor efficacy as a monotherapy in East Africa (<85% 
cure)(World Health Organization, 2010). 
1.1.7.4 Combination therapy 
Different combinations of the above drugs have been trialled in both India and Africa with 
a view to shortening lengthy treatment regimens (Musa et al., 2012; van Griensven J. et al., 
2010). Experience from other infectious diseases including HIV and tuberculosis (TB) has 
shown that combination therapy can help to prevent resistance (Gazzard, 2001). However a 
cautionary note is that resistance to all combinations has been easily selected for over a 10 
week period in the laboratory (Garcia-Hernandez et al., 2012).  Due to the excellent 
efficacy of L-AMB, combination regimes are not being routinely used in India, whereas in 
Africa SSG and PMM is the first line recommended treatment of lasting just 17 days 
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(World Health Organization, 2010).  Further work is required to identify the most 
appropriate, effective and safe regimes. 
There has been some interest over the years in combining conventional treatment 
with immunological adjuncts due to VL’s profound effect on the immune system (Section 
1.1.5) and additionally due to the immunological arm of the mode of action of antimonials 
(Section 1.2.4).  In a small trial in Bihar comparing IFN-γ with SSG and SSG alone there 
was an accelerated rate of parasite clearance in the IFN-γ treated group (Sundar et al., 
1995).  Further trials in Bihar of this combination were hindered due to low response in 
both arms likely due to high levels of antimonial resistance (Sundar et al., 1997).  
Experimental evidence showing the inhibitory effect on parasite growth of the monoclonal 
antibody anti IL-10 on fresh splenic aspirates (Gautam et al., 2011) and the dose sparing 
effect of anti IL-10 combined with pentavalent antimony in murine models (Murray, 2005) 
provides support for anti IL-10 as a therapeutic target in human VL.  
1.1.7.5 Outcome monitoring 
As mentioned in Section 1.1.2 there is under reporting of the incidence of VL.  As well as 
improving incidence figures, record keeping is vital for control and resistance monitoring. 
If treatment outcomes are accurately recorded at all levels from district health care centres 
to tertiary hospitals it can help to preserve essential drug function.  VL care can learn from 
TB care in this and a recent pilot study using a retrospective quarterly cohort monitoring 
model in Nepal has shown good feasibility (Ostyn et al., 2013). This design will catch the 
late relapses which have been occurring with the use of Miltefosine and L-AMB (Burza et 
al., 2014b). 
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1.1.7.6 Drug development 
Better treatment options for VL are desperately needed. The Drugs for Neglected Diseases 
Initiative which is a collaborative, not for profit research and development organisation 
have set out an ideal product profile for new therapeutics.  Products should be a once daily 
oral formulation that is active against all species and resistant strains, compatible for 
combination therapy, < $10/course, safe in pregnancy and immunocompromised persons 
and stable in tropical conditions5. 
Amphotericin B, miltefosine, and paromomycin were all initially developed for 
other conditions. Repurposing of drugs could continue to provide exciting new VL 
therapies as 2 of the most promising candidates fexinidazole (clinical trial phase II/II HAT) 
and PA824 (clinical phase II TB) have recently been shown to have excellent efficacy in 
vitro and in vivo against L donovani (Wyllie et al., 2012) (Patterson et al., 2013).  Due to 
preliminary work on fexinidazole for HAT, fexinidazole has been able to enter directly into 
phase II clinical trials against VL in Sudan6. VL-2098 is another promising compound7 . 
1.1.8 Sand flies and VL control  
There are many factors that a country requires for adequate control of vector borne 
diseases: peace, long-term political commitment, finance, robust control methods and 
public health education.  The control methods must address all aspects of the Leishmania 
life cycle including the parasite, the human host, any animal reservoirs if applicable and the 
sand fly vector (Chappuis et al., 2007).  Accurate diagnosis and effective treatment (Section 
1.1.7 and 1.1.7) are essential but without focus on the sand fly vector VL control will not be 
achieved.   
                                                          
5 http://www.dndi.org/diseases-projects/diseases/vl/tpp/tpp-vl.html 
6 http://clinicaltrials.gov/show/NCT01980199, accessed 11.04.14 
7 http://www.dndi.org/diseases-projects/portfolio/vl-2098.html 
Figure 1.8  Life cycle of a sand fly 
The life cycle occurs in a terrestrial environment with eggs being laid in moist 
organic matter.  There are 4 larval instars prior to pupation and adult 
emergence. Source: pcwww.liv.ac.uk/leishmania/life_cycle_habitats.htm 
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1.1.8.1 Sand fly life cycle, feeding and breeding 
Ninety three out of 800 species of sand fly are proven or possible vectors of Leishmania 
(World Health Organization, 2010).  The main species transmitting human pathogenic 
Leishmania are summarised in Table 1.1.  The lifecycle of a sand fly is shown in Figure 
1.8.  The eggs develop in moist organic matter and this development is hastened by high 
temperatures. The larval stage is 3 weeks, their food source during this time is largely 
unknown though rat faeces has been implicated (Mascari et al., 2013).  Adult flies emerge 
after pupation of 10 days. 
Only female sand flies take blood meals and are therefore involved in transmission, 
requiring the blood for egg development.  Both male and female sand flies require sugar 
meals and many species feed on aphid honey dew as a sugar source. During the day sand 
flies rest in cool, humid niches including cracks in poorly maintained houses, bedrooms, 
latrines and dense vegetation.  Females bite at night time but vary between species on 
whether they bite in/outdoors (endo/exophagic) and rest to mature their eggs in/outdoors 
(endo/exophilic) (Lane, 1993). These distinctions are important for vector control measures 
such as indoor residual spraying and bed net usage.  Sand flies cannot fly at speeds greater 
than 1 m s-1.  They can move 1 km in a night but do not tend to disperse greater than 1 km 
in a lifetime. The sand fly life expectancy is mainly unknown but is thought to be at least 
1.5 ovarian cycles (approximately 9 days) (Dye et al., 1987). Factors which favour sand fly 
breeding in the Indian subcontinent are higher indoor temperature and relative humidity 
marshy land and orchard/settlement and areas with higher soil pH and moisture content 
(Kesari et al., 2011; Lane, 1993). 
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1.1.8.2 Vector control methods 
Vector control mechanisms must be designed on the known feeding and resting habits of 
the sand fly species being targeted. In the 1950s and 1960s VL was almost eliminated in 
India as a secondary result of the National Malaria Eradication programme which employed 
the technique of indoor residual spraying (IRS) with the organochloride insecticide 
dichlorodiphenyltrichloroethane (DDT) (Ostyn et al., 2008).  A recent review of vector 
control in the Indian subcontinent concluded that IRS can dramatically reduce sand fly 
density (Picado et al., 2012). A recent Indian trial of long lasting insecticide (deltamethrin) 
treated bed nets (LN) did not show an impact on VL transmission, calling into question the 
presumed endophilic and endophagic habits of P.argentipes (Picado et al., 2010).   
Manipulating the food source of sand flies to include a form of paratransgenetic 
Bacillus subtilis, which produces leishmanicidal molecules, is one of the novel mechanisms 
of control that are being developed (Hurwitz et al., 2011). Further study on sand fly 
behaviour and prospective studies on VL control is required. 
1.1.8.3 Reservoir Control 
In areas where the life cycle involves mammals various methods have been employed.  The 
widespread culling of infected dogs is now controversial and treatment has not been shown 
to be infective and carries the risk of generating resistant parasites.  Deltamethrin 
impregnated dog collars are effective (Chappuis et al., 2007). In areas where the life cycle 
is anthropogenic, PKDL is an important reservoir as the lesions are highly parasitised.  
Active case finding is important for PKDL and is particularly effective for VL in areas with 
little public health intervention (Mondal et al., 2009). The impact of sub-clinically infected 
persons on transmission is a controversial topic (Singh et al., 2014).   
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1.1.8.4 Vaccination 
There is no available vaccine for VL but the strong immunity that follows cured infection 
implies that vaccination is highly possible.  Vaccination should be attractive economically 
to affected countries, not only due to the high burden of morbidity and mortality that VL 
carries, but also because for most families the cost of treatment and loss of work time 
substantially increases their poverty index (Chappuis et al., 2007). However, vaccination 
has not been taken up by any industrial company (Kaye and Aebischer, 2011). 
The century old practice of ‘Leishmanization’ where naïve patients were 
deliberately infected with L. major, although providing further hope for the vaccine 
approach, does not confer protection for VL.  There are 4 developed vaccines currently in 
clinical development. The most developed, Leish-111f, a fusion protein of the thiol-specific 
antioxidant protein tryparedoxin peroxidase, stress inducible protein 1 and elongation 
initiation factor, has entered phase II clinical trials as a therapeutic vaccine. Ten other 
vaccination candidate proteins are undergoing pre-clinical research (Alvar et al., 2013). 
There is hope that this post genomic, bio-informatic era will bring new promising vaccine 
candidate molecules (Kaye and Aebischer, 2011). 
1.1.8.5 Visceral Leishmaniasis Elimination Initiative 
The countries of India, Nepal and Bangladesh joined together in 2005 to form the Visceral 
Leishmaniasis Elimination Initiative (Sundar et al., 2008).  At this point elimination by 
2015 was thought possible because in India, humans are the only disease reservoir, the sand 
fly is responsive to IRS, the rK39 is an effective diagnostic and miltefosine, the first oral 
drug for VL, had recently been registered.  However, although the rK39 is working well, 
there are issues with miltefosine (1.1.6) and IRS programmes have been sub optimal.  
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Property Antimony Arsenic 
Symbol Sb As 
Electronic configuration [Kr] 4d10 5s2 5p3 [Ar] 4s2 3d10 4p3 
Atomic number 51 33 
Atomic mass 121.76 74.92 
Melting point 630.8 ⁰C 816.8 ⁰C 
Boiling point 1587  ⁰C 613  ⁰C 
Form found in nature Stibnite (antimonite), 
valentinite 
Arsenic, orpiment, 
realgar, arsenopyrite, 
scorodite 
Relative abundance 0.2 ppm 1.8 ppm 
    
Table 1.3 Properties of the elements arsenic and antimony 
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There is hope with single dose L-AMB but there is still a long way to go for elimination to 
be achieved (Matlashewski et al., 2011). 
1.2 Antimony 
1.2.1 Description 
Antimony is a chemical element with the symbol Sb and atomic number 51, belonging to 
the metalloids and Group 15 of the Periodic Table of Elements (Figure 1.9) (Table 1.3). 
Metalloids are chemical elements with properties in between metals and non-metals 
(Sekhon, 2013).  They are too brittle to be structural and are only weak conductors of 
electricity. As a group, the metalloid’s main uses are in alloys, biological agents, retardants, 
glasses, optical storage, pyrotechnics, semiconductors and electronics. 
Antimony mainly occurs in nature as stibnite/antimonite (Sb2S3) or valentinite 
(Sb2O3) found commonly in copper, silver and lead ores, mined from Bolivia, China and 
Africa  (McCallum, 1977). It is a silvery lustrous grey metal, stable at room temperature but 
reacts with oxygen if heated.   It can occur in the oxidation states of –III, 0, III and V but is 
mainly found in III and V (Filella et al., 2002). Its relative abundance is 0.2 parts per 
million (ppm) where silver is 0.007 ppm and arsenic is 1.5 ppm. Antimony is mined mainly 
for use as an alloy, a semi-conductor and as a flame retarding additive  
(Sundar and Chakravarty, 2010).  
1.2.2 History of therapeutic use 
Antimony has a long history of use as a medicine.  The ancient Egyptians used it for fevers, 
skin irritations and internal tumours as well as for cosmetic purposes.  Famously the 
reaction between wine and antimony goblets meant it was used as an emetic to allow for 
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over eating in banquets in the Roman times.  The compound potassium antimony tartrate 
was not officially discovered until the early 1600s by Adrian von Mynischt the German 
biochemist. Antimony was popular throughout the 16th to 17th century as the ‘universal 
medicine’ for pneumonia, melancholy, chest pains, plague and cancers (Yan et al., 2005). It 
was paraded by a Benedictine monk in the publication ‘The Triumphal Chariot of 
Antimony’ (Valentinus and Kerkringius, 1893) written under the pseudonym Basil 
Valentine which extensively lists its medicinal and toxic properties. Antimony became less 
popular in the 18th and 19th century due to its toxicity but returned to favour in the 20th 
century when its anti-parasitic effects against Leishmania and Schistosoma were discovered 
(Sekhon, 2013).  
When Leishman and Donovan first described the Leishmania parasite at the 
beginning of the twentieth century there was not any known effective treatment. The 
sensitivity of the related parasite trypanosomes to the arsenic compound Atoxyl, discovered 
by H.W.Thomas (Thomas, 1905) and subsequently confirmed and developed by Paul 
Ehrlich (Frith, 2013), prompted the young Brazilian physician, Gaspar Vianna, to use 
potassium antimony tartrate against MCL (Goodwin, 1995). Independently, Leonard 
Rogers started using the trivalent compound against visceral leishmaniasis and in 1921, 
20,000 injections were administered in Assam with an 88% cure rate.  However the toxicity 
of severe vomiting was such that over a third of patients did not complete their treatment 
course and distrust of the medical profession developed (Singh and Roy, 2009).   
The issue of toxicity was improved in India by Bramachari’s development of the 
pentavalent urea stibamine (Brahmachari, 1989). This compound had a cure rate of 90% 
and significantly less toxicity (Singh and Roy, 2009).  By 1933, 328,591 patients had been 
cured.  Later in the twentieth century urea stibamine was replaced by sodium 
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stibogluconate developed by Len Goodwin at the Wellcome laboratories, Euston road, by 
monitoring response in leishmania parasite load in freshly harvested hamster spleen 
(Goodwin, 1995). 
Pentavalent antimonials, in the form of sodium stibogluconate (generic SSG, Albert 
David or Pentostam, GlaxoSmithKline) or meglumine antimonite (Glucantime™, Sanofi) 
are currently used worldwide in the treatment of both VL and CL (World Health 
Organization, 2010).  Up until the late 1990s there were issues with different batches of 
generic SSG having unexpectedly high toxicities, likely due to the presence of 
contaminating trivalent antimony which is reflected by increased osmolarity (Sundar et al., 
1998).  Since then the International Dispensary Association (IDA) have taken on regular 
quality testing. Generic SSG has been shown in clinical trial format to be non-inferior to the 
significantly more expensive GSK compound Pentostam (Veeken et al., 2000) and this is the 
form used in most developing countries.   
Although trivalent antimonial preparations are active against schistosomiasis, they 
have seldom been used since the 1970s as the discovery of Praziquantel provided a more 
effective and less toxic alternative (Sundar and Chakravarty, 2010). 
1.2.3 Antimony in the environment and toxicities 
The general population in the US are exposed to low levels of antimony at 5 µg day-1 from 
both inhalation and consumption of food and water.  Antimony is present in aerobic fresh 
water in the pentavalent state and in anaerobic conditions in trivalent state, usually at a 
level of 0.1 to 0.2 µg L-1. Less than 5 µg L-1 is the WHO recommendation8.  Toxicity 
therefore usually stems from exposure via occupation (workers in the antimony production 
                                                          
8 http://www.who.int/water_sanitation_health/dwq/chemicals/antimony.pdf 
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Figure 1.10 Postulated antimony mechanism of action (Section 1.2.4) 
SbV is taken up by the macrophage and either reduced to SbIII in the macrophage 
(Hansen et al., 2011) or the amastigote (Shaked-Mishan et al., 2001; Wyllie et al., 
2004).  The transporter for SbV is unknown but SbIII is taken up into the amastigote, 
as a glycerol mimic, via the aquaglyceroporin channel AQP1 (Gourbal et al., 2004).  
The action of SbIII is through inhibition of trypanothione reductase (TryR) and of the 
biosynthetic pathway of trypanothione (T[SH]2) synthesis (Wyllie et al., 2004). SbIII 
forms a complex with T[SH]2 and is effluxed out of the cell via the ATP binding 
cassette transporter MRPA (Legare et al., 2001; El Fadili et al., 2005). All of these 
actions lead to decreased levels of intracellular T[SH]2, leaving the amastigote 
vulnerable to oxidative stress from the macrophage.  This oxidative stress is 
additionally increased by SbV induced increased IFN-γ production (Murray et al., 
2000).  
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industry and other metal mining) or from antimony therapy (Sundar and Chakravarty, 
2010). 
At the current recommended therapeutic dose of 20 mg kg-1 day-1 for 30 days 
(Barrett, 2010), treatment with antimony is accompanied by many minor side effects 
including myalgia, arthralgia, electrocardiogram (ECG) changes and transient elevation in 
hepatic enzymes (Sundar et al., 1998).  However, in up to 9% of cases serious 
cardiotoxicity can occur. Abnormal ECG changes progress to the life threatening 
arrhythmias of torsade de pointes and ventricular fibrillation therapy (Sundar and 
Chakravarty, 2010). The proportion of patients experiencing cardiotoxicity was higher prior 
to the introduction of IDA testing (Section 1.2.2).  Pancreatitis, another potentially fatal 
adverse effect, is more common in HIV co-infected patients (Delgado et al., 1999). Regular 
monitoring of hepatic and pancreatic enzymes and ECG changes is recommended during 
therapy but this is not practical in the rural settings where antimony is often administered. 
Instead, antimony is not recommended for patients with co-morbidities (Barrett, 2010). 
1.2.4 Antimony mechanism of action 
The mechanism of action of pentavalent antimonials has not been fully elucidated 
despite almost a century of use.  The toxic action has been established to be multifactorial 
with both direct and indirect actions and is mainly based around the thiol systems of the 
macrophage and parasite including the unique thiol of the kinetoplastid family 
‘trypanothione’ (T[SH]2) (Fairlamb et al., 1985; Wyllie et al., 2004). The mechanism of 
how antimony in its pentavalent form enters the amastigote and the exact mechanism of 
reduction to its trivalent form are still to be established. A summary of the mode of action 
of antimony can be found in Figure 1.10. 
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1.2.4.1 Direct action 
Pentavalent antimonials are prodrugs which require to be reduced to trivalent form for their 
action. It is a remaining mystery, partly due to the technical difficulties of antimony 
speciation, as to where SbV is reduced to SbIII – in the macrophage, in the amastigote or 
both?  Both glutathione (GSH) and T[SH]2, the latter more potently than the former due to 
the reducing activity of its dithiol structure, are able to non-enzymatically reduce 
SbV (Ferreira et al., 2003).  GSH performs this optimally at pH 4.7-5.2 in vitro which, 
although this is not compatible with the neutral pH of the cytosol, could occur instead in the 
phagolysosome (Frezard et al., 2001).  However, the predominant thiols in the 
phagolysosome are cysteine and cysteinyl glycine and not glutathione.  A recent study 
found that the SbV treated uninfected macrophages contained up to 23% SbIII (Hansen et 
al., 2011) although this analysis was performed in an acidic pH of 4.5 which may have led 
to an artificially elevated level of SbIII through spontaneous reduction. T[SH]2, found in the 
cytosol of the amastigote, reduces SbV at both pH 5 and 7, with a greater affinity than 
glutathione, resulting in formation of a complex of SbIII and T[SH]2 (Ferreira et al., 2003), 
(Yan et al., 2003).   
The relative toxicity of SbV and SbIII in different cell types, provides further 
evidence that reduction to toxic SbIII may occur in the cytosol of the intracellular 
Leishmania amastigote.  Whilst macrophages, are refractory to SbV at concentrations up to 
1000 µg ml-1 (Wyllie et al., 2004), SbV has an EC50 against promastigotes of 8700 µg ml-1 
(Roberts et al., 1995) and an axenic amastigote line was sensitive with an EC50 of just 200 
µg ml-1 (Wyllie and Fairlamb, 2006a).  This is in stark contrast to the similarities in 
sensitivity of the macrophage, promastigote and axenic amastigote to SbIII with IC50s of 
25, 11 and 8 µg ml-1, respectively (Wyllie and Fairlamb, 2006a) (Wyllie et al., 2004).  
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Two thiol dependent enzymes have been suggested to catalyse antimony reduction.  
The first is thiol dependent reductase -1 (TDR1) whose presence was found to be 10-fold 
greater between amastigotes and promastigotes in a thiol enriched parasite lysate. This 
however does not fully account for the 60 to 600 fold difference in susceptibility between 
promastigotes and amastigotes (Roberts et al., 1995). The enzyme is thought to work on a 
spontaneously formed thiol metalloid compound rather than on the individual compounds 
(Denton et al., 2004).  Although its structure has been solved (Fyfe et al., 2012) fuller 
experimental evidence is required to demonstrate this enzyme is definitively responsible for 
SbV reduction. 
The other putative reductase was identified through working from the similarity 
between the metalloids arsenic and antimony: the sequence of an arsenate reductase, 
ScAcr2p from Saccharomyces cerevisiae, was used to identify a closely related L. major 
enzyme, LmACR2 (Zhou et al., 2004).  Transfection of this enzyme into promastigotes 
conferred increased sensitivity to SbV in the differentiated intracellular amastigote form 
showing that it may have an activating role. Further studies demonstrate that this enzyme is 
also involved in the phosphotyrosine pathway (Zhou et al., 2006).   
1.2.4.2 Transport 
It has been known for over 30 years that antimony accumulates within the Leishmania 
parasite (Croft et al., 1981). More recent studies, using inductively coupled plasma mass 
spectrometry (ICP-MS) which allows for speciation, have been able to demonstrate that 
both SbV and SbIII enter the parasite via different routes (Brochu et al., 2003) and that 
reduction from SbV and SbIII occurs within the amastigote (Shaked-Mishan et al., 2001). 
Furthermore, there is a greater accumulation of antimony into the amastigote than the 
promastigote form (Shaked-Mishan et al., 2001). 
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The mechanism of entry of trivalent metalloids into Leishmania has been 
established as the aquaglyceroporin (AQP) channel through transfection of AQP1 into 
promastigotes of L.tarentolae, L.major and L.infantum leading to increased production, 
accumulation and sensitivity to SbIII (Gourbal et al., 2004).  The transporter for entry of 
SbV has not as yet been identified. 
1.2.4.3 Thiol perturbation 
Once SbIII is inside the amastigote it is thought to exert its toxic effect by 2 mechanisms.  
When axenic amastigotes are incubated with SbIII there is a time dependent decrease in 
intracellular thiols (Wyllie et al., 2004) which can be detected in the supernatant.  The SbIII 
forms a complex with either T[SH]2 or GSH and is effluxed from the amastigote into a 
vacuole or into the phagolysosome via PgpA transporters (Dey et al., 1996) including 
MRPA (El Fadili et al., 2005; Légaré et al., 2001).  The inhibition of trypanothione 
reductase leads to an accumulation of the disulphide forms of trypanothione and 
glutathione, which combined with the efflux leads to a reduction in the thiol buffering 
capacity of the leishmania parasite and adversely affects the redox potential (Wyllie et al., 
2004).  This oxidising environment induces amastigote apoptosis and nuclear fragmentation 
– a mode of cell death that has been established to occur (Sereno et al., 2001) (Sudhandiran 
and Shaha, 2003).  
1.2.4.4 Action on immune system 
As well its direct toxic effect antimonials have an essential indirect mode of action via the 
immune system.  Pentavalent antimonials are profoundly less effective in both T-cell 
deficient BALB/c mice (Murray et al., 1989) and severe combined immune deficiency 
(scid) mice (Escobar et al., 2001). Additionally SbV has an inhibitory effect on the tyrosine 
phosphatase SHP-1 (Pathak and Yi, 2001) leading to increased IL-12 and IFN-γ (Murray et 
Figure 1.11  Decline in efficacy of antimonials at 20 mg kg-1 in Bihar: results of 
clinical studies between 1980 and 2004  
The graph is data extracted from a table in (Guerin et al 2002). Doses regimes are 
indicated in the figure key. 
Linear regression correlation coefficient = -0.83. (Perry et al., 2011) 
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al., 2000).  This and other effects on protein kinase signalling result in increased production 
of reactive oxygen and nitrogen species which ultimately lead to Leishmania cell death 
(Mookerjee et al., 2006; Rais et al., 2000). 
1.2.5 Resistance development and mechanisms 
Chemotherapy with pentavalent antimonials was effective in all regions of the world until 
the 1990s despite inherent interspecies differences in antimonial susceptibility (Allen and 
Neal, 1989).  A decrease in treatment efficacy was first noted when VL re-emerged in India 
in the late 1970s following its near eradication as a secondary effect of a National Malarial 
Eradication programme in the 1950s and 60s (Peters, 1981). On re-emergence, the prior 6 
day regime was found to be ‘grossly inadequate’ (Thakur, 1984) and was increased to 10 
mg kg-1 for 20 days, and then to 20 mg kg-1 for 30 days over the next 20 years, in an effort 
to retain efficacy of this drug which was the sole established treatment for VL at this time.  
However despite this, there were reports of declining cure rates from the field (Sundar et 
al., 2000) and in the context of clinical trials (Olliaro et al., 2005).  By the end of the 
twentieth century the cure rate was less than 1 in 2 (Figure 1.11). 
The reason for the dramatic development of treatment failure in India was thought 
to be the misuse of antimony in the under-regulated private health care sector. In 1994 a 
study reported that 227/312 (73%) of patients obtained treatment from an unqualified 
medical practitioner.  Two hundred and twenty five (72%) did not complete a treatment 
course that complied with the current WHO guidelines, 132 (42%) did not take it regularly 
and 112 (36%) stopped on their own initiative (Sundar et al., 1994).  All of the above 
situations could lead to sub therapeutic delivery of SSG and allow for the development of 
resistance. 
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Although parasitologists had been inducing resistance to antimonials using trivalent 
metalloids and laboratory parasite strains since clinical failure was reported (Detke et al., 
1989), it was not until 1998 that SSG resistance in clinical isolates was reported that was 
related to clinical response.  This study showed, although the numbers are small, a high 
correlation between SSG susceptibility of the amastigote in an in vitro intracellular 
environment and clinical outcome from SSG treatment (Lira et al., 1999).  Since then, 
although many studies have been performed on resistant and sensitive clinical isolates, the 
correlation between SSG susceptibility and clinical response has been called into question 
(Rijal et al., 2007).  
1.2.5.1 Selection of Leishmania parasite resistance 
This section will look at the molecular mechanisms of SSG resistance in L.donovani and 
discuss how these relate to findings in clinical isolates and to clinical failure per se. 
Mechanisms of parasite antimony resistance have now been being investigated for over 
30 years and have been found to be multifactorial including drug metabolism, drug influx, 
membrane transport and sequestration, thiol metabolism, genome plasticity, programmed 
cell death and manipulation of macrophage functions (Croft et al., 2006).  It is important to 
note the variability in methods that have been used to investigate drug resistance: 
• Parasite species: Antimonial resistance has been extensively studied in L.tarentolae, 
a Leishmania species found in the white-spotted wall gecko (Tarentola annularis) 
that is non-pathogenic to humans (Brochu et al., 2004; Dey et al., 1994; Dey et al., 
1996; Guimond et al., 2003; Haimeur et al., 2000; Légaré et al., 1997; 
Mukhopadhyay et al., 1996). The work on this species, although it has identified 
many common mechanisms has also identified differences between L.tarentolae and 
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the Leishmania species relevant to humans.  For example the level of trypanothione 
is 50 fold greater in L.infantum than L.tarentolae (El Fadili et al., 2005).  
Interestingly, the genome of L.tarentolae has recently been assembled and, although 
there is a high degree of synteny, the species is missing many genes relating to the 
pathogenic intracellular amastigote stage of the life cycle (Raymond et al., 2012). 
• Parasite phenotype: Resistance has been studied in promastigote, axenic amastigote 
and intracellular amastigote forms (Croft et al., 2006). 
• Method of resistance development:  As well as selecting for resistance with SbIII 
and SbV, in laboratory strains resistance has been selected using AsIII because 
selection for resistance to AsIII also leads to cross resistance to SbIII (Brochu et al., 
2004; Dey et al., 1994; Dey et al., 1996; Guimond et al., 2003; Haimeur et al., 
2000; Légaré et al., 1997; Mukhopadhyay et al., 1996). Some SbV preparations used 
in early studies were subsequently discovered to contain the preservative 
chlorocresol which has its own leishmanicidal action (Ephros et al., 1997), thus 
resistance was selected for to the chlorocresol as well as to SbV itself. The final 
method of resistance development is within the patient: clinical isolates from 
patients and dogs have been extensively studied both before and after exposure to 
SbV treatment (Decuypere et al., 2005; Faraut-Gambarelli et al., 1997; Gramiccia et 
al., 1992). 
1.2.5.2 Loss of SbV activation as a resistance mechanism 
Inhibition of the activation of SbV by reduction to SbIII has been proposed to be a 
mechanism of SbV resistance based on studies that demonstrated the lack of toxicity of SbV 
against a SbIII generated resistant axenic amastigote line compared with control (Shaked-
Mishan et al., 2001).  Although transfection of the proposed SbV activator, LmACR2, led to 
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increased sensitivity to sodium stibogluconate in intracellular amastigotes (Zhou et al., 
2004), no evidence of changes in expression levels of this enzyme or the other putative 
reductase, TDR1, were identified in a study of resistant and sensitive clinical isolates in 
Nepal (Decuypere et al., 2005). 
1.2.5.3 Changes in transport of SbIII as a resistance mechanism 
Evidence for the involvement of drug influx in antimonial resistance was demonstrated by 
the overexpression of LmAQP1 into both selected for and natural resistant strains leading to 
increased susceptibility to both SbIII and AsIII as promastigotes and SbV as amastigotes 
within macrophages (Gourbal et al., 2004).  Additionally an induced point mutation in 
LmAQP1 led to marked decrease in susceptibility to SbIII and AsIII in promastigotes 
(Uzcategui et al., 2008).   
Analysis of antimony sensitive and resistant field isolates only weakly support 
AQP1 as a mechanism for antimonial resistance with contradictory results. Analysis of 14 
field isolates (5 sensitive and 9 resistant) from VL and PKDL patients in Bihar (Mandal et 
al., 2010) showed good correlation between accumulation of SbIII and AQP1 expression 
levels and antimonial resistance.  Gene expression analysis of Nepalese isolates (2 sensitive 
and 2 resistant) showed a lower expression of AQP1 in resistant strains (Decuypere et al., 
2005). However, in another study from India, although there was evidence of decreased 
accumulation of SbIII, analysis of 6 clinical isolates (2 sensitive and 4 resistant) showed no 
correlation between AQP1 expression levels and antimonial resistance and an increased 
copy number of AQP1 in resistant isolates (Maharjan et al., 2008).   
The importance of ATP-dependent efflux pumps of PgpA in conferring resistance to 
metalloids in micro-organisms has been well researched (Cervantes et al., 1994).  The 
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MRPA metalloid thiol efflux pump has been implicated in antimonial resistance in both 
laboratory generated resistance (El Fadili et al., 2005; Grondin et al., 1997; Guimond et al., 
2003; Haimeur et al., 2000) and as an extra chromosomal amplification in natural resistant 
isolates (Brotherton et al., 2013; Leprohon et al., 2009; Mukherjee et al., 2007)).  
Transfection of MRPA into L.infantum confers high level antimonial resistance in both 
axenic and intracellular amastigotes (El Fadili et al., 2005): the Sb-thiol conjugate is 
thought to be sequestered inside a vacuole or extruded from the parasite. Of note, 
macrophages infected with antimonial resistant isolates also upregulate their MRP1 and 
PgpA transporters in their host cells (Mookerjee et al., 2008). 
1.2.5.4 Upregulation of thiol synthesis in leishmania as a resistance mechanism 
The result of upregulation of MRP transporters is low levels of intracellular metalloid 
decreasing the toxic effect on the leishmania parasite. However, overexpression of the 
MRPA means that protective thiols are being pumped out of the amastigote.  Resistant 
parasites have higher levels of the protective intracellular trypanothione than sensitive 
parasites (Mandal et al., 2007) – this is achieved by upregulation of the biosynthetic 
pathways and maintaining trypanothione in a reduced form.  Elevated levels of 
trypanothione reductase (TR), ornithine decarboxylase (ODC) and gamma-glutamyl 
cysteine synthetase (γ-GCS) are implicated in clinical isolates from India (Mittal et al., 
2007; Mukherjee et al., 2007), TR and ODC in Nepal (Decuypere et al., 2005)  and TR and 
ODC in L.braziliensis in Brazil (Adaui et al., 2011). This high intracellular thiol level is 
likely to be partially responsible for increased tolerance to nitric oxide (NO) (Holzmuller et 
al., 2005) and hydrogen peroxide (H2O2) (Carter et al., 2005).  However, upregulation of 
tryparedoxin peroxidase to reduce levels of reactive oxygen species has also been identified 
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Figure 1.12 Postulated antimony mechanisms of resistance (Section 1.2.5) 
The changes in metabolic state of the resistant leishmania amastigote are depicted in 
blue.  Established mechanisms of resistance include downregulation of the influx 
pump aquaglyceroporin (AQP), upregulation of the efflux pump MRPA, and 
upregulation of trypanothione peroxidase (TryP) and enzymes of trypanothione 
biosynthesis (ornithine decarboxylase, ODC and gamma glutamylcysteine 
synthetase, γ-GCS) . This results in elevated levels of thiols within the amastigote, 
increasing it’s defences against oxidative stress. Other proposed mechanisms of 
resistance include downregluation/loss of the SbV transporter and 
downregulation/loss of the activation step from SbV to SbIII. Reviewed in (Ait-
Oudhia et al., 2011). 
 
32 
 
in laboratory generated antimonial resistant L.tarentolae (Wyllie et al., 2008) and field 
isolates (Wyllie et al., 2010).    
1.2.5.5 Manipulation of the immune system as a mechanism of resistance 
As well as ensuring high levels of protective intracellular thiols antimonial resistant 
Leishmania have also been shown in vitro to manipulate the host immune response with 
inhibition of the PI3 kinase/AKT and NFκβ pathways (Haldar et al., 2010) and increased 
levels of IL-10 (Haldar et al., 2010; Mukhopadhyay et al., 2011).  Patients who did not 
respond to SSG therapy were more likely to have a TH2 response to VL infection with low 
levels of IFN-γ (Thakur et al., 2003).  Whether this immune reaction is parasite or host 
driven has not yet been elucidated. 
1.2.5.6 Additional mechanisms of resistance 
Additional reported mechanisms involve changes in membrane fluidity and over expression 
of terminal glycoconjugates (Mukhopadhyay et al., 2011).  Overexpression of heat shock 
protein has also been implicated (Brochu et al., 2004). Use of proteomic techniques 
(Brotherton et al., 2013; El Fadili et al., 2009; Kaur and Rajput, 2014) such as stable 
isotope labelling of amino acids in culture (SILAC) has confirmed known resistance 
mechanisms and will hopefully identify new ones.  However care needs to be taken on what 
phenotype of Leishmania resistance is being generated and analysed. 
1.2.5.7 Summary 
There is heterogeneity in resistance mechanisms but a schematic overview of the resistant 
parasite is illustrated in Figure 1.12. Once parasites have become resistant to metalloids the 
resistance is mainly thought to be stable even in the absence of metalloid pressure (El Fadili 
et al., 2005; Grogl et al., 1989) and in fact may have a selective advantage over sensitive 
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parasites with increased metacyclogenesis, infectivity and parasite growth within hosts 
(Vanaerschot et al., 2011; Vanaerschot et al., 2013; Vanaerschot et al., 2010). The ultimate 
goal is to find a parasitic marker that correlates highly with patient treatment failure that 
could act as a clinical test for resistance at the bedside pre-treatment. 
1.3 Arsenic 
1.3.1 Description of metalloid 
Arsenic is a chemical element with the symbol As, belonging to the metalloids and Group 
15 of the Periodic Table of Elements (Figure 1.9) and (Table 1.3)(Sekhon, 2013). Arsenic’s 
main use is to strengthen copper and lead alloys (e.g. in a car battery). It is also used in 
semiconductors, herbicides, pesticides and insecticides as well as medicines (Section 1.3.3). 
It is an important ingredient found in flypaper, cosmetics, glass, ceramic enamels, paints, 
metallurgy, tanning, taxidermy and in candles (Doyle, 2009). 
Arsenic can exist in oxidation states of +5, +3 and 0. It readily forms covalent bonds 
with hydrogen, oxygen and carbon and alloys with metals. The pentavalent arsenates, in the 
form of H3AsO4, act as phosphate mimics, are taken up into cells by phosphate transporters 
and interfere with energy metabolism. Trivalent arsenic compounds are derived from 
arsenite H2As2O3 and arsenic trioxide As2O3 and are more toxic than pentavalent 
compounds.  Arsenic has a strong affinity to sulphur which predicts its accumulation in 
body organs (Ho, 2005). 
1.3.2 Arsenic metabolism 
Humans readily absorb arsenic through their gastrointestinal system and metabolise the 
inorganic forms via a series of reduction and methylation reactions leading to the 
Figure 1.13  Human metabolism of arsenic Arsenic is metabolised via a series of 
reduction and methylation reactions.  The main site of methylation is the liver 
although most organs are thought to have some methylation capacity.  The majority 
of ingested arsenic is excreted in the urine within 48 hours of ingestion in the 
chemical forms of 10–30% inorganic arsenic, 10-20% MMA, 60-80% DMA (Vahter 
et al., 2001) 
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pentavalent compound dimethylarsenic acid (DMA) (Figure 1.13).  Following bioactivation 
from AsV to AsIII, AsIII is thought to bind to dithiol groups before methylation (Vahter and 
Concha, 2001).  Arsenic (+3 oxidation state) methyltransferase (AS3MT) (Lin et al., 2002) 
is able to methylate both AsIII and monomethylarsenic acid (MMA) but has a different 
affinity for the 2 substrates (Engstrom et al., 2013).  Methyltransferases can be inhibited by 
excess substrate. The main site of methylation is the liver but most tissues have methylation 
capacity (Vahter, 2002). 
A decreased methylation capacity leads to increased tissue concentrations of 
arsenic.  Methylation capacity is influenced by age, gender, ethnicity, dose, pregnancy, 
nutrition and genetic polymorphism.  However in general, arsenic in urine consists of 10–
30% inorganic arsenic, 10–20% MMA, and 60–80% DMA (Vahter, 2002).  Although 
methylation was initially viewed as a detoxification mechanism, and indeed the pentavalent 
methylated species have lower affinity for sulfhydryl groups, lower cellular uptake and 
higher excretion, the trivalent mono methylated species is the most toxic (Styblo et al., 
2000) and is thought to play a key role in the carcinogenicity of arsenic (Kojima et al., 
2009).  Mechanisms other than methylation (e.g. protein binding) are likely to be important 
in detoxification of inorganic arsenic (Vahter, 2002). 
Although the majority of arsenic is excreted within 48 hours of ingestion, 
accumulation has been observed in hair, nails, skin (Vahter and Concha, 2001) and liver 
(Mazumder, 2005) in humans.  In animal studies arsenic levels in organs are related to dose 
and duration of exposure (Das et al., 2005).  However the relationship is more complex in 
humans, likely due to differences in methylation capacity and membrane transporters 
between and within population groups (Drobna et al., 2010; Melak et al., 2014). 
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1.3.3 History of therapeutic use 
Although infamous as a poison, arsenic also has a long history of use as a treatment. The 
therapeutic properties of arsenic in the form of orpiment (As2S3) and realgar (As2S) have 
been utilised for more than 3000 years in ancient Chinese and Hindu medical practices and 
the tonic ‘arseniko’ was described by Hippocrates (469-377 BC) (Doyle, 2009). Arsenic 
compounds were successfully used internally by Paracelsus in the 15th Century AD.  Dr 
Thomas Fowler (1736-1801) developed 1% potassium arsenite (KAsO2, Fowler’s solution) 
which was widely used throughout the 19th century for many different ailments including 
goitre, Hodgkin’s disease and Herpes Zoster. It remained on the US pharmacopeia as late as 
1950 (Kritharis et al., 2013). 
Paul Ehrlich (1854-1915) was responsible for producing the drug arsphenamine 
which was found to be effective against syphilis.  This led to the effective use of the arsenic 
compound salvarsan against syphilis and yaws (Doyle, 2009) and the development of the 
compound melarsoprol for trypanosomiasis (Friedheim, 1951; Friedheim, 1949). Over the 
course of the 20th century, arsenic was replaced by penicillin in the treatment of syphilis but 
its use of arsenic as an anti-cancer agent re-emerged. Arsenic trioxide (ATO) is now fully 
licenced by the FDA as a treatment for relapsed acute promyelocytic leukaemia (APML).  
ATO is undergoing trials as chemotherapy for many different solid tumours (Kritharis et 
al., 2013) and recent results suggest its place may be in combination with other agents 
(Subbarayan and Ardalan, 2014). 
The effect on arsenic on cellular metabolism is diverse, including actions within the 
mitochondria, endoplasmic reticulum and nuclear bodies (found in the nuclei of malignant 
mammalian cells) (Ho, 2005; Kritharis et al., 2013).  Its therapeutic effect in APML is 
Figure 1.14 Arsenic global geocycle 
Figure from (Mukhopadhyay et al., 2002) 
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thought to be secondary to arsenic-induced degradation of all PML isoforms which is 
dependent on the ubiquitin E3 ligase RNF4 (Hands et al., 2014).   
Reported toxic effects from pharmacological doses of arsenic include 
gastrointestinal effects, flushing, fatigue, dysesthesias and dizziness. QT prolongation and 
ventricular tachycardia, neutropenia, thrombocytopenia, hyperglycemia, hepatic enzyme 
elevations can be observed.  There have only been 2 cases reported of fatal encephalopathy 
with arsenic trioxide in Taiwan at 0.24 mg kg-1 day-1 (Subbarayan and Ardalan, 2014). The 
higher dose required for the arsenical based drug melarsoprol, still in use for HAT in some 
regions (Kuepfer et al., 2012), has led to fatal encephalopathy in more than 8% of patients.  
1.3.4 Arsenic contamination of water 
Arsenic is present all around us and forms a geocycle that man takes part in (Figure 1.14) 
(Mukhopadhyay et al., 2002).  The main source of arsenic is igneous. Arsenic is 
widespread in the upper part of earth’s crust with an average concentration in seawater of 
2.6 ppb, fresh water 0.4 ppb, atmospheric dust of 50 – 400 ppm and soil 0.1 – >1000 ppm 
kg-1 (Mukhopadhyay et al., 2002). 
1.3.4.1 Discovery and epidemiology of arsenic contamination 
Although an abundant natural element, the occurrence of arsenic in natural waters has only 
been known about for just over 100 years (Ravenscroft et al., 2009).  The first recorded 
arsenic measurement in water was by the German chemist Fresnius at Wiesbaden Spa in 
1885 and the first recorded adverse health effect was skin cancer in Poland in 1898 
(Mandal and Suzuki, 2002). Despite an endemic outbreak in Argentina in the 1920s, arsenic 
contamination of water and its impact on health remained largely unknown until the latter 
37 
 
part of the 20th Century when publications on ‘blackfoot disease’ emerged from Taiwan 
(Chen et al., 1985; Tseng et al., 1968). 
In tropical Asia in the 1970s there was an accelerated use of groundwater through 
the drilling of tens of millions of shallow tube wells to provide clean, microbiologically 
safe sources of drinking water.  This policy was promoted by the United Nations Children’s 
Fund (UNICEF) and supported by the World Bank due to high under five diarrhoeal 
mortality in these countries, secondary to bacterial pollution of shallow, open dug wells 
leading to outbreaks of dysentery and cholera (Meharg, 2005). Tube wells are closed 
systems in which a stainless steel pipe covered with a strainer accesses water from an 
underground aquifer which is drawn up to the surface through the use of a hand pump. In 
large geographical areas, these shallow tube wells accessed arsenic contaminated ground 
water leading to the most extensive case of arsenic poisoning in world history (Ravenscroft 
et al., 2009).  That arsenic is colourless, odourless and tasteless catastrophically delayed the 
discovery of its presence in drinking water. 
The occurrence of arsenic in groundwater was established as an issue in the US in 
1988 (Welch et al., 2000). Although the first report from West Bengal was in 1983, it was 
not until a publication which described the extent of poisoning in six districts of West 
Bengal and political pressure exerted Dipankar Chakraborti at the School of Environmental 
Studies that the issue was brought to the international media including CNN and BBC 
(Ravenscroft et al., 2009).  This prompted widespread testing in neighbouring Bangladesh 
and extensive arsenic pollution was also discovered here and in the river basins of Nepal, 
Myanmar, Cambodia, Vietnam and Pakistan (Nordstrom, 2002).  Following the turn of the 
20th Century arsenic was detected upstream of the Ganges in Bihar (Chakraborti et al., 
2003) and Uttar Pradesh (Ahamed et al., 2006) and extensively mapped in Chinese 
Figure 1.15 Worldwide distribution of arsenic in groundwater 
Geographical representation of documented problems with arsenic in groundwater 
(>50 µg l-1 ). Source: British Geological Survey, updated from Smedley and 
Kinniburgh 2002. 
Figure 1.16  Distribution of arsenic contamination in West Bengal, Bangladesh, 
Nepal and Bihar 
Sources: West Bengal; School of Environmental Studies, Jadvapur University (Panel 
A); Bangladesh: British Geological Survey (Panel B); Nepal: Genesis report, 2005 
(Panel C); Bihar: Public Health and Education Department (Panel D).  
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Country/region 
Concentration 
(μg l-1) 
Potential exposed population Environmental conditions 
Bangladesh < 1 to 2,500 30,000,000 Natural; alluvial/deltaic sediments with high phosphate,* organics 
West Bengal, India < 10 to 3,200 6,000,000 Similar to Bangladesh 
Vietnam 1 to 3,050 > 1,000,000 Natural; alluvial sediments 
Thailand 1 to > 5,000 15,000 Anthropogenic; mining and dredged alluvium 
Taiwan† 10 to 1,820 100,000 to 200,000 Natural; coastal zones, black shales 
Inner Mongolia < 1 to 2,400 100,000 to 600,000 Natural; alluvial and lake sediments; high alkalinity 
Xinjiang, Shanxi 40 to 750 > 500 Natural; alluvial sediments 
Argentina > 1 to 9,900 2,000,000 Natural; loess and volcanic rocks, thermal springs; high alkalinity 
Chile‡ 100 to 1,000 400,000 
Natural and anthropogenic 
volcanogenic sediments; closed 
basin; lakes, thermal springs, mining 
Bolivia§ - 50,000 Natural; similar to Chile and parts of Argentina 
Brazil∥ 0.4 to 350 - Gold mining 
Mexico 8 to 620 400,000 Natural and anthropogenic; volcanic sediments, mining 
Germany < 10 to 150 - Natural: mineralized sandstone 
Hungary, Romania < 2 to 176 400,000 Natural; alluvial sediments; organics 
Spain¶ < 1 to 100 > 50,000 Natural; alluvial sediments 
Greece# - 150,000 Natural and anthropogenic; thermal springs and mining 
United Kingdom** < 1 to 80 - Mining; southwest England 
Ghana < 1 to 175 < 100,000 Anthropogenic and natural; gold mining 
USA and Canada < 1 to > 100,000 - 
Natural and anthropogenic; mining, 
pesticides, As2O3 stockpiles, 
thermal springs, alluvial, closed 
basin lakes, various rocks 
Table 1.4  Worldwide distribution of arsenic 
Source: Adapted from (Nordstrom et al., 2002)  
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provinces.  Although arsenic contamination can be found throughout the world, Asia is 
thought to be the worst effected with likely more than 100 million people drinking water 
with arsenic levels greater than the WHO recommendation of ≥10 µg L-1  (Sen and Biswas, 
2013).  Figure 1.15 and Table 1.4 give a summary of the global distribution of arsenic 
contamination. 
In the Indian subcontinent the River Ganges exits the Himalayas in Northern India 
and runs through the states of Uttar Pradesh, Bihar, Jharkland and West Bengal before 
joining with the Brahmaputra in Bangladesh where the highest levels of arsenic 
contamination are found (Argos et al., 2010). Figure 1.16 shows the relative distribution of 
arsenic contamination in Nepal, Bangladesh and the worst affected states of India: West 
Bengal and Bihar. Importantly, the Bangladesh, Nepal and West Bengal maps represent 
exhaustive testing of every tube well in affected areas whereas the map of Bihar only 
represents surveys where approximately 10% of the wells were sampled with no sampling 
having been performed in some areas. In Bihar this is mainly due to a priority to sample 
within 10 km of the River Ganga (Pi et al., 2000).   
1.3.4.2 Natural causes of arsenic contamination 
In the Earth’s crust the most important accumulations of arsenic are found associated with 
sulphides and oxides. In the Indian subcontinent the arsenic is present in subsurface water 
as a result of rock weathering, downstream transport and sediment deposition of arsenic 
rich minerals originally present in the Himalayas leading to a concentration of arsenic 
contaminated groundwater in the tropical river basins of Asia (Nickson et al., 1998). 
Release of arsenic into water occurs where neither sulphides nor oxides can remove 
arsenic from solution (Ravenscroft et al., 2009). The four mechanisms of this are listed 
Figure 1.17  Three mechanisms of arsenic mobilisation by metal reducing 
bacteria 
The micro-organisms oxidise organic matter and use AsV and FeIII as their terminal 
electron acceptor. It is possible that all these mechanisms can occur simultaneously 
in the same aquifer. Figure from (Oremland and Stoltz, 2005) 
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below.  Reductive dissolution is the mechanism which occurs in the Indian subcontinent 
and the one which will be focussed on in this study. 
1. Reductive dissolution: Arsenic is often found adsorbed onto the surface of iron 
oxides, which are the most important minerals for controlling the occurrence of 
arsenic in groundwater. When iron oxides are broken down and dissolve under the 
influence of oxygen consuming decaying organic matter, arsenic is released 
(Oremland and Stolz, 2005). The groundwater produced is strongly reducing and 
contains high levels of iron and bicarbonate.  Characteristically nitrate and sulphate 
are absent. Figure 1.17 show the action of dissimilatory arsenic reducing 
prokaryotes (DARPs) which respire using arsenate’s similarity to phosphate 
producing AsIII (Oremland and Stolz, 2005). 
2. Alkali desorption:  This occurs in the presence of oxygen, nitrogen or sulphate, at 
high pH ≥8.0 and produces alkali-oxic water typically with low levels of iron and 
manganese. 
3. Sulphide oxidation:  If suphide minerals e.g. pyrite are exposed to oxygen, often at 
the water table, acidic (pH 1-6) and sulphate-rich waters are produced. 
4. Geothermal waters: Waters of high temperature and arsenic correlated with chloride 
are produced from deep and sometimes volcanic waters that leach arsenic from the 
country rocks (Ravenscroft et al., 2009) 
1.3.4.3 Anthropogenic arsenic contamination 
Humans are responsible for arsenic pollution as a result of mining for coal and metal 
(Figure 1.15).  The exposure and thus oxidisation of sulphide-rich ores to air and rainwater 
produces acid mine drainage which contains high levels of arsenic.  Spoil heaps from mines 
can lead to contamination of soil that is present for decades after mining has ceased – for 
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example in the tin mines of Cornwall, UK (Ravenscroft et al., 2009).  Additionally, the 
smelting of sulphide ores pollutes the air with arsenic and the burning of coal is a major 
contributor to arsenic in the surface environment.  Pesticides previously contained high 
levels of arsenic and although this composition has been abandoned in Western countries 
arsenic pesticides are still in use in developing countries (Jayatilake et al., 2013) 
1.3.5 Detection and assessment of exposure 
1.3.5.1 Analytical techniques 
Arsenic can be detected in water in the field using of field testing kits which utilise the 
reaction between zinc and water and arsenic to produce arsine gas (AsH3) which reacts 
with mercury bromide paper and produces a colorimetric indication of the presence of 
arsenic (Williams et al., 2007a). 
As(OH) + 3Zn + 6HCl AsH3 + 3ZnCl2 + 3H2O 
H3AsO4 + 4Zn + 8HCl AsH3 + 4 ZnCl2 + 4H2O 
These tests are semi quantitative as the shade of colour on the mercury bromide 
paper relates to the quantity of arsenic gas produced. The test vary in their accuracy and to 
try and improve the results of field sampling UNICEF have now published a list of 
approved arsenic test kits9. 
Atomic absorption spectrometry (AAS) is a technique which quantitates arsenic 
through the absorption of optical radiation by gaseous free atoms (Chakraborti et al., 2003). 
ICP-MS ionises the arsenic atoms which are then detected by a mass spectrometer 
(Williams et al., 2007b).  These analytical methods are reference methods which require 
                                                          
9 www.unicef.org/supply/files/Monitoring_Arsenic_in_Water.pdf 
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skilled personnel and advanced laboratories10 but are routinely used in research whilst the 
field kits are used for surveying and detection9. 
Both the field kits and AAS and ICP-MS detect “total” arsenic.  If urine is being 
analysed it is important to know if a patient has consumed seafood in the preceding 4 days 
as the tests would detect arsenobetaine,  a non-toxic organic form of arsenic that naturally 
occurs in fish (Vahter, 1994). If speciation is required then the reference methods can be 
coupled with high performance liquid chromatography (HPLC) (Engstrom et al., 2013). 
1.3.5.2 Individual assessments of exposure 
Arsenic exposure has been assessed in many ways.  The concentration of arsenic in an 
individual’s primary water supply together with daily volume consumption will give a good 
approximation, but, ideally, length of exposure should also be considered (Argos et al., 
2010).  This method does not take into account exposure from other tube wells, food and 
other sources.  The latter’s contribution can be considerable depending on the region 
(Ravenscroft et al., 2009).  In view of this, arsenic in urine is a very valuable biomarker of 
the exposure over the last 24 h (Concha et al., 2006).   Ideally this should be collected as a 
24 h sample but many studies report spot urine for which there is not an established cut off. 
There is no definitive cut-off for elevated arsenic in urine. The normal range is thought to 
be 5-40 μg L-1 (Mandal and Suzuki, 2002; Ravenscroft et al., 2009).   In 2001, D.N.G. 
Mazumder recommended a level of > 50 μg L-1 urinary arsenic (Mazumder, 2001), but this 
was to diagnose ‘arsenicosis’ and is coupled with drinking water at >50 μg L-1 and levels < 
50 μg L-1 have been found to be relevant in disease pathogenesis. Urine arsenic levels can 
also be presented as µg g-1 creatinine but this is controversial as arsenic exposure itself can 
increase creatinine clearance (Gamble and Liu, 2005) (Basu et al., 2011). The arsenic level 
                                                          
10 http://www.who.int/water_sanitation_health/dwq/chemicals/arsenic.pdf  
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in nails and hair gives an indication of exposure over the last 6 months; however removal of 
external contamination from water and soil is an issue and this measure correlates less well 
with primary water supply (Concha et al., 2006).  
1.3.6 Health effects of arsenic  
1.3.6.1 Exposure pathways 
Arsenic can enter the body in 3 ways – respiratory, dermal and by ingestion.  As mentioned 
in Section 1.3.5 respiratory exposure tends to be from industrial emissions or domestic fuel 
but can also be from aerial pesticide spraying, cigarette smoking and painted wallpaper 
(Ravenscroft et al., 2009).  The dermal exposure pathway is through washing, bathing, 
swimming and working in arsenic contaminated water bodies (Lowney et al., 2005) as well 
as from non–aerial pesticide application, water effluents and phosphate detergents.  
Although inorganic arsenic can be readily absorbed in the gastrointestinal tract from food 
and water, dissolved arsenic is absorbed more easily.  Therefore a weight per gram of food 
is less toxic than the same weight in water (Ravenscroft et al., 2009).  However, in the rice 
eating communities of the Indian subcontinent the contribution of locally grown rice to 
arsenic exposure is not negligible (Williams et al., 2007b). 
1.3.6.2 Acute arsenic poisoning 
The lethal dose of arsenic for a human is 1-3 mg kg-1.  Acute poisoning causes 2 
syndromes: acute paralytic syndrome where death occurs within hours secondary to 
cardiovascular collapse and depression of the central nervous system. More common is the 
acute gastrointestinal syndrome which is characterised by violent vomiting often leading to 
rupture of organs, diarrhoea, dehydration and circulatory failure.  The progression to death 
43 
 
can be reversed by irrigation of the gastrointestinal system and chelation with dimercaprol 
(Kosnett, 2013).  
1.3.6.3 Chronic arsenic poisoning 
The levels of arsenic in well water has only rarely been reported to cause acute symptoms 
and lethality (Feinglass, 1973).  However, in well-designed prospective longitudinal studies 
in Bangladesh arsenic exposure has been shown to increase all-cause mortality (Argos et 
al., 2010; Mogi et al., 1999). A trend of increasing mortality risk with increasing arsenic 
exposure was demonstrated which was applicable to the subgroups of cancer, infection and 
cardiovascular disease related deaths (Sohel et al., 2009). 
1.3.6.3.1 Oncogenic effects 
The association between arsenic exposure and mortality from cancers of the lung, liver, 
bladder, kidney and skin has well established since 1988 (Chen et al., 1988).  The 
population of Antofagasta, Chile, demonstrates the delay in effect of arsenic exposure. For 
12 years people were exposed to high levels of arsenic which was then removed (Yuan et 
al., 2007); 20 years later the cancer mortality rates rose.  In Nepal, Vietnam, Myanmar and 
Cambodia with only a short duration of arsenic exposure it is thought that the rise in 
mortality rates is yet to come (Berg et al., 2007). 
The mechanism of carcinogenicity has been extensively studied and include 
changes at a genetic level of aneuploidy, comutagenesis and delayed mutagenesis.  Arsenic 
is thought to interact with poly(ADP ribsose) polymerase and to effect DNA repair through 
activation of p53 (Rossman and Klein, 2011). Other mechanisms of toxicity are oxidative 
stress, induction of apoptosis, chromosomal aberration, epigenetic modification, 
micronuclei formation and effects on stem cell populations (Dangleben et al., 2013). 
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Individuals who excrete a higher proportion of urinary MMA than DMA have a higher risk 
of skin cancers (Chen et al., 2003) indicating that MMA is a potent carcinogen. 
1.3.6.3.2 Dermatological effects 
The dermatological changes of hyperkeratosis, and hypo or hyperpigmentation, as an 
outward manifestation of arsenic exposure was established as early as 1984 (McDowell and 
Sacks, 1999).  The dermatological changes typical of ‘arsenicosis’ (Section 1.3.6.3.4) 
include as well as palmar plantar hyperkeratosis and abnormal pigmentation of the skin, 
pigmentation involving the undersurface of the tongue and nodular lesions, verrucous 
lesions and cracks and fissures over palms and soles (Mazumder, 2001). 
Bowen’s disease, a precancerous lesion in the top layer of skin is often present. 
These skin changes can develop into the cancerous lesions of squamous cell carcinoma and 
leucomelanoma.  There is a clear dose response between the level of arsenic in drinking 
water and the development of skin lesions as demonstrated in West Bengal in 1998 (Guha 
Mazumder et al., 1998). In Bangladesh people drinking arsenic contaminated water 
between 8.1-40 µg L-1 were 1.91 times as likely to have skin lesions than those drinking 
water <8.1 µg L-1.  This odds ratio (OR) rises to 5.39 for people drinking water between 
175-864 µg L-1.  Based on a study by a Taiwanese group, The Agency For Toxic 
Substances and Disease Registry (ATSDR), developed a minimum risk level for 
development of dermatological lesions of 0.3 µg kg-1 day-1 (Tseng et al., 1968).  It is 
thought that vascular, hepatic and neurological disease have similar thresholds. 
1.3.6.3.3 Health effects on other systems 
Arsenic exposure has been linked to many other diseases as well as cancer.  The well-
established associations are with peripheral vascular disease (‘blackfoot disease’ in Taiwan 
(Tseng et al., 1968) , cardio- and cerebro-vascular disease (Yuan et al., 2007), respiratory 
   
Diagnostic category 
 
Criteria 
1. Exposure At least 6 months exposure to arsenic levels of 
greater than 50 µg L-1 or exposure to high arsenic 
levels from food or air 
2. Dermatological Features of chronic arsenicosis: hyperkeratosis, 
hyper/hypopigmentation 
3. Non carcinomatous 
manifestations 
Weakness, chronic lung disease, non cirrhotic portal 
fibrosis of liver with/without portal hypertension, 
peripheral neuropathy, peripheral vascular disease, 
non pitting oedema of feet/hand 
4. Cancers Bowens disease, Squamous cell carcinoma, Basal 
cell carcinoma at multiple sites and unexposed 
regions  
5. Biological evidence of 
exposure 
Arsenic level in hair/ nails > 1 mg kg-1 and 1.08 mg 
kg-1 respectively and/or arsenic level in urine > 50 µg 
L-1 (with a history of no recent seafood consumption) 
A definite case is criteria 1-5, 1-4 or 2-5 if dermatological manifestations are moderate/severe.   
A probable case is criteria 1-5 or 2-5 with mild dermatological manifestations, 2-4 with 
moderate/severe manifestations or 3 & 5 or 4 & 5.     
Table 1.5  Diagnostic criteria for ‘arsenicosis’ 
Adapted from (DNG Mazumder, 2001) 
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illnesses including bronchiectasis, diabetes and peripheral neuropathy. Exposure in utero is 
thought to increase the risk of these diseases in adulthood (Smith et al., 2006).  Increasing 
levels of arsenic exposure during pregnancy increases risks of infant mortality (Rahman et 
al., 2010). In addition arsenic has also been found to adversely affect the intellectual 
function of children and mental health in all ages (Tyler and Allan, 2014).  Socially, the 
dermatological manifestations have considerable stigma and can prevent children from 
being sent to school and your women from being able to marry (Hassan et al., 2005). 
1.3.6.3.4 Arsenicosis 
Table 1.5 summarises the diagnostic criteria for the chronic disease “arsenicosis” 
(Mazumder, 2001). There is no satisfactory treatment although supplementation of diet 
with zinc, selenium and retinoic acid has been proposed.  Discontinuation of the exposure is 
the most effective treatment (Ravenscroft et al., 2009) and can lead to 
improvement/regression of skin lesions in half of cases.  However the cancer risk remains 
(Berg et al., 2007). Although chelation is effective in acute arsenic poisoning currently 
there is no indication for use of chelation therapy in chronic arsenic exposure11 (Kosnett, 
2013).   
1.3.6.3.5 Geographical variation 
There are geographical differences between the health effects of arsenic contamination 
(Ravenscroft et al., 2009).  This may be related to the differences in water chemistry, 
genetic susceptibility of populations, methylation capacity and nutritional factors. The poor 
                                                          
11 http://www.who.int/water_sanitation_health/dwq/arsenicun4.pdf 
Figure 1.18  Summary of the effect of arsenic exposure on the immune system 
Figure from (Dangleben et al 2013) 
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suffer the worst symptoms of arsenicosis12 and nutritional deficiencies have been 
demonstrated to increase the risk of skin lesions (Mitra et al., 2004). 
1.3.7 Arsenic and the immune system 
Research on the relationship between arsenic and the immune system has largely been 
driven by the oncogenic effect of arsenic.  However interest is growing on the interplay 
between arsenic and infectious diseases (Spivey, 2011). The studies of human immune cells 
extracted from arsenic-exposed subjects provide directly relevant data as there is 
controversy relating to the relevant dose conversion for in vitro and in vivo work and 
significant differences in arsenic metabolism in animal data. This is particularly relevant in 
immune studies due to arsenic’s pleiotropic effect on the immune system at different doses. 
Figure 1.18 is a summary of the overarching effects of arsenic on the immune system 
drawing on data from in vitro, in vivo and clinical research (Dangleben et al., 2013). The 
results of human studies are outlined below.  
Arsenic is progressively being shown to have immunotoxic effects (Dangleben et 
al., 2013). One study used microarrays of peripheral blood monocytes to compare 2 groups 
exposed to 0.7 µg L-1 and 32 µg L-1 in the US and demonstrated differences in T cell 
receptor signalling, increased expression of inhibitors of cytotoxic natural killer cell activity 
and decreased expression of defense response and inflammatory genes as well as MHC II 
DRB1, DQP1 and DPA1 in the exposed groups (Andrew et al., 2008). 
Further evidence of decreased expression of inflammatory cytokines was found in 
studies from Bangladesh and Mexico (Argos et al., 2006; Salgado-Bustamante et al., 2010).  
These findings were contradicted by a study from Taiwan that found a generally pro-
                                                          
12 
http://journals.lww.com/epidem/Fulltext/2005/09000/Social_Dimensions_of_Chronic_Arsenicosis_in_West.1
65.aspx# 
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inflammatory state with higher arsenic exposure; however it used blood levels as a marker 
of exposure and pooled samples (Wu et al., 2003). All these studies used small numbers 
and the contradiction in data may demonstrate responses to arsenic toxicity which change 
over time or differences in exposure assessment and study design.  
Directly measured reductions in lymphoproliferation and cytokine levels of IFNγ, 
TNFα, IL-2, IL-4, IL-5, IL-10 were found in patients from West Bengal (Biswas et al., 
2008). This contradicts a Chilean study of miners exposed to arsenic through inhalation 
(Escobar et al., 2010) where greater lymphocyte proliferation was seen in the arsenic 
exposed group. 
Immunosuppression was confirmed further from studies on peripheral blood 
monocytes (PBMCs) from exposed individuals in Eastern India which were found to have 
inhibited macrophage function including reduced nitric oxide production and phagocytic 
function (Banerjee et al., 2009). Beta defensins, antimicrobial peptides associated with 
innate immune defense found in macrophages, granulocytes and NK cells, were also found 
to be inversely correlated urinary As levels in a population in Chile (Hegedus et al., 2008) 
and maybe particularly important in the development of the chronic lung disease 
bronchiectasis.  
The effect of arsenic in children seems to follow a similar pattern. Arsenic exposed 
children in Mexico have lower levels of the major proinflammatory cytokine IL-2 and low 
CD4+ cells together with elevated GM-CSF and decreased lymphocyte proliferation but no 
change seen in IL-4, IL-10, IFNγ, to PHA, CD8+, B and NK cells (Soto-Pena et al., 2006).  
Arsenic exposure in different studies, has been shown to both increase and decrease levels 
of reactive oxygen species in children but a recent paper confirms a reduction in both the 
Photo of public health arsenic 
education from Mahudin 
Nagar, Bihar. 
Figure 1.19  Public health education picture, Samastipur, Bihar 
This picture depicts a tube well tested for arsenic - blue painted: arsenic level < 50 
µg L-1 red painted: ≥ 50 µg L-1. The translation of the Hindi text is “Water fit for 
drinking and cooking/water not fit for drinking and cooking. P.H.D. Samastipur”.   
P.H.D. = public health department. Photo: author’s own. 
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inflammatory cytokines Tumour necrosis factor-α (TNF-α) and IL-2 (Ahmed et al., 2014). 
The exposure of the foetus to arsenic, as it readily crossed the placenta, has an important 
effect on the infant immune system as it is associated with an increased risk of lower 
respiratory tract infections (69%) and diarrhoea by (20%) in infancy (Rahman et al., 2011). 
There are few direct studies of arsenic’s effect on outcome of infectious diseases in 
humans although the above studies point towards a compromised response to pathogens.  A 
Chilean study reported an increased risk of tuberculosis 20 years post high level exposure 
(Smith et al., 2011).  Animal studies have reported delayed clearance of Influenza A (Kozul 
et al., 2009) and Staphylococcus aureus (Bishayi and Sengupta, 2003) but a faster clearance 
of Giardia muris (Escudero-Lourdes et al., 2005). These contradictory results may be 
related to dose or the type of organism.  Further work is required. 
1.3.8 Mitigation of arsenic exposure 
There is not a simple or easy strategy for arsenic mitigation of a water supply for a 
community.  There are 3 main approaches that have been employed: treatment of the 
contaminated water, development of a surface water supply or sinking of an alternative well 
either deeper or in another location.  Educating the users of a well by testing the water and 
painting the result on the well: red for unsafe and blue for safe (Figure 1.19), is the most 
effective method so far with a third of villagers switching their wells (Ahmed et al., 2006).  
1.3.8.1 Treatment of contaminated water 
The methods of arsenic removal are many and varied and tend to work better for AsV. They 
include oxidation and filtration using membranes or sand, lime softening, adsorption onto 
metal oxides, ion exchange resins and phytofiltration (Ravenscroft et al., 2009). These 
systems require community acceptance, safe removal of toxic waste and regular 
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maintenance and funding.  These are prevalent issues in many villages in Bihar leading to 
defunct systems as discovered by a recent survey conducted by 2 Dutch students for their 
Masters’ degree from Delft University (Brouns et al., 2013).  
It is also possible to try and treat the aquifer itself by cyclically injecting oxidised 
water or compressed air into reducing aquifers (Brunsting and McBean, 2014). Another 
option is performing an aquifer ‘clean-up’ where the finite amount of arsenic is extracted 
from the aquifer.  This latter technique risks drawing down arsenic from other sources 
(Ravenscroft et al., 2009). 
1.3.8.2 Use of surface water 
The use of treated surface water and the return to conventional dug wells has been strongly 
supported in Bangladesh’s National Policy for Arsenic Mitigation13 and by arsenic trace 
analytical specialists (personal communication Dipankar Chakraborti and Joerg Feldmann).  
Unfortunately, the control of human pathogenic bacteria remains a serious issue and 
contamination has still been found in the use of modified traditional dug wells despite 
attempts to control this (Hira-Smith et al., 2007).   
1.3.8.3 Accessing groundwater at a deeper level 
The digging of deeper wells is positively viewed and has the advantage of low maintenance 
and no waste production (Ahmed et al., 2006).  In forty six wells >150 m deep, from across 
the arsenic-polluted area of south-central Bangladesh, groundwater composition remained 
unchanged between 1998 and 2011 (Ravenscroft et al., 2013).  The disadvantage of this 
approach has the unknown factor of what risks extensive use of deeper aquifers will bring. 
                                                          
13 http://www.dphe.gov.bd/pdf/National-Policy-for-Arsenic-Mitigation-2004.pdf 
Figure 1.20  Distribution of water sources in low – income countries 
Source: Drinking water.  Equity, safety and sustainability. UNICEF, WHO 2011. 
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1.3.8.4 Support for arsenic mitigation 
Multiple non-governmental organisations are involved in arsenic mitigation with the 
disadvantage of uncoordinated activity and inconsistent cover and funding as alluded to in 
Bihar in Section 1.3.8.  Consequently, UNICEF and the WHO have taken the approach of 
supporting the public health and education departments in affected countries in health and 
sanitation education and installation of appropriate community treatment plants and other 
mitigation strategies14.  The Indian Bureau of National Standards still has a limit15 of 50 µg 
L-1 arsenic but is receiving pressure from UNICEF and WHO for this to be reduced in line 
with the WHO limit of 10 µg L-1. The ultimate solution of piped water for everyone is part 
of their long term goal though would require enormous resources for installation (Figure 
1.20) and maintenance in these rural areas. 
1.3.9 Resistance to arsenic in microorganisms 
Resistance selection of microorganisms to environmental arsenic has been well studied. 
From an evolutionary perspective AsIII transporters were present in micro-organisms first 
due to exposure to AsIII and the arsenic reductases appeared when the environment became 
oxidising 3.8 billion years ago well before eukaryotes 850 Mya.  This is a good 400 million 
years before the kinetoplastids. The mechanism of arsenic resistance developed was 
through the ARS operon which exists in 3 parts, ArsC, an arsenate reductase produces AsIII 
which reacts with ArsB to activate ArsA which is a soluble ATPase subunit that effluxes 
AsIII from the cell (Mukhopadhyay et al., 2002).  Loss of the ArsC leads to sensitivity to 
arsenate in Escherichia Coli (Mukhopadhyay et al., 2002). The only identified eukaryotic 
arsenic reductase is the yeast Arc2p which is the enzyme which led to the identification of 
                                                          
14 JMP Thematic Report on Drinking Water 2011 
http://www.wssinfo.org/fileadmin/user_upload/resources/report_wash_low.pdf 
15 http://bis.org.in/sf/fad/FAD25(2047)C.pdf 
1 
Figure 1.21  District distribution of arsenic contamination, VL endemicity and 
antimonial resistance in Bihar 
Figure from (Perry et al 2011). 
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LmACR2 (Zhou et al., 2004). It is paradoxical that the function of reductases that evolved 
to protect against arsenate, which has its own unique toxicity in interference with cellular 
respiration as a phosphate analogue, maybe responsible for the activation of SbV to the 
toxic SbIII and hypothetically without which cells are resistant to SbV. 
 
1.4 Hypothesis 
This study aims to explore a hypothesis that draws together arsenic, antimony and 
Leishmania. We propose that arsenic contamination of drinking water may have 
contributed to antimonial treatment failure.  
The Indian sub-continent is the only place world-wide where arsenic contamination 
and VL co-exist and it is the area where the highest rates of antimonial treatment failure are 
found. Of note, antimonial contamination of the ground water is not thought to be an issue 
in this region (McCarty et al., 2004).  In the map of Bihar in Figure 1.21 information on VL 
endemicity, antimonial treatment failure and arsenic contamination has been collated. Even 
in the context of under-reporting of VL and its treatment outcomes and the absence of a 
state-wide arsenic survey there are 10 districts where antimonial treatment failure in VL 
and arsenic contamination co-exist (Perry et al., 2011). There is minimal reported arsenic 
contamination in the north of Bihar yet resistance is present at high levels (Sundar et al., 
2000).  Resistant strains may have disseminated through their stability and established 
increased fitness compared to sensitive strains. Worker migration (Deshingkar et al., 2006) 
is also common between the south and the north. In Bangladesh where minimal antimonial 
resistance has been reported, arsenic contamination is found in the south and VL in the 
north. 
4 Exposu
re to arsenic
 in 
drinkin
g water 
Le
ish
m
an
ia
 
infectio
n & 
selectio
n for 
resista
nce to As 
Antimo
nial 
treatm
ent failure
 
1 
3 
2 
Propag
ation o
f 
antimo
ny resi
stance 
Norma
l 
Arsenic
 expose
d 
Arsenic
 expose
d with 
VL 
Sb resi
stant V
L 
Fi
gu
re
 1
.2
2 
 A
rs
en
ic
 h
yp
ot
he
si
s o
f a
nt
im
on
y 
re
si
st
an
ce
 in
 v
is
ce
ra
l l
ei
sh
m
an
ia
si
s 
St
ep
 1
: d
rin
ki
ng
 o
f 
ar
se
ni
c 
co
nt
am
in
at
ed
 w
at
er
 le
ad
s 
to
 a
n 
ac
cu
m
ul
at
io
n 
of
 a
rs
en
ic
 in
 s
ki
n,
 h
ai
r, 
na
ils
 a
nd
 li
ve
r. 
 S
te
p 
2:
 u
po
n 
in
fe
ct
io
n 
w
ith
 
Le
is
hm
an
ia
 t
he
 p
ar
as
ite
 i
s 
ex
po
se
d 
to
 a
rs
en
ic
 w
ith
in
 t
he
 l
iv
er
 a
nd
 d
ev
el
op
s 
re
si
st
an
ce
 m
ec
ha
ni
sm
s 
(S
ec
tio
n 
1.
2.
4)
. S
te
p 
3:
 t
he
se
 r
es
is
ta
nc
e 
m
ec
ha
ni
sm
s 
ar
e 
th
en
 e
ff
ec
tiv
e 
ag
ai
ns
t a
nt
im
on
ia
l t
re
at
m
en
t w
he
n 
ad
m
in
is
te
re
d.
  S
te
p 
4:
 a
nt
im
on
ia
l r
es
is
ta
nt
 p
ar
as
ite
s 
ha
ve
 a
 fi
tn
es
s 
ad
va
nt
ag
e 
an
d 
ar
e 
pr
ef
er
en
tia
lly
 tr
an
sm
itt
ed
 le
ad
in
g 
to
 a
 p
ro
pa
ga
tio
n 
of
 re
si
st
an
ce
 th
ro
ug
ho
ut
 th
e 
po
pu
la
tio
n 
(V
an
ae
rs
ch
ot
 e
t a
l, 
20
10
) a
nd
 (V
an
ae
rs
ch
ot
 e
t 
al
, 2
01
1)
 
52 
 
As noted in Section 1.2.5 exposure of Leishmania parasites to arsenic in vitro leads 
to cross resistance to antimonial species.  The metabolism of arsenic within the human 
body (Section 1.3.2) is such that there is accumulation in the liver over time at levels up to 
6 mg kg-1 dry weight (Mazumder, 2005).  Levels of arsenic in the other organs that 
Leishmania resides in (spleen and bone marrow) have not been established in humans 
though high splenic accumulation has been described in the offspring of orally exposed 
Wistar rats (Zhang et al., 1998). 
If arsenic was freely available in the liver and other organs it is possible that high 
levels of arsenic exposure could be partially protective against established infection with 
Leishmania.  What is more likely is that the exposure to arsenic that the Leishmania 
parasite would experience within a chronically arsenic exposed person is sub-lethal.  
Although accumulation of arsenic within macrophages has not been directly established it 
can be assumed that this occurs as antimony accumulates well in macrophages and both 
AsIII and SbIII are taken up by AQP9 in undifferentiated human leukaemia cells 
(Bhattacharjee et al., 2004). 
Our hypothesis is that arsenic exposure would allow the parasite to develop 
mechanisms of resistance over the clinical incubation period of weeks to months.  These 
mechanisms of resistance would be effective against antimonial treatment leading to 
treatment failure (Figure 1.22). 
Development of arsenical resistance through sub-acute exposure is a process that is 
well researched in micro-organisms (Mukhopadhyay et al., 2002).  This hypothesis also has 
parallels with the administration of chloroquine-treated salt to the populations of South 
America, South East Asia and Africa that is thought to have contributed to the development 
of chloroquine resistance (Payne, 1988). 
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It is worth noting that Leishmania, antimonial treatment and arsenic exposure have 
significant effects on the immune system (Section 1.1.5, 1.2.4.4, 1.3.7).  Perturbation of 
immune function, as well as biochemical causes, may also contribute to treatment failure of 
VL with antimonial compounds in arsenic exposed areas. 
1.5 Aims of project 
This overall of this project is to investigate the relationship between arsenic, antimony and 
Leishmania. 
The specific aims are to: 
• Investigate the development of resistance in Leishmania to antimonials through 
different methods of exposure in vitro to the metalloids arsenic and antimony 
• Develop an environmentally relevant model of arsenic exposure in BALB/c mice 
• Establish proof of concept in the laboratory of the hypothesis that arsenic 
contamination of drinking water could induce antimonial resistance in Leishmania 
using an in vivo model 
• Evaluate, through a field study, whether arsenic exposure is related to antimonial 
treatment failure in Bihar, India. 
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Chapter 2 - 
Materials and methods 
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Section A: laboratory work 
2.1 Material 
All chemicals were from Sigma Aldrich unless otherwise stated. The highest grade and 
purity of reagents and chemicals that are available were used in this work. The solids of 
Sb
V
 as sodium stibogluconate, free of m-chlorocresol was a kind gift from 
GlaxoSmithKline, Sb
III
 was used as potassium antimony tartrate and As
III
 as sodium meta 
arsenite.  Concentrations of antimony compounds are traditionally quoted in μg ml-1 using 
the absolute amount of Sb content within the compound.  However throughout, for ease of 
presentation with arsenic and other compounds, results will be presented in molar form 
with μg ml-1 in brackets. MMAIII and DMAIII were synthesised by Dr. Andrea Raab at 
Aberdeen University. 
 
2.2 Animals and animal ethics 
Golden Syrian Hamsters, BALB/c and C3H mice were commercially acquired from Harlan. 
All animal experiments were performed in compliance with the Animals (Scientific 
procedures) Act 1986 (UK Home Office Project License PPL 60/4039) in accordance with 
the European Communities Council Directive (86/609/EEC) and approved by the Ethical 
Review Committee at the University of Dundee. 
 
  
* Foetal Bovine Serum ( GE Healthcare) 
All media adjusted to neutral pH except LdBob axenic amastigote media 
pH 5.66 at 22°C (pH 5.5 at 37°C). 
Media Cell type FBS*, 
% 
Composition 
LdBob M199 
media 
promastigote 10  M199 ( Caisson Labs) 
25 mM HEPES 
12 mM NaHCO3 
1 mM glutamine/1x GlutaMAX 
1x RPMI 1640 vitamin mix 
10 μM folic acid 
100 μM adenosine 
150 μg ml-1 haemin 
LdBob axenic 
media 
amastigote 20  15 mM KCl 
136 mM KH2PO4 
10 mM K2HPO4.3H20 
0.5mM MgSO4.7H20 
24 mM NaHCO3 
22 mM glucose 
1 mM glutamine/1x GlutaMAX 
1 x RPMI 1640 vitamin mix 
10 μM folic acid 
100 μM adenosine 
1x RPMI amino acid mix 
5 μg ml-1 haemin 
0.0005% phenol red 
25 mM MES 
M199 media promastigote 10 % M199 (Caisson Labs) 
4 mM  HEPES 
100 μM adenosine 
50 μg ml-1 haemin 
Grace’s Media promastigote 10% 200 μg ml-1 haemin 
Supplemented 
RPMI 
promastigote 20 % RPMI 1640 (R0883) 
20 mM HEPES  
100 μM adenine 
3.26 μg ml-1 haemin 
3 μM dihydrobiopterin 
1 % penicillin/streptomycin 
1 mM glutamine/1x GlutaMAX 
DMEM ex vivo 
amastigote 
10 % Dulbecco’s Modified Eagle’s 
Medium (Bio Whittaker) 
RPMI macrophage 20% RPMI 1640 (R0883) 
   
Table 2.1 Composition of different media  
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2.3 Leishmania cell culture 
Media used for culturing cells was filter-sterilised using filtering units with a 0.22 μm PES 
(polyethersulfone) membrane (Nalgene or Steriflip). All Leishmania cultures were 
routinely grown, with or without shaking at 200 rpm, over 72 h to a density of 2 -3 x 107 
ml-1 which represented stationary phase and then passaged into fresh medium at a density 
of 5 x 105 ml-1.  
 
2.3.1 L. donovani 1S2D (LdBob) 
A clonal line of L. donovani 1S2D (WHO designation: MHOM/SD/62/1S-CL2D), also 
known as LdBob (Goyard et al., 2003), was used in this study. LdBob has the ability to 
differentiate readily between promastigotes and axenic amastigotes.  In the promastigote 
stage parasites were grown in LdBob M199 medium (Table 2.1) and incubated at 28 °C.  
For differentiation to axenic amastigotes, stationary phase promastigotes were passaged 
into LdBob amastigote medium (Table 2.1) at pH 5.5 and grown at 37 °C with 5% CO2.  
Parasites were maintained for at least 2 passages in the appropriate medium prior to 
commencement of any experiment. For routine culture, parasites were cycled between 
developmental stages every 4-5 passages. 
  
2.3.2 LV9 
L. donovani promastigotes LV9 strain (WHO designation MHOM/ET/67/HU3) were 
cultured by serial passage in supplemented Grace’s Insect Medium (BioWhittaker) at 28 
°C. Amastigotes of L. donovani LV9 were freshly isolated from the spleen of infected 
Golden hamsters, as previously described (Wyllie and Fairlamb, 2006b). Briefly, infected 
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spleen were homogenised and washed in Dulbecco’s Modified Eagle’s Medium 
(BioWhittaker) supplemented with 10% FCS (v/v) (2600 g, RT, 6 min) (Glaser et al., 
1990). Red cells were lysed using saponin 0.1% (w/v) and 2 further washes performed prior 
to passage through a 23G needle and numeration as in section 2.3.3.  These ex vivo 
amastigotes were used directly for experimentation or serially passaged through BALB/c 
mice by intraperitoneal (i.p.) injection of 0.2 ml of 1 × 107 amastigotes harvested from 
freshly prepared splenic homogenate every 1-2 months. 
For differentiation of ex vivo amastigotes to promastigotes, an aliquot of the ex vivo 
amastigote preparation was placed in either supplemented Grace’s Insect Medium as above 
or in 20 % FCS RPMI media (Table 2.1).  
 
2.3.3 Cell density measurements 
Leishmania were fixed in 2 % formaldehyde with a dilution of 1 in 10 prior to being 
counted manually using a Neubauer haemocytometer chamber under a light microscope 
(Zeiss).  Alternatively, cell size and number were determined using a CASY® cell counter 
according to manufacturer’s guidelines (Model TT Sharfe). Macrophages were enumerated 
using the same methods only without fixing and dilution. 
 
2.3.4 Cloning 
Parasites were cloned by limiting dilution. Following determination of cell density, the cell 
suspension of the relevant line was diluted to 1.5 cells ml -1 and dispersed as 200 μl aliquots 
in 96 well plates to obtain the equivalent of one parasite every 3 wells. Following a 7 -10 
days incubation viable parasites were available for transfer to culture flasks in up to a third 
of the wells. 
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2.4 Macrophage cell culture 
THP-1 cells (ECACC) were grown in RPMI-1640 medium (Invitrogen) (Table 2.1) and 
maintained between the concentrations of 3-8 (x 10
5
) cells ml-1 at 37°C with 5% CO2.  
Differentiation of THP-1 monocytes to macrophages was achieved by adding 10 nM 
phorbol 12-myristate 13-acetate (PMA) (Park et al., 2007) to cultures for 24-48 h.  
For mouse derived macrophages BALB/c mice were prestimulated with an 
intraperitoneal injection of 2% soluble starch (w/v).  Peritoneal macrophages were 
harvested at least 24 h later using peritoneal lavage with ice cold phosphate buffered saline 
with 5 mM EDTA. Harvested cells were then centrifuged at 350 x g for 10 min at 4 °C and 
the resulting pellet was incubated with 1 ml of Red Cell Lysis buffer (Sigma, 8.3 g L-1 
ammonium chloride in 0.01 M Tris-HCl buffer, pH 7.4 ) for 1-2 min.  This solution was 
diluted with RPMI macrophage medium (Table 2.1) and two further washes with RPMI at 
(350g, 5 min, 4 °C) 2 were carried out.   
2.5 Growth inhibition studies (EC50) 
The EC50 of a compound is the effective concentration at which cell growth is inhibited by 
50%. In 96 well plates (TPP/Greiner) fresh media, containing varying concentrations of the 
compound to be tested, were incubated with Leishmania, from a stock culture of cells at log 
phase (1 x 107 cells ml-1), at a final concentration of 1 x 105 cell ml-1, as previously 
described (Jones et al., 2010; Shimony and Jaffe, 2008). The cells were incubated in the 
presence of the drug for 72 h and following a 3 h incubation with resazurin at a final 
concentration of 5 μM, the plates were read for the formation of resorufin, using a 
fluorescent microplate reader at λexcitation = 528 nm and λemission = 590 nm.   
Data were corrected for background fluorescence and expressed as a percentage of non- 
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treated cells. EC50 values were determined using the EC50 3 parameter equation provided 
with the computer programme GraFit: 
s
x
Rangey






+
=
50IC
1
 
where y is the percentage growth at inhibitor concentration ‘ x ’ and ‘s’ is the slope factor.  
EC10 can be calculated from the same equation. Measurements were repeated in triplicate 
(unless otherwise stated) and data presented as weighted mean ± weighted standard error of 
the mean where ‘a’, ‘b’ and ‘c’ are the errors of the mean values of ‘A’, ‘B’, ‘C’….’H’ 
respectively. 
 
 
If parasite growth in a 96 well plate was sub optimal then the cells were incubated with 
drug in 25 cm2 culture flasks (Cell star) for 72 h and 200 µl aliquots incubated in triplicate 
in a 96 well plate with resazurin as above. The same method was used for the determination 
of macrophage EC50 values using a starting concentration of macrophages of 2.5 x 10
5.  
2.6 Selection of drug-resistant axenic amastigote cell lines  
Wild type LdBob axenic amastigotes were cloned by limiting dilution (Section 2.3.3). Four 
of the resulting clones were tested for their sensitivity to trivalent arsenic (AsIII) and 
antimony (SbIII) and LdBobSu3 was chosen as the starter clone for the selection of resistant 
lines.  Four lines were cultured in parallel with continuous exposure to AsIII, SbIII, SbV and 
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no drug, respectively. The cells were continuously passaged as axenic amastigotes 
throughout drug selection. Starting at a sublethal concentration of the relevant compound, 
approximately equal to the established EC10, the drug concentration in the culture medium 
was increased in a stepwise fashion, as previously described (Detke et al., 1989; Dey et al., 
1996).  At regular intervals, cells were cryopreserved prior to the next increase in drug 
concentration. Parasites were cultured until they were able to grow at 64 times the starting 
concentrations of AsIII and SbIII and 32 times the starting concentration of SbV.  These lines 
were then cloned in the absence of drug and tested for susceptibility to both metalloids in 
axenic amastigote form and intracellular form. 
2.7 Optimisation of in macrophage assay 
The following conditions were examined to optimise an assay for determination of the 
EC50 of amastigotes in their intra-macrophage environment (Chang and Dwyer, 1978): 
• Parasite/macrophage ratios – 40:1, 10:1, 2:1 
• Macrophage cell line – differentiated THP-1, mouse peritoneal macrophages 
• Parasite cell line – promastigote, axenic amastigote, ex vivo amastigote 
• Infection incubation time 
• Medium and serum proportion 10 vs 20% 
• Length of time course 
In the final assay harvested mouse peritoneal macrophages (Section 2.4) were plated in 
Lab-Tek glass 8 well chamber slides (VWR International, Thermo Fisher Scientific) at a 
concentration of 1 x 105 cells per well. Cells were  left to adhere in RPMI 20% medium for 
at least 2 h prior to infection with 1 x 106 cells per well of freshly harvested Leishmania ex 
Doubling dilutions 
SbV 4.1 mM 
No Drug 
8 well chamber 
slide with 
1⁰ mouse 
macrophages 
Infection 
Collection 
Multiplication Metacyclogenesis 
Promastigote 
culture 28 ⁰C 
Figure 2.1 Generation of antimonial resistant Leishmania in macrophage 
Starch elicited macrophages harvested from mouse peritoneum  were plated and 
infected with late stationary phase promastigotes.  Following infection the doubling 
dilutions of SbV were added with a top concentration of 4.1 mM. Following a 5 day 
incubation the medium was replaced with supplemented RPMI promastigote 
medium, the infected macrophages were mechanically disrupted and the amastigotes 
allowed to differentiate back into promastigotes for 7 days at 28 ⁰C.  Promastigotes 
grown from the well with the highest SbV concentration were harvested and 
expanded in culture bottles. On reaching late stationary phase the cycle was 
repeated.  Following three cycles EC50 values were determined to antimonial 
compounds in both promastigote and intracellular amastigote form. Method and 
figure adapted from (Hendrickx et al., 2012). 
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vivo amastigotes or late stationary phase promastigotes from in vitro culture. Following a 4-
h incubation, the wells were washed with Hanks’ balanced salt solution (Gibco) to remove 
any remaining non-phagocytosed parasites. Infected macrophages were incubated for 72 h 
with varying concentrations of drug in RPMI 20 %.  The slides were then fixed in ice-cold 
methanol and stained with Giemsa (BDH, VWR International) for 30 min. The number of 
infected cells and number of amastigotes per cell were determined in 100 macrophages 
using a light microscope (Zeiss Standard 20) with a 100x oil immersion lens. EC50 values 
were determined as described in section 2.5. 
 2.8 Selection of resistance in macrophage 
LV9 promastigotes were cloned by limiting dilution (Section 2.3.4). One of the resulting 
clones was split into 6 parasite lines, 3 of which were exposed as intracellular amastigotes 
to SbV up to 500 μg ml-1 in macrophage for 5 day periods interspersed with non-exposed 
promastigote cycles (Figure 2.1)(Hendrickx et al., 2012). The other 3 parasite lines were 
cycled through macrophages in the absence of drug.  Differentiation from amastigote to 
promastigote form was achieved by changing to promastigote RPMI medium, mechanical 
disruption of the infected macrophage culture and incubation at 28 °C.  After 3 
amastigote/promastigote cycles EC50 values were obtained for both promastigote and 
intracellular amastigote forms.  
2.9 Arsenic and antimony detection and quantification 
2.9.1 Indicators 
The following indicators were purchased from Invitrogen and evaluated for their ability to 
detect and differentiate between SbIII and SbV: 
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• Newport green (2 μM) 
• Phen Green (2 μM) 
• TSQ (N-(6-methoxy-8-quinolyl)-p-toluenesulfonamide) (10 μM) 
• Calcein (0.5 μM) 
• Calcium Green (0.2 μM) 
Indicators were diluted to their recommended concentrations (in brackets above) and 
incubated with 10-fold concentrations, ranging from 1 mM to 1 μM, of SbIII, SbV or a 
control compound containing ZnII (ZnCl2).  The control was TPEN. The plates were read 
on an EnVision plate reader at λexcitation = 473 nm and λemission = 520 nm. 
2.9.2 Atomic absorption spectrometry 
This method was used in the analysis of arsenic levels in samples acquired during field 
work studies from India and a full description is found in the field work methods, Section 
2.18. 
2.9.3 Inductively coupled Mass Spectrometry 
All arsenic measurements were performed in collaboration with Professor Joerg 
Feldmann’s group at the University of Aberdeen. Final sample preparation was performed 
in Aberdeen by me or Dr. Andrea Raab and analysis was performed by Dr. Andrea Raab. 
Samples (100-mg wet weight where possible) were weighed out into polypropylene 
tubes and 0.5 ml nitric acid was added and left to incubate overnight. One hundred 
microliters of H2O2 was then added and the samples were digested using microwave 
heating (temperature program: to 55 °C for 10 min,  75 °C  for 10 min then 90 °C  for 30 
min) (Williams et al., 2007b). The samples were then diluted to 5 ml with double distilled 
water.  For water samples, no digestion or dilution was performed. 
63 
 
An Agilent 7500c (Agilent Technologies, Tokyo, Japan) ICP–MS with a Meinhard 
nebulizer was used to measure the elements As (m/z 75) and Sb (m/z 121). Each sample 
was measured in triplicate and expressed as mg (kg wet weight)-1. The average limit of 
detection was 0.2 μg As (kg wet weight)-1. Arsenic values measured in certified reference 
material (Seronorm Trace Elements Urine; Seronorm) were 197 ± 5 μg  L-1 of As (n = 3, 
certified value 184 ± 17 μg L-1 of As), and those measured in TORT-216 were 20 ± 0.4 mg 
(kg dry weight)-1 of As (certified 21.6 ± 1.8 mg (kg dry weight)-1of As. 
To determine the conversion factor from wet weight to dry weight, livers and 
spleens of 3 BALB/c mice were harvested, weighed and then freeze dried (Micro Modulyo, 
Thermo Savant) for 48 h.  The dried organs were then weighed and the ratio of wet to dry 
weight was calculated with standard deviation. 
2.10 Arsenic exposure in BALB/c mice 
An arsenic exposure model was designed to recreate two environmentally relevant 
situations reported from the Indian sub-continent within our mouse model. An established 
dose-equivalent equation based on body surface area was used to equate arsenic exposure 
in humans to mice (Reagan-Shaw et al., 2008): 
 
human equivalent dose (mg kg-1) = animal dose (mg kg-1) x (animal Km/human Km) 
 
where Km is weight/body surface area of the relevant mammal (mouse Km = 3, human adult 
Km = 37).  A 60-kg man drinking 3 L day
-1
 (Watanabe et al., 2004) of water contaminated 
                                                          
16 Lobster Hepatopancreas; National Research Council Canada; http://archive. nrc-cnrc.gc.ca/obj/inms-
ienm/doc/crm-mrc/eng/TORT-2_e.pdf) 
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with arsenic at 1,200 μg L
-1
 is equivalent to the intake of BALB/c mice drinking water 
containing AsIII at 10,000 μg L
-1 (hereafter 10 ppm is equivalent to 133 μM). This 
concentration has been reported in arsenic-contaminated tube wells in Bihar (Chakraborti et 
al., 2003). Levels of up to 6 mg kg-1 (dry weight) have been reported from liver biopsies in 
patients exposed to 220 to 2000 μg L
-1
 arsenic for 1 to 20 years (Mazumder, 2005). 
Although the higher level of 100,000 μg L
-1
 (hereafter 100 ppm, equivalent to 1.33 mM) is 
equivalent to concentrations greater than those reported from Bihar this concentration was 
chosen to recreate these elevated hepatic arsenic levels over months rather than years. 
Six to ten week old BALB/c mice were divided into three separate groups that received 
either normal tap water (hereafter 0 ppm), AsIII at 10 ppm (10 mg L
-1
), or AsIII at 100 ppm 
(100 mg L
-1
). Fresh water was given to all groups once or twice a week, water intake was 
measured, and the weights of the animals were measured weekly. All mice were fed a 
standard autoclavable murine chow pellets (RM1 A, Special Diets Services). 
Three mice from each exposure level were euthanized at days 7, 14, 28 and 56. 
Harvested liver and kidney were placed in pre-weighed CK14 tubes containing ceramic 
beads with 500 μl double-distilled water. Harvested spleen was placed in pre-weighed 
MK28R tubes containing metal beads with 500 μl double-distilled water. Both types of 
tubes were supplied by PeqlabBiotechnologie GmbH.  The samples were homogenized at 2 
× 5,000 rpm for 10 s with a 20 s gap, using a PreCelleys 24 homogenizer (Bertin 
Technologies). Harvested bone was crushed with a pestle and mortar before mechanical 
homogenization, in pre-weighed MK28R tubes with 500 μl double-distilled water, at 2 × 
5,900 rpm for 30 s with a 15 s gap. Separation of blood cells and sera was achieved by 
centrifugation at 15,000 × g for 90 s. Murine chow was also included for digestion and 
analysis. 
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2.11 Arsenic and macrophages 
Peritoneal macrophages from mice exposed to arsenic at 0, 10 and 100 ppm for 28 or 56 
days were harvested following pre-stimulation with 2% (w/v) starch as in section 2.4.  The 
sensitivity of the resulting macrophages to AsIII and SbIII was determined using the 
resazurin assay (Section 2.5). The exposed macrophages were also assessed for their ability 
to kill intracellular amastigotes in the in-macrophage assay described above.  Further 
exposed macrophages were pelleted and freeze dried and analysed for arsenic content with 
ICP-MS as described in 2.8.3. 
Peritoneal macrophages from BALB/c mice and differentiated THP-1 cells were 
incubated with 0, 1, 2, 4 and 8 μM As
III
 for 72 h.  They were then removed by treatment 
with lidocaine HCl (4 mg ml-1) plus 5 mM EDTA using a cell scraper, then pelleted by 
centrifugation, snap frozen and freeze dried (Micro Modulyo, Thermo Savant) for 24 h 
before preparation for ICP-MS, as above. 
2.12 In vivo selection of Sb V resistant line 
Six to ten week old BALB/c mice were exposed to As
III 
at 0, 10, or 100 ppm in their 
drinking water for 1 month prior to infection by i.p. injection of 0.2 ml of 1 × 107 L. 
donovani ex vivo splenic amastigotes from BALB/c mice, as described (Section 2.3.2). At 
28 days post-infection, the mice were euthanized, hepatic and splenic imprints taken, fixed 
in methanol, stained with Giemsa and parasites quantified, as described below. The spleens 
of each group were prepared separately for harvest of ex vivo amastigotes. These 
amastigotes were used in the in-macrophage assay (Section 2.7), for assessment of their 
5th 
passage 
3rd 
passage 
Infect groups of AsIII pre-exposed 
mice at 0, 10 and 100 ppm 
respectively 
Infect BALB/c mice with LV9 
amastigotes derived from 
hamster spleen 
8 passages 
 (12 months) 
Determine in 
vivo 
response to 
SbV 
Determine 
amastigote 
sensitivity in 
macrophages 
7th 
passage 
3 passages and 
AsIII (3 months) 
2 passages and 
AsIII 
(2 months) 
2 passages without AsIII 
(4 months) 
Figure 2.2 Experimental flow diagram of generation of antimonial resistant 
Leishmania in vivo through oral exposure to AsIII 
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sensitivity to Sb V and to reinfect further arsenic pre-exposed groups of mice. See Figure 
2.2 for an experimental flow diagram. Leishmania-infected liver and spleen were also 
prepared and analyzed for arsenic content by ICP-MS, as above.  After the fifth passage, ex 
vivo amastigotes were used to infect groups of non-arsenic exposed mice to assess stability 
of resistance. Following 4 months of passaging in BALB/c mice, these parasites were 
reassessed for their sensitivity to Sb V in vitro. 
2.13 In vivo assessment of SbV resistance  
At the end of the fifth passage in vivo sensitivity to Sb V and miltefosine was assessed: at 28 
days post-infection, groups of mice from each exposure level were treated with Sb V (50 mg 
kg
−1
, subcutaneous (s.c.)), miltefosine (12 mg kg
−1
, orally) or with drug vehicle only (sterile 
water, s.c. injection), once a day for 5 d. Drug dosing solutions were prepared on the day of 
administration and were not reused. Seventy two hours after the final treatment, on day 35 
post infection, all animals were euthanized, hepatic and splenic imprints were taken, fixed 
and stained and parasite burdens were determined by blinded counting. The total number of 
parasites per liver was calculated by multiplying the parasites per organ cell nucleus by 2 × 
10
5 
by the weight of the liver in mg (Stauber, 1958).  The unpaired student t test was used 
to compare the differences in response to Sb V and miltefosine between arsenic exposure 
groups and control. Samples of the liver and spleens from all animals were prepared for 
analysis for both arsenic and antimony by ICP-MS. 
 
67 
 
2.14 Analysis of resistant lines in vitro 
2.14.1 Extraction of genomic DNA from L. donovani 
Twenty five ml of the relevant L. donovani cell line was cultured in a 75 cm2 flask to 1 x 
107 cells ml-1. These cells were then centrifuged at 2600 g, 10 min, room temperature prior 
to incubation overnight at 56 °C in 450 μl TENS buffer (10 mM Tris-HCl, pH 8.0, 25 mM 
EDTA, 100 mM NaCl, 0.5% (w/v) SDS) with 0.1 mg ml-1 proteinase K.  Tris-buffered 
phenol/chloroform/isoamyl alcohol (PCI, 25:24:1) at pH 8.0 was used to extract DNA 
which was separated by centrifugation at 16,000 x g for 1 min at RT. The upper aqueous 
phase was carefully removed and used for further extraction with PCI and then CI (24:1) 
with the lower organic phase being discarded at each step.  The extracted DNA was then 
precipitated using molecular grade 100% ethanol and washed twice in 70% ethanol to 
remove any inorganic contaminants.  The DNA was then air dried and resuspended in 10 
mM Tris- HCl (Qiagen), pH 8.5 and stored at 4 °C. 
 
2.14.2 Scanning Electron Microscopy (SEM) 
Glutaraldehyde was added directly to culture medium in a dropwise fashion to a final 
concentration of 2.5% (v/v) and fixed for at least 24 h at 4 °C.  Subsequent preparation for 
EM was carried out by Mr. Martin Kierans, College of Life Sciences, Dundee. Cells were 
collected on Whatman nucleopore membranes and washed with 0.2M PIPES buffer (2 x 15 
min) at pH 7.2.  The membranes were then incubated for 16- 18 h in 0.2% aqueous osmium 
tetroxide and washed with distilled water (2 x 15 min) prior to dehydration through a 
graded ethanol series.  Critical point drying was performed using a BAL-TEC CPD 030.  
Aluminium stubs with carbon adhesive tabs were used to mount membranes which were 
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then coated with Au/Pd using a Cressington 208 HR sputter coater.  A Philips XL 30 
ESEM or a Hitachi S- 4700 SEM operating at an accelerating voltage of 15kV was used by 
Martin Kierans and me to examine the samples.  
2.14.3 Western blotting 
Whole cell protein lysates were prepared from cell culture by centrifugation, re-suspended 
in Laemmli buffer (Biorad) containing 0.5% (v/v) 2-mercaptoethanol and boiled for 10 min 
prior to separation by SDS PAGE gel against a SeeBlue® Plus2 marker 
(LifeTechnologies).  Towbin transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) 
methanol: Towbin et al 1979) was used to equilibrate unstained SDS-PAGE gels. Gels 
were either stained using the Coomassie stain (40% (v/v) methanol, 10 % acetic acid and 
0.1 % (w/v) Coomassie Brilliant Blue R250) and destaining solution (20% v/v methanol 
and 10 % acetic acid) or proteins were transferred onto Protan™ nitrocellulose membrane 
(Whatman) for 25 min using Trans-blot ® SD semi-dry electrophoretic transfer cell (Bio-
Rad) at 25 V. Membranes were incubated for at least 1 h with 5% (w/v) dry milk in PBS 
containing 0.5% (v/v) Tween ® 20 to block non-specific binding sites. Following this blots 
were incubated for 2 sequential 1 h periods with primary and then secondary horseradish 
peroxidase (HRP)-conjugated antibodies in PBS containing 1% (w/v) dry milk and 0.5% 
(v/v) Tween ® 20, with an intermediate washing step (3 x 10 min) in antibody dilution 
buffer.  Membranes were then washed (3 x 10 min) in buffer without milk and incubated 
with Amersham ECL™ detection reagent prior to exposure to Hyperfilm ECL™ (GE 
Healthcare). 
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2.14.4 Thiol analysis 
From late log phase culture, triplicate samples of 5 x107 cells from each Leishmania cell 
line, were centrifuged at 3500 rpm for 10 min at 4 °C, washed in ice cold PBS and spun 
down briefly in an Eppendorf bench top microfuge at 4500g for 3 min.  The supernatant 
was carefully aspirated and 50 μl of HEPPS buffer (40 mM HEPPS, 4 mM 
diethylenetriaminepentaacetic acid, pH 8) added followed by 50 μl of 2 mM 
monobromobimane and the pellet was resuspended. The sample was then heated for 3 min 
at 70 °C, cooled briefly on ice prior to the addition of  100 μl of 4 M methanesulphonic acid 
(pH 1.6) (Shim and Fairlamb, 1988).  Following a further 30-min cooling period on ice the 
samples were centrifuged (14,000 rpm, 10 min) and the supernatant collected and stored at 
-20 °C prior to analysis. Acid-soluble thiols were separated by ion-paired, reverse phase 
HPLC on an ion paired Ultrasphere C18 column using a Dionex Ultimate 3000 instrument 
fitted with a Dionex RF-2000 fluorometer. 
Section B: Field work 
2.15 Ethics 
Ethical clearance was obtained from Banaras Hindu University in Varanasi, the Kala Azar 
Medical Research Center (KAMRC) in Muzaffarpur, India and the University of Dundee, 
Scotland. Individual written consent was obtained from each patient (or their guardian) 
included in the study (Appendix A). Any person identified with symptoms of VL or post 
kala azar dermal leishmaniasis (PKDL) during the study was referred to an appropriate 
health care facility. Data from the arsenic analysis of tube well samples was referred to the 
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Public Health and Education Department, which is running the arsenic mitigation 
programme in Bihar. 
2.16 Study area 
The study took place in Mahudin Nagar block in the Samastipur district of the state of 
Bihar, India. Bihar is the third largest state in India and has the lowest literacy rate. 
Mahudin Nagar block lies just north of the River Ganges and has a mainly rural population 
of 184,521 (Census Organization of India, 2011). It is known to be endemic for VL; 
between 2006-2010, the average reported yearly incidence of VL was 7.78 per 10,000 
population (Source: District Malaria Office records, Patna, Bihar) and Samastipur district, 
in which it lies, has been mapped as an area with ‘high’ levels of resistance to SSG 
(Sundar, 2001). A survey performed by the School of Environmental Studies, Jadavpur 
University in 2005 identified over 40% of the wells surveyed in this district to have arsenic 
levels above the World Health Organization (WHO) recommended limit of 10 µg L-1 
(School of Environmental Studies, 2002). 
2.17 Study design and population 
A retrospective cohort design had to be employed because SSG treatment for VL is no 
longer recommended for routine use in Bihar (Sundar et al., 2008). We identified VL 
patients treated with SSG between 2006 and 2010 in the block of Mahudin Nagar from two 
sources. First, in January and February 2012, potential SSG treated subjects were identified 
from the VL patient register at the Primary Health Centre (PHC) in Mahudin Nagar and 
were searched for in their listed villages, at least twice, for inclusion in the study. Second, 
additional VL patients were identified in the visited villages. The patients were included in 
the study if they gave a clear history of having been treated with SSG (see below) and at 
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least one of the SSG treatments fell inside the study recruitment period (e.g. 2006 to 2010). 
Patients were excluded if they did not receive SSG treatment or if their SSG treatment was 
terminated due to unavailability of SSG. 
The study subjects were visited in their own home. A modified form of a previously 
validated questionnaire was used (Hasker et al., 2010) to gather information on age, sex, 
caste, VL symptoms, health seeking behaviour, treatment(s) and response from the time of 
first onset of VL symptoms to the time of the field study (Appendix B). Additional data 
was collected on other illnesses, prior VL in the family and water sources used (e.g. local 
tube wells). The interviews were performed by experienced field workers. If the patient was 
a minor at the time of VL, his/her guardian was interviewed and if the patient had passed 
away or was unavailable due to relocation for marriage or work, then a relative was 
interviewed instead. The household tube well and local tube wells were geo-located by the 
research team using a GPS. The household tube well coordinates were used to identify 
patients’ location (e.g. within or outside Mahudin Nagar town). 
Clinical records, either the patient’s own documents or those held at the PHC, as 
well as data gathered during the interviews were reviewed by an experienced physician to 
ascertain VL cases and treatment. In absence of treatment records, the information provided 
by patients or relatives allowed identifying the type of treatment received as the 3 main 
drugs for VL are given via different routes: (1) SSG is an intramuscular injection usually 
administered for 30 days in the lateral upper thigh or buttock area; (2) amphotericin B is 
given via an intravenous drip in the forearm or hand for either 5 days or 30 days dependent 
on formulation used and (3) miltefosine is administered for 28 days as a capsule for oral 
use. 
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Patients were classified into the following treatment outcome categories: success, 
no clinical improvement, relapse, death and toxicity taking 6-month cut off time from end 
of treatment as reference, in accordance with WHO guidance and VL clinical trial protocols 
(Sundar et al., 2000). ‘Treatment success’ was defined as patients who received SSG 
treatment and had not required another VL treatment within 6 months. ‘No clinical 
improvement’ were patients who experienced no change or a worsening of their original 
symptoms during or by the end of a full course of treatment who required a further VL 
treatment. This subgroup included patients who reported a treatment course of  60 days or 
more which is 2 times the recommended SSG treatment duration. ‘Relapse’ were patients 
who experienced a return of signs or symptoms of VL, for which they required further 
treatment, after initially having experienced a return to health following a course of 
treatment. If the outcome was ‘Death’, a verbal autopsy was carried out by the physician on 
the field team to ascertain if the subject died directly as a result of VL, (Appendix C). 
‘Toxicity’ were patients whose treatment was terminated due to untolerated side effects. 
The term ‘treatment failure’ in this study covers all adverse outcomes that occurred within 
6 months of VL treatment: no clinical improvement, relapse, death due to VL and toxicity.  
2.18 Evaluation of arsenic exposure 
2.18.1 Tube well water 
The average arsenic concentration of the patient’s main water source and 4 tube wells 
surrounding the patient’s home was taken as an indication of the level of arsenic exposure 
for the patient. This exposure variable was chosen instead of the arsenic concentration in 
the patient’s primary tube well (Sohel et al., 2009) in the context of this study as many 
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patients reported that their current primary tube well had been inserted in the years after 
their first SSG treatment for VL. 
At the time of interview samples were collected from these 5 tube wells in a 15 ml 
Falcon tube after pumping off water for two minutes. Water samples were preserved with a 
drop of concentrated nitric acid until analysis. Flow injection hydride generation – atomic 
absorption spectrometry (FI-HG-AAS) was used to quantify the total arsenic content in 
water samples at the School of Environmental Studies (SOES), Jadavpur University, 
Calcutta as described previously (Chakraborti et al., 2003). A standard sample from the 
Environmental Protection Agency was used as a reference. The lower detection limit was 3 
µg L-1 of arsenic. For quality control, 25% of the primary tube well water samples were 
selected to represent the low (n=6 (<10 µg L-1)), medium (n =15 (10-50 µg L-1)) and high 
(n=9 (>50 µg L-1)) arsenic concentrations detected. These samples were re-analysed by 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) at Aberdeen University using a 
method described previously (Williams et al., 2007b).  
2.18.2 Urine samples 
At the time of field questionnaire patients were requested to provide a sample of urine of at 
least 5 ml. Urine samples were preserved with a drop of hydrochloric acid and kept in cold 
conditions. 
Prior to analysis, the urine samples were centrifuged at 3000 rev min-1 for 10 min 
and filtered through a 0.45-µm membrane filter (Chromatodisc 25A) to remove the 
suspended particulate. The urine was then digested for total arsenic analysis: 1 ml of the 
urine sample was placed in a small Kjehldahl flask and to this was added Suprapur® acid 
(0.5 ml HNO3, 0.2 ml H2SO4 and 0.2 ml HC1O4). The sample was heated using a small 
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funnel at the top of a sand-bath until it became clear. If necessary, a 0.2 ml aliquot of 
HNO3 was subsequently added. Again the sample was heated until fumes of SO3 evolved. 
The solution was cooled and made up to a volume of 5 ml. Total arsenic in the urine 
samples, as stable urinary metabolites of arsenic, was measured using FI-HG-AAS against 
a standard reference material (SRM 2670) obtained from the National Institute of Standards 
and Technology (NIST, Gaithersburg, MD, USA). 
For quality control, 18 (26%) of the available urine samples were selected to 
represent normal (n=9; 5-40 µg L-1) and elevated (n=9; >40 µg L-1) urinary arsenic levels 
detected. These samples were re-analysed by ICP-MS at Aberdeen University as in Section 
2.18.1 (Williams et al., 2007b). 
2.19 Data management 
The average arsenic concentration in the 5 tube wells was dichotomised using the WHO 
threshold for arsenic (As) in water: >= 10 µg L-1. The three outcome variables are: (1) SSG 
treatment outcome (primary outcome) and (2) all-cause and (3) VL mortality (secondary 
outcomes). For the primary analysis, VL patients were classified based on their SSG 
treatment outcome as “treatment failure” or “treatment success” as described above. For the 
secondary mortality analyses, the study subjects were classified as “alive” or “dead” at the 
time of the field study. A sub-group identifying those that died due to VL was created 
based on the data from the verbal autopsies (see above).  
The urine arsenic exposure variable was created with a binary cut off of arsenic 
contamination for a spot urine sample above the normal range of 5-40 µg L-1 (Mandal and 
Suzuki, 2002; Ravenscroft et al., 2009). In patients for whom it had not been possible to 
obtain a biological sample, an imputed value for their urinary arsenic level was calculated, 
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using the arsenic water level variable described above, in a regression prediction model 
controlling for age, sex and geographical location.  
Data from the field interviews were double entered in a Microsoft Excel database 
independently by 2 data entry operators. The covariates included in the analyses are shown 
in Table 3.7. Briefly, age was split into 3 categories (e.g. < 5, 6-15 and > 16 years old) and 
SSG treated patients were dichotomized based on their “treatment course” using the 
duration of 30 days recommended by WHO (World Health Organization, 2010). Patients 
were classified based on their location (e.g. in or outside of Mahudin Nagar town), the 
“time to treatment” (e.g. < 12 weeks and ≥ 12 weeks in accordance with previous literature 
(Rijal et al., 2010)) and “the place of treatment” (e.g. government or private facilities). 
Finally, patients were classified into whether they had family members treated for VL with 
SSG prior to the patients’ VL episode. 
2.20 Statistical analyses 
2.20.1 Raw data 
2.20.1.1 Tube well water 
Dot plots of the log of arsenic exposure from tube well water were drawn for the outcomes 
(1) SSG treatment outcome, (2) all-cause mortality and (3) VL mortality and the median 
arsenic exposures were compared using Mann Whitney U test. Receiver Operating 
Characteristic (ROC) curves were used to evaluate the WHO cut off for arsenic in water 
(10 µg L-1) against the primary and secondary outcomes (e.g. SSG treatment, all-cause and 
VL mortality). The Kappa index was used to evaluate the agreement between the arsenic 
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levels reported by the two laboratories (SOES and Aberdeen University) that analysed the 
quality control samples.  
2.20.1.2 Urine samples 
Dot plots of the log of urinary arsenic level and Mann Whitney U tests were used to 
describe the relationship between urinary arsenic level, as a continuous variable, and SSG 
treatment outcome. Receiver Operating Characteristic (ROC) curves were used to evaluate 
the cut off for arsenic in urine (40 µg L-1) against the outcome of SSG treatment. The 
Kappa index was used to evaluate the agreement between the arsenic levels reported by the 
two laboratories (SOES and Aberdeen University) that analysed the quality control 
samples.  
2.20.2 Logistic regression 
2.20.2.1 Tube well water 
A logistic regression model was employed to assess if arsenic contamination in the local 
environment increased the risk of treatment failure in SSG treated patients. First, each 
covariate was analysed against the main outcome using logistic regression. Then, a 
multivariate logistic regression model was built, using a forwards stepwise method, with 
three a priori selected variables (“forced” variables: age, sex and location). Any additional 
variables which had a p value of <0.2 in the bivariate analyses were evaluated in the 
multivariate model and retained if they had a p value of < 0.05. The results were presented 
as odds ratios (OR) and their 95% Confidence Intervals (CI). 
2.20.2.2 Urine samples 
The same method from Section 2.20.2.1 was applied to both the biological samples and the 
biological samples with the imputed data set (Section 2.20.1.2). 
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2.20.3 Survival analysis 
Survival analysis methods were used to compare survival in subjects exposed to elevated 
(>= 10 µg L-1) versus normal arsenic water levels. The time origin for the survival analysis 
was the reported start date of symptoms. The date of 01/02/12, mid date of field visits, was 
used as the censor date.  First, a Kaplan Meier (KM) survival curve and the log-rank test 
were used to evaluate the association between arsenic in water and all-cause mortality. Cox 
regression was used to estimate the risk of all-cause mortality in patients exposed to arsenic 
contaminated wells while controlling for possible confounding factors. The proportional 
hazards assumption was tested using visual methods and on the basis of scaled Schoenfield 
residuals (Hess, 1995). If the proportional hazard assumption was invalid the effect of 
arsenic exposure was allowed to vary over time by fitting 2 time varying covariates in the 
model. The KM plots were used to determine the temporal periods in which the effect of 
arsenic changed. The final regression model included arsenic exposure, three a priori 
selected variables (“forced” variables: age, sex and location) and any variables that were 
associated with mortality as assessed by the log rank test (p <0.2) and remained significant 
(p <0.05) in the final model. Hazard ratios (HR) and their 95% CI were used to express the 
risk in the final model. Analogous analyses (e.g. KM and Cox regression model) were used 
to study the risk of VL mortality associated with arsenic exposure. 
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Chapter 3- 
Results 
       
   
Cell line AsIII, μM SbIII, μM SbV, μM 
LdBob amastigote 
clonesϯ 
8.21 ± 1.1 
(2.45 ± 0.2) 
355 ± 29 
(2.82 ± 0.3) 
40,000 ± 490 
(1.53 ± 0.3) 
LV9 promastigote 
clonesϯ 
21.5 ± 1.6  
(2.49 ± 0.16) 
139 ± 8 
(2.14 ±0.13) >40,000 
BALB-c  peritoneal 
macrophages 
4.95 ± 0.37 
(3.08 ± 0.2) 
22.9 ± 5.9* 
(1.7 ± 0.4) 
11,600 ± 160* 
(1.3 ± 0.2) 
THP-1 monocytes 
12.2 ± 0.9 
(1.57 ± 0.8) 
124 ± 8 
(3.15 ± 0.5) >8,210 
THP-1 macrophages 
31.9 ± 1.7 
(2.18 ± 0.1) 
182 ± 12 
(2.61 ±0.22) >8,210 
NMRI peritoneal 
macrophages 
3.22 ± 0.17* 
(2.61 ± 0.22) 
24.6 ± 0.9 
(2.34 ± 0.0) >8,210 
C3H peritoneal 
macrophages 
3.91 ± 0.13* 
(3.39 ± 0.3) 
  
Table 3.1 Sensitivity of Leishmania cell lines and macrophages to metalloids As
 
and Sb 
Data are weighted mean ± standard error of 3 separate experiments from late log growth 
phase, using triplicate measurements, except where indicated. The bracketed figures are the 
mean ± standard error of the hill slope. 
*Weighted mean ± standard error of 2 separate experiment of triplicate measurements 
ϯ
Clones derived from LdBob and LV9 displayed similar sensitivities to the metalloids and are each 
grouped together.  
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Figure 3.1 Susceptibility to metalloids in Leishmania axenic amastigotes
EC50 values for sodium arsenite (AsIII, ), potassium antimonyl tartrate ( SbIII, )
and sodium stibogluconate (SbV, ) respectively were determined against the
LdBob clone LdSu3. The cells were axenically cultured in 96-well plates using a 72
hour resazurin-based assay. Curves are the nonlinear fits of data using the EC50 3
parameter equation in GraFit. Data are the mean of triplicate measurements.
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Section A: Laboratory work 
3.1 Sensitivity of cell lines to metalloids 
3.1.1 Sensitivity of Leishmania to metalloids 
The axenic cell line LdBob was cloned and one of the clones was arbitrarily picked. To 
assess the relative potency of the metalloids against this clone LdSu3 the EC50 values of 
AsIII, SbIII and SbV were determined (Figure 3.1) and (Table 3.1).  The order of EC50 
values obtained for AsIII (8.21 μM), SbIII (355 μM), and SbV (40.4 mM) were in keeping 
with published data (Brochu et al., 2003; Goyard et al., 2003). However the LdBob 
clone is considerably more resistant to antimonial compounds than previously observed 
(Brochu et al., 2003; Goyard et al., 2003; Wyllie et al., 2004). The results obtained 
demonstrate the higher potency of the trivalent form of the elements and that arsenic, by 
molar comparison, is more toxic than antimony.  Although the toxicity of SbIII is similar 
between amastigotes and promastigotes (Table 3.1), SbV accumulates less in the 
promastigote form of Leishmania, than in the axenic amastigote form, and is thought to 
be pharmacologically inactive in the promastigote (Brochu et al., 2003; Wyllie et al., 
2004). The finding that the EC50 of LV9 promastigotes is greater than 40 mM SbV 
supports this.  
The high level of baseline sensitivity to SbV of the LdBobSu3 clone of 40.4 ± 
4.9 mM warranted further investigation. At this concentration it was hypothesized that 
the mechanism of action for cell death may be ionic strength. Therefore the sensitivity 
of the SbV exposed clone was tested against sodium gluconate, a compound without an 
active anti-leishmanicidal ingredient. The EC50 of sodium gluconate was comparable at 
24.3 ± 3.1 mM demonstrating that the SbV in sodium stibogluconate was not the 
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leishmanicidal ingredient and this SbV appears to be pharmacologically inactive. The 
original LdBob stabilate was retested for sensitivity to SbV and had an EC50 of 1 ± 0.04 
mM, comparable to the previously published value from this laboratory of 1.64 mM 
(200 μg ml-1) (Wyllie et al., 2004). Unexpectedly, it transpired that the LdBob that had 
been continuously passaged for some time from which the clone LdSu3 was derived, 
was found to have lost sensitivity to SbV, with an EC50 in the same range of LdSu3. The 
reason for this loss of sensitivity is unknown but this finding is interesting in light of the 
controversies of the sensitivity of axenic amastigotes to SbV (Vermeersch et al., 2009; 
Wyllie et al., 2004). 
The susceptibility of the axenic amastigote line to AsIII was strongly affected by 
the density of the stock culture from which cells were taken (Figure 3.2); if the parasites 
had reached stationary phase, the EC50 for AsIII was around 0.98 ± 0.37 µM whereas 
cells in late log were less sensitive with an average EC50 of 7.58 ± 1.5 µM 
(p<0.0001)(Figure 3.2B). This effect was present with SbIII but there was not a 
significant difference between the 2 groups (p=0.13)(Figure 3.2C). All subsequent 
EC50s presented in this study are on cells taken from late log phase stock cultures. 
The relative toxicity of the metabolites of arsenic (Section 1.3.2) MMAIII and 
DMAIII were additionally assessed in the axenic amastigote line.  Both metabolites were 
greater than 8 fold more toxic than AsIII with EC50s of 0.97 ± 0.08 µM and 0.34 ± 0.03 
µM, respectively.  This relative potency is in keeping with the literature on mammalian 
cells (Styblo et al., 2000) although MMAIII is generally thought to have a higher 
toxicity DMAIII. The difference seen in the axenic amastigote susceptibility may be due 
to the preparation of DMAIII which had to be purified in oil and may be contaminated 
with H2S, a toxic compound in itself (personal communication Dr. A. Raab). 
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3.1.2 Sensitivity of uninfected macrophages to metalloids 
The sensitivities of different lines of macrophages were determined to establish the 
difference between macrophage and parasite sensitivity and for development of the in-
macrophage assay (Section 3.2). No difference in sensitivity to AsIII between starch 
elicited and non-elicited NMRI mouse macrophages was detected (3.22 ± 0.17 and 3.10 
± 0.21 respectively). No significant difference between the species BALB/c, NMRI and 
C3H was detected (Table 3.1).  However, when compared to BALB/c mouse 
macrophages, the laboratory line THP-1 were > 2 fold less sensitive to arsenic as 
monocytes and > 6 fold less sensitive to arsenic as differentiated macrophages (p=0.03) 
consistent with previous literature (Sakurai et al., 2004). This effect is present but non-
significant with SbIII (p=0.25). In view of the sensitivity of macrophages to AsIII it was 
not possible to select for resistance in intracellular amastigotes or accurately study the 
effect of AsIII on parasite growth in this in vitro setting.   
3.2 Optimisation of in macrophage assay 
The in-macrophage assay was developed to optimise the assessment of amastigote 
killing within the macrophage, particularly in reference to SbV.  The initial comparison 
of parasite to macrophage ratios had the same result in all parasite and macrophage cell 
types – a ratio of 40 to 1 killed most of the macrophages present and a ratio of 2 to 1 
gave only a low level and inconsistent infection.  A ratio of 10 to 1 was chosen as 
optimal, in keeping with KP Chang’s work on parasite macrophage interactions (Chang 
and Dwyer, 1978). Using peritoneal-derived mouse macrophages rather than 
differentiated THP-1 cells increased the number of macrophages infected with either 
form of Leishmania parasite. When using mouse macrophages there was no significant 
difference in infection levels whether the infection period was 4 hours or up to 16 hours.  
          
Parasite 
 
Media Amastigotes cell-1 % infected 
LV9 promastigotes 10% FBS, RPMI 2.27 67 
LV9 promastigotes 20% FBS, RPMI 3.3 71 
LV9 promastigotes 
10% FBS, M199    
(+ adenosine) 0.46 32 
LV9 promastigotes 
20% FBS, M199   
(+ adenosine) 0.16 11 
LV9 ex vivo 
amastigotes 10% FBS, RPMI 13.1 95 
LV9 ex vivo 
amastigotes 20% FBS, RPMI 12.7 94 
LV9 ex vivo 
amastigotes 
10% FBS, M199    
(- adenosine) 2.33 65 
LV9 ex vivo 
amastigotes 
20% FBS, M199    
(- adenosine) 4.23 89   
Table 3.2 Parasite strain and media type affect L. donovani amastigote infection 
levels within mouse peritoneal macrophages  
Starch elicited mouse peritoneal macrophages were incubated in different media at a 
ratio of 10:1 with different forms of the parasite for 16 hours, extracellular parasites 
were washed away and infected macrophages were incubated for 72 h prior to 
Giemsa staining and enumeration using a 100x oil immersion lens.  Each figure 
represents the average no of amastigotes per macrophage having counted 100 
macrophages per well. 
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Figure 3.3 Histogram of amastigote growth post incubation period with
macrophages
Starch elicited mouse peritoneal macrophages were incubated for 4 hours with ex
vivo amastigotes after which all extracellular parasites were washed away and the
macrophages were subsequently cultured in RPMI 20% FCS medium in chamber
slides. Slides were fixed stained with Giemsa at 0 h (Panel A) and 72 h (Panel B)
post incubation and the number of amastigotes per macrophage was enumerated
manually using a light microscope with a 100x oil immersion lens.
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At a ratio of 10 parasites to 1 mouse macrophage, ex vivo LV9 amastigotes were 
markedly more efficient than the laboratory line of LV9 promastigotes and axenic 
amastigotes at gaining entry to the macrophage (Table 3.2).  Furthermore, it was 
important that the LV9 promastigotes were in late stationary phase (days 6-9) with 
visible dead or dying parasites, otherwise there was decreased infectivity and 
macrophage viability.  This has previously been observed and explained by the presence 
of phosphatidylserine on the surface of these promastigotes helping to protect against 
host inflammatory responses (Wanderley et al., 2009). Another group has proposed that 
acidic preconditioning of promastigotes further improves infection levels (da Luz et al., 
2009).  
The composition of the medium also affected infectivity (Table 3.2). The type of 
medium used can have a profound effect on infection levels but there was no significant 
difference between using 10% versus 20% FBS supplementation.  The high 
concentration of adenosine (100µM) in M199 media led to a considerable reduction in 
macrophage infection levels. The adenosine may have directly inhibited phagocytosis 
consistent with literature on macrophage function (Eppell et al., 1989). 
It was found that intracellular growth and division of amastigotes had started to 
occur by 72 h in cell cultures with RPMI medium (Figure 3.3) but not in those with 
M199 medium. A growth study performed with time points 0, 24, 72 and 116 h 
demonstrated an initial lag phase in growth between 0 and 24h, minimal growth at 72h 
and doubling of amastigote levels by 116 h.  This is consistent with studies on hamster 
macrophages and L. donovani (Chang and Dwyer, 1978).   
The above results led to a final protocol using peritoneal mouse macrophages, a 
parasite macrophage ratio of 10:1 and an infection incubation time of 4 h with ex vivo 
amastigotes where possible  (Section 2.7).  The assay length chosen was 72 h as this did 
           
Cell line 
As III, 
µM RF 
Sb III, 
µM RF 
SbV, 
µM RF 
Ratio 
SbV/SbIII 
LdBob 
original nd 
 
234.5 ± 
27.1 
 
1000 ± 
40  
 
4.3 
LdSu3 
clone 
7.4 ± 
0.1 1 
239 ± 
37 1 
40,400 
± 4,900 1 169 
Control 
line no 
drug 
6.9 ± 
0.6 0.9 246 ± 3 1 nd  -  
LdSu3SbIIIR 
clones 
5.2 ± 
0.3 0.8 
230 ± 
15 1  nd - 
 
LdSu3AsIIIR 
clones 
69.1 ± 
5.2*   10 
2383 ± 
320* 10  nd - 
 * p<0.05 compared to baseline LdSu3 clone  
Table 3.3 Susceptibility to metalloids in baseline and cloned resistant 
Leishmania axenic amastigotes 
Leishmania axenic amastigotes were grown in flasks in the presence of varying 
concentrations of metalloid and a resazurin based assay was used for determination 
of EC50 values for As
III, SbIII and SbV respectively. Clones were generated by limiting 
dilution of resistant lines growing well at the top concentration of the relevant 
metalloid. EC50 were calculated from 3 parameter equation in GraFit. Data are the 
mean of triplicate measurements. RF = relative factor in relation to baseline clone.  
 
Figure 3.4 Generation of resistant lines of L. donovani to metalloids
Panels A and B represent exposure of LdBobSu3 to stepwise increasing
concentrations of sodium arsenite ( AsIII,) potassium antimonyl tartrate ( SbIII , ),
respectively. Each symbol represents a culture passage at that drug concentration.
The growth rate at each culture passage was quantified using a haemocytometer.
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Figure 3.5 Susceptibility to trivalent metalloids in baseline and cloned AsIII
resistant Leishmania axenic amastigotes
Determination of EC50 values for sodium arsenite (baseline LdSu3, , AsIII resistant
LdSu3, ●) and potassium antimonyl tartrate(baseline LdSu3, , AsIII resistant
LdSu3, ■) respectively was performed using a resazurin based assay with against
axenically cultured LdSu3 and clone B7 of the generated AsIII resistant LdBobSu3.
The curves are the nonlinear fits of data using the EC50 3 parameter equation in
GraFit. Data are the mean of triplicate measurements.
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not require a change of media. No significant difference was seen in SbV EC50 results 
between 72 and 120 h in incubations with no media replenishment. 
3.3 Selection of drug resistant axenic amastigotes 
A resistant line to the trivalent metalloids of Sb and As was generated in axenic 
amastigotes with the intention of performing a comparison between the associated 
mechanisms of resistance developed.  This could potentially provide tools to test the 
hypothesis of parasite resistance selected for by exposure to arsenic present in the 
exposed population of Bihar. A clone of LdBob, hereafter LdSu3, was used. The 
starting concentrations were chosen to be approximately equal to the EC10 of the 
respective compounds, SbIII and AsIII. It took 125 versus 108 days respectively to 
produce a SbIII (LdSu3SbIIIR) and AsIII (LdSu3AsIIIR) resistant line with a normal growth 
rate at 64x the starting concentration (Figure 3.4). Large inoculums were required at 
high drug concentrations to maintain the culture. 
The parasite line, LdSu3SbIIIR, growing at 64x the starting concentration SbIII was 
cloned by limiting dilution in the absence of drug. Assessment of sensitivity of the 
resulting LdSu3SbIIIR clones to AsIII, SbIII and SbV demonstrated that stable resistance 
had not been generated (Table 3.3), implying that tolerance to the metalloids was not 
retained through the cloning process.  
Based on the above finding LdSu3AsIIIR, was maintained at the top concentration 
of 64 μM AsIII for 3 months prior to cloning.  The AsIII cloned lines showed 
approximately 10 fold resistance, with respect to baseline LdSu3, to AsIII and SbIII 
(Figure 3.5), (Table 3.3). There was no difference in sensitivity between control and 
clones to the control drug amphotericin B. 
5 µm 10 µm 
20 µm 10 µm 
A B 
C D 
Figure 3.6 Scanning electron microscopy of LdBob and LdSu3 
Log phase parasites were fixed using a final concentration of 2.5% glutaraldehyde 
and prepared for EM as in Section 2.14.2.  Panels A and B represent the original 
LdBob clone in axenic amastigote and promastigote form respectively.  Panel C 
represents the heterogenous population visible in the clone LdSu3 that was selected 
for AsIII resistance. Panel D of LdBobSu3 cycled continuously in axenic amastigote 
form for > 120 d  demonstrates classic rosetting usually only seen in promastigote 
cultures. 
              
 
 
Intracellular 
amastigote  
Promastigote 
Line from LV9 clone SbV, µM 
 
SbIII µM 
GSH, 
nmol (108 
cells)-1 
T(SH)2,  
nmol (108 
cells)-1 
SbV exposed A  > 4100 
 
102 ± 6.7 2.62 ± 0.26 6.06 ± 0.33 
 
B  > 4100  
 
88.4 ± 19 2.11 ± 0.17 4.98 ± 0.47 
 
C  > 4100 
 
106 ± 2.8 2.50 ± 0.65 6.77 ± 0.14 
No drug 
exposure D 468 ± 200  
107 ± 12.8 1.68 ± 0.45 4.69 ± 0.36 
 
E 436 ± 100 
 
115 ± 10.6 1.27 ± 0.27 2.95 ± 0.23 
 
F 441 ± 40† 
 
121 ± 5.8 1.61 ± 0.16 3.60 ± 0.33 
Table 3.4 Susceptibility to antimony species and intracellular thiol levels in 
Leishmania parasites exposed to Sb
V
 and control 
A clone of LV9 was split into 6 lines, A-C that were exposed to increasing 
concentrations of Sb
V
 in macrophages and D-F that were passaged through non drug-
exposed parasites. Following 3 passages, the sensitivity of the parasites to Sb
V
 was 
assessed using an in-macrophage assay (exposed vs unexposed groups: relative 
factor >9, p<0.05) and the sensitivity of promastigotes to Sb
III
 was assessed using a 
resazurin based assay (exposed vs unexposed groups: relative factor 0.86, p>0.05). 
Levels of intracellular thiols were measured in triplicate. On average, there was a 1.5 
fold higher thiol levels in the exposed versus the non-exposed promastigotes 
(p<0.05) 
† This EC50 was calculated using a 2 parameter equation as it was unable to be fitted to the 3 
parameter model. 
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LdSu3 was cultured continuously in axenic amastigote conditions for up to 200 
days during the selection of these resistant lines without cycling back to the 
promastigote stage. Under these conditions, the parasites in the control line, and the 
lines exposed to metalloids, developed a thinner, longer body, a visible flagellum and 
were observed to grow in culture in rosette formation.  These are all features of the 
promastigote phenotype (Chang, 1979). In all cultures heterogenous populations are 
visible (Figure 3.6). Resistant lines have previously been created using axenic 
amastigote lines (El Fadili et al., 2009; El Fadili et al., 2005) but these morphological 
changes were not reported.  
To assess whether this axenic amastigote line LdSu3 was sensitive to SbV within 
the macrophage it was tested in the in - macrophage assay at the same time as the 
LdSu3AsIIIR clone.  Although both of the axenic lines were able to enter the macrophage, 
neither of them showed sensitivity to SbV within the macrophage.  
In view of the above issues with the axenic line and experiments from other 
groups from our department showing that LdBob did not establish an infection in vivo 
no further experiments or analysis of this line were carried out. 
3.4 Selection of SbV resistant L.donovani in macrophage 
In order to select for resistance in vitro, in an environment as close to the conditions in 
humans as possible, resistance to SbV was selected for in amastigotes within 
macrophages using a modified version of a newly established method (Hendrickx et al., 
2012). A clone of LV9 promastigotes recently isolated from BALB/c mice was 
passaged 3 times through SbV exposed (Lines A-C) and non-exposed macrophages 
(Lines D-F) (Figure 2.1). The resulting parasite sensitivities are summarised in Table 
3.4.  A stage-specific resistance was generated with no shift in promastigote sensitivity 
to SbIII but intracellular amastigotes that had rapidly gained resistance to SbV up to 4 
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mM (relative factor >9). The speed of resistance selection and amastigote stage-specific 
resistance also occurred with the induction of paromomycin resistance using this 
method (Hendrickx et al., 2012). 
Thiol levels measured in the parasite lines A-C and D-F were significantly 
different (Table 3.4) but only a 1.5 fold shift which would not fully account for the 
difference in sensitivity to SbV between the 2 groups. As the exposed and non-exposed 
lines have been selected for in triplicate they will be suitable for sequencing where 
known mechanisms of resistance will be assessed and changes in putative reductases 
can be assessed. 
It is worth noting that the hill slope for SbV in macrophage assays is consistently 
shallow (range 0.4 to 0.6) in all experiments compared to axenic trivalent metalloid 
assays in amastigotes or promastigotes (range 1.5-4.5).  This is likely to be 
representative of the need for activation of SbV and implies that this may be a rate 
limiting step. Additionally SbV, at the top concentration of 4.1 mM, never eradicated all 
the intracellular amastigotes.  This may be due to the in macrophage assay used; longer 
exposures may result in more complete clearance of intracellular amastigotes. 
It is important to establish where SbV is reduced – the macrophage, the 
amastigote or both and whether loss of this metabolic activation step is associated with 
SbV resistance. The current method of antimony speciation involves separation by 
HPLC coupled to ICP-MS (Hansen et al., 2011), a method not available in our 
laboratory. The indicators listed in Section 2.9.1 were tested for change in fluorescence 
in the presence of varying concentrations of SbIII and SbV and the control compound 
ZnII. There was no linear change in fluorescence of the indicators detected in the 
presence of 10 fold dilutions of SbIII or SbV where a linear change for ZnII was 
observed.  The indicators were originally designed for divalent transition metal ions 
Fig. 3.7 Arsenic levels in organs of BALB/c mice.
At day 28 (A) and day 56 (B), three mice from each group (clear bars, 0 ppm; grey
bars, 10 ppm; and black bars,
100 ppm) were culled, and liver, spleen, bone, and kidneys were harvested,
homogenized, and digested before analysis of their total arsenic content by ICPMS
(Section 2.X). In the case of spleen, kidney, and bone of the D28 control samples,
these are the weighted mean of two independent analyses. Values are mean ± SE in
mg per kg wet weight.
*p < 0.05 compared with 0-ppm group.
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although have been demonstrated to work for the trivalent ions TbIII (Terbium) and LaIII 
(Lanthanum)(Figure 1.9). The hypothesis that this SbIII may have a similar effect on 
fluorescence as these ions, has not, in my hands, been found to be the case. 
3.5 Arsenic exposure in BALB/c mice 
3.5.1 Arsenic exposure model 
For Leishmania parasites to become resistant to antimony they require to be exposed to 
arsenic in the organs they reside in.  To establish whether arsenic accumulates in the 
target organs, levels of total arsenic in liver, spleen, bone and blood, together with 
kidney as a marker of excretion, were measured at D28 and D56 of exposure to 0, 10 
and 100 ppm of arsenic in their drinking water (Figure 3.7). 
The mice in both 0 and 10 ppm groups gained weight at a similar rate and had a 
fluid intake of approximately 2 ml day-1.  In the 10 ppm group this is equivalent to 20 
µg of arsenic mouse-1 day-1. The mice exposed to 100 ppm gained weight in a slower 
fashion and their fluid intake fell from 1 ml day-1 to 0.5 ml day-1 over the course of the 
56 d, indicating cumulative toxicity.  This fluid intake was equivalent to 50 – 100 µg of 
arsenic mouse-1 day-1.  
Food intake was not directly measured but BALB/c ByJ mice are known to have 
a daily intake of 16g per 100g body weight (Bachmanov et al., 2002). The arsenic 
content of standard laboratory chow was measured to be 0.048 ± 0.005 µg g-1 which 
allows an estimation of the daily arsenic intake from food in each mouse of only 0.15 
µg, a negligible amount. 
Figure 3.7 shows that the concentration of arsenic in the drinking water of the 
mice correlated with the levels of arsenic detected in tissues.  Of note, the levels of 
arsenic represented are from whole bone and may differ from those in the bone marrow 
           
      
Table 3.5 Total arsenic and antimony in organs of BALB/c mice exposed to 
arsenic in drinking water 
Arsenic levels were measured by ICP-MS in the livers and spleens of mice that have 
been exposed to 0, 10 and 100 ppm for 56 -63 days.  The results represent the mean 
and standard error of measurements from 3 infected mice at passages 2, 3, 4 and 5 
for liver and at passages 3 and 5 for spleen and from uninfected mice at 56 days. 
Total antimony results are mean and standard error of measurements from 3 mice 
from each arsenic exposure level at 5
th
 passage, 72 h post sub-cutaneous injection of 
50 mg kg
-1
 of Sb
V
.  
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itself. However, the collagen of bone outer cortex is not cysteine rich so it is unlikely to 
hyperaccumulate arsenic. 
In mice drinking 10 ppm of arsenic in their water the levels of arsenic in their 
tissues increased or were maintained at the same level between day 28 and day 56.  In 
mice drinking 100 ppm of arsenic in their water their tissue levels fell reflecting the 
drop in their daily arsenic dose secondary to decreased fluid intake.  
The main sites of arsenic metabolism and excretion are the liver and kidney and 
this is reflected in the elevated levels of arsenic in these organs (Vahter and Concha, 
2001). Chronically exposed patients in Bangladesh were demonstrated on liver biopsy 
to have high levels of arsenic of between 0.5 and 6 mg (kg dry weight) -1 (Mazumder, 
2005). The conversion factor for wet to dry weight of mouse livers was calculated, from 
the freeze drying of three non-arsenic exposed BALB/c livers to be 3.53 ± 0.04.  The 
levels of 0.4 to 1.5 mg (kg wet weight) -1 seen over the 56 day time course in the 100 
ppm group is thus equivalent to 1.41 ± 0.02 to 5.29 ± 0.06 mg (kg dry weight) -1.  These 
levels are similar to those found at similar arsenic exposure levels in C3H mice in the 
literature (Ahlborn et al., 2009; Kitchin and Conolly, 2010). 
In Table 3.5 the mean arsenic contents of Leishmania infected and uninfected 
spleens and livers are compared at D56 of arsenic exposure.  No significant differences 
were seen implying that that there is no interference in arsenic metabolism in mice due 
to the presence of Leishmania. Additionally, arsenic levels in the livers and spleens of 
arsenic exposed mice did not impact on the clearance of antimony by 72 h post SbV 
treatment, demonstrated by the similarity of antimonial levels in all mouse groups. The 
high standard error for the arsenic level in the non-exposed infected spleen in Table 3.5 
is reflective of the small amounts of spleen available for analysis as most of the spleen 
was needed for isolation of parasites for drug sensitivity assays and further passage into 
Figure 3.8 Accumulation of arsenic in mouse macrophages and THP-1
macrophages measured by ICP-MS
Differentiated THP-1 cells and ex vivo peritoneal macrophages were incubated for
72 hours with a range of AsIII concentrations, removed, washed and their arsenic
content measured by ICP- MS. The volume of 1 x 10 6 macrophages is equal 20L
as measured by Casey counter. The degree of linear regression is related to the IC
50 for mouse macrophages (, 3.22  0.17 M) and differentiated THP-1
macrophages (, 31.9  1.65 M)
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mice.  The low sample size and low arsenic content resulted in high variable count rates 
in ICP-MS analysis.  ICP-MS analysis was repeated in an independent experiment using 
larger splenic samples from 3 infected mice with no arsenic exposure and the results are 
shown in Table 3.5 in parentheses. 
3.5.2 Arsenic exposure and macrophages 
Although it is known that antimony enters the macrophage (Berman et al., 1987) there 
is no experimental evidence of arsenic accumulation in macrophages in the literature 
which is important for this hypothesis. The current study shows a clear linear 
relationship between arsenic exposure in vitro and total arsenic content in-macrophage 
(mouse macrophage R-squared = 0.97, p= 0.002, THP-1 R-squared=0.90, p=0.014) that 
is macrophage dependent (Figure 3.8).  In keeping with the difference in their EC50s 
(Table 3.1) differentiated THP-1 cells accumulate arsenic less efficiently than mouse 
derived peritoneal macrophages.  
The effect on peritoneal macrophages in mice exposed to arsenic at 0, 10 and 
100 ppm was explored.  There was no difference, in both mice with 28 and 56 day 
exposure, in the sensitivity of the macrophages from mice exposed to AsIII in an in vitro 
resazurin assay when compared to macrophages from the control group (0 ppm 4.04 ± 
0.32, 28 d, 10 ppm 3.82 ± 0.19, 100 ppm 3.00 ± 0.15, 56 d, 10 ppm 3.6 ± 0.19, 100 ppm 
3.35 ± 0.11).  However arsenic-exposed macrophages showed a trend towards a 
decreased ability to kill intracellular hamster ex vivo amastigotes using SbV (0ppm 
exposed macrophages 243 ± 59 µM, 10 ppm exposed macrophages 306 ± 49 µM, 100 
ppm exposed macrophages 505 ± 93 µM).   
Exposure to arsenic upregulates  haem oxygenase which is cytoprotective (Wang 
et al., 2012). Its upregulation also leads to decreased levels of haem within the 
macrophage which decreases the activity of NO and NADPH oxidase (Alderton et al., 
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2001). This could also leads to increased vulnerability of the intracellular amastigote, 
which is incapable of haembiosynthesis (Chang and Chang, 1985).  The upregulation of 
haemoxygenase could explain why no difference was observed in sensitivity of the 
macrophages to arsenic.  The trend in decreased efficacy of SbV against the amastigotes 
in arsenic exposed macrophages could be explained by the potential decreased activity 
of NO and NADPH as a result of decreased levels of haem. Other immunotoxic effects 
of arsenic on macrophage function may also play a role (Banerjee et al., 2009).  
Measurement of the arsenic content of peritoneal derived macrophages in mice 
exposed to arsenic showed a significant difference in ng of arsenic (106 macrophages) -1  
between control and arsenic exposed groups (0ppm 0.01 ± 0.002, 10 ppm 2.39 ± 0.03, 
100 ppm 2.24 ± 0.02).  The injection of starch mobilises circulating blood monocytes 
and macrophages resident in the bone marrow to the peritoneum. This arsenic content, 
however, may not be reflective of the arsenic content of macrophages in the bone 
marrow as the cells will experience different arsenic exposures during migration and in 
residence in the peritoneum.   
3.6 Selection of SbV resistance in vivo 
3.6.1 Evaluation of a chronic visceral leishmaniasis model 
Fifteen BALB/c mice were infected with an i.p. injection of 1 x 107 ex vivo amastigotes.  
On days 7, 14, 28, 56 and 110, 3 mice were sacrificed and parasite load quantified. 
Apart from an initial peak at D14 of 2 x 107 parasites per liver the parasite burden 
remained stable at 1.5 x 107 at all other time points. These parasites loads are similar to 
those reported in a methodological comparison study which favoured intraperitoneal 
injection over intravenous injection for homogeny of results (Rolao et al., 2004).  
              
  
 
Intracellular 
amastigote  
Promastigote 
Arsenic 
exposure 
level 
SbV, µM 
 
SbIII, µM AsIII, µM 
GSH,  
nmol (108 
cells)-1 
T(SH)2, 
nmol (108 
cells)-1 
0 ppm  590 ± 250 
 
76.9 ± 2.2  15 ± 0.3 1.75 ± 0.20 5.03 ± 0.67 
10 ppm  > 4100 
 
85.9 ± 2.8  36.4 ± 0.5  1.52 ± 0.49 5.21 ± 0.90 
100 ppm  > 4100 
 
154 ± 3.4 27.7 ± 0.4  1.84 ± 0.10 4.65 ± 0.21 
Table 3.6 Susceptibility in vitro to antimony species and intracellular thiol levels 
in Leishmania parasites previously exposed to arsenic in vivo 
BALB/c mice were exposed to 0 ppm, 10 ppm and 100 ppm arsenic and infected 
with L.donovani (Figure 2.2). Harvested amastigotes from each group were 
differentiated into promastigotes. The sensitivity of the parasites to Sb
V
 was assessed 
using an in-macrophage assay (exposed vs unexposed groups: relative factor >7, 
p<0.05) and the sensitivity of promastigotes to Sb
III
 (exposed vs unexposed groups: 
relative factor of 1.5, p>0.05) and As
III
 (exposed vs unexposed groups: relative factor 
of 2.1, p>0.05) was assessed using a resazurin based assay. Levels of intracellular 
thiols were measured in triplicate. There was no significant difference in thiol levels 
between the 3 groups. 
 
Fig. 3.9 Susceptibility of ex vivo amastigotes to SbV in-macrophage 
BALB/c mice were exposed to 0 ppm (), 10 ppm () and 100 ppm () arsenic
and infected with L.donovani (Figure 2.2). Harvested amastigotes from each group
were assessed for their sensitivity to SbV for 72 h within mouse peritoneal
macrophages. Results from the 5th passage are presented here. Parasites recovered
from the 10 and 100 ppm groups of mice remained insensitive to SbV at
concentrations up to 4.1 mM. Amastigotes from the unexposed BALB/c mice had an
EC50 value for SbV of 0.338 ± 0.058 mM.
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3.6.2 Sensitivity of ex vivo amastigotes in in macrophage assay 
The LV9 parasites exposed to arsenic within BALB/c mice for serial passages (Figure 
2.2) gradually developed resistance to antimonial preparations.  Following 3 passages, 
the parasites exposed at 100 ppm were already refractory to SbV at levels up to 4.1 mM 
(500 μg ml−1).  Those at 10 ppm were fivefold less sensitive to SbV compared to the 
control group at 0 ppm (0 ppm, 0.353 ± 0.049 mM (43 ± 6 μg ml−1), 10 ppm, 1.87 ± 
0.62 mM (228 ± 75 μg ml−1)). After the fifth passage, both groups of parasites exposed 
at 10 ppm and 100 ppm showed no response to SbV at 4.1 mM (relative factor >7) 
where the control group 0 ppm remained sensitive with an EC50 0.317 ± 0.032 mM 
(41.1 ± 7.0 μg ml−1)(Figure 3.9).  The resistance observed in the 10 and 100 ppm groups 
was retained following passage in mice not exposed to arsenic for 4 months. The EC50 
in the control group of 0 ppm was 0.500 ± 0.19 mM (60.9 ± 24 μg ml−1) at this time 
point. 
Differentiation of ex vivo amastigotes proved problematic and several attempts 
were made using different media including NNN with rabbit blood. It was discovered 
that ex vivo amastigotes from all groups required supplemented RPMI medium to 
differentiate into promastigotes whereas ex vivo amastigotes from hamsters will 
differentiate easily in Grace’s medium (Table 2.1). It should be noted that when the time 
this issues was resolved the parasite had been passaged in mice for 8 months in the 
absence of AsIII pressure. The 0 ppm, 10 and 100 ppm promastigotes were tested for 
sensitivity to SbIII and AsIII and only small and non-significant shifts in EC50s were 
observed (Table 3.6). Thiol levels in the promastigotes were measured but no difference 
was observed in levels of GSH or T(SH)2 between the 3 groups.  
When these promastigotes were used to infect macrophages in the in 
macrophage sensitivity assay the intracellular amastigotes from the 10 and 100 ppm 
groups were again refractory to SbV at 4100 µM (500 μg ml−1) implying a stage-specific 
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Fig. 3.10 Effect of drug treatment on the parasite burden of arsenic-exposed
BALB/c mice.
Parasite burden is expressed as total parasite numbers per liver (A) and response to
treatment as a percentage of the respective untreated control group (B). Following 28
d of infection, at each arsenic exposure level group (clear bars, 0 ppm; grey bars, 10
ppm; and black bars, 100 ppm), BALB/c mice were treated daily for 5 d with either
s.c. injections of drug vehicle alone (n = 4, 5, and 5 at each arsenic exposure level),
50 mg kg−1 SbV s.c. (n = 3, 5, and 5), or miltefosine 12 mg kg−1 (n = 3, 4, and 4).
Values are mean ± SE. *p < 0.05 compared with 0 ppm group.
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resistance mechanism (Table 3.6). The 0 ppm group remained sensitive to SbV with an 
EC50 of 590 ±250 µM. Promastigotes from all groups were also resistant to the 
methylated pentavalent arsenic metabolite MMAV at concentrations up to 15.4 mM 
(2500 µg ml−1).  In the in-macrophage assay the intracellular amastigotes from 0 ppm 
had an EC50 of 364 µM (59.0 ± 9.3 µg ml−1) but the parasites from the 10 and 100 ppm 
group were refractory up to 1543 µM (250 µg ml−1). MMAIII is the most potent of 
arsenic metabolites and these results suggest that the MMAV reductase may have been 
lost or downregulated as a protective mechanism. 
The putative SbV reductase TDR1 is known to reduce MMAV (Denton et al., 
2004).  The antibody against the putative reductase TDR1 generated by Graham 
Coombs lab was tested directly against ex vivo amastigotes that had previously been 
exposed to 0, 10 and 100 ppm as there is reported differential expression between 
phenotypic stages.  No response to the TDR1 antibody was generated on Western Blot 
in any group despite a positive response to the control pteridine reductase-1 antibody.   
3.6.3 In vivo assessment of SbV resistance 
At the end of the fifth passage all groups of mice were treated with drug vehicle, SbV or 
miltefosine with ongoing arsenic exposure in drinking water.  In the 10 and 100 ppm 
administration of SbV s/c at 50 mg kg-1 only reduced the parasite burden to 
approximately 80% of control whereas in the 0 ppm SbV achieved suppression down to 
33.6% of control (Figure 3.10). Miltefosine had a similar effect on parasite burden in all 
groups (Figure 3.10, Panel A).  In the 10 ppm group in Figure 3.10, panel B, there is a 
significant difference in % suppression of parasite burden compared to control but this 
may be related to the variability of parasite count within the control group. This 
difference could also be attributed to arsenic’s immunosuppressive effect, as part of the 
mechanism of action of miltefosine is to increase the sensitivity of the macrophage to 
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IFN-γ receptors (Dorlo et al., 2012).  This latter explanation is less likely though as a 
significant difference in miltefosine sensitivity was not observed in 100 ppm group. The 
ineffectiveness of SbV at reducing the parasite load demonstrated that the cross-
resistance between arsenic and antimony is active in vivo as well as in vitro. 
3.6.4 Effect of arsenic exposure on parasite load 
When parasites are passaged in the presence of 10 or 100 ppm there is a clear trend of 
increased parasite burden in the liver over multiple passages (Figure 3.11).  The large 
error bars at the end of the 5th passage represent the presence of amastigote clumping on 
the hepatic smears in the arsenic exposed groups making the parasite load difficult to 
quantify. 
Although the trend is visible in the 10 ppm group the variation falls within the 
mean ± confidence interval of the non-arsenic exposed group.  In the 100 ppm group, as 
noted in Section 3.6.1, the mice did not gain weight as rapidly as the control group.  
This increase in parasite load to levels similar to the 0 ppm group is in the context of 
consistently smaller liver (0 ppm 950 ± 52 mg, 100 ppm 688 ± 68 mg).  This change in 
parasite burden may represent an initial treatment effect of the arsenic exposure which 
is overridden as the parasites develop resistance (Section 3.6.2 and 3.6.3). 
Aliquots of 108 ex vivo splenic amastigotes from each group were taken at the 
end of the second passage and measured for their total arsenic content. The results 
confirmed that the arsenic content was higher in the mice exposed to arsenic at 10 and 
100 ppm.  Calculations of the intracellular arsenic content of 0, 10 and 100 ppm 
exposed amastigotes gave values of 8 ± 0.5, 44.0 ± 2.2 and 57.3 ± 1.6 µM. It would 
have been useful to track this but the amastigotes at the end of each passage were 
needed for re-infection and for assessment of sensitivity to SbV in the in-macrophage 
assay. 
Fig 3.12 Flow chart of individuals identified as having received SSG treatment 
between 2006 and 2010 
Additional outcomes: One patient had a still birth during antimonial treatment.  One 
patient was identified with PKDL at the time of study.  
Figure 3.13 Map of Mahudin Nagar showing town boundary, distribution of 
arsenic contaminated wells (A), treatment failure (B), all-cause (C) and VL 
mortality (D) 
Arsenic levels represented are the mean of water samples taken from 5 wells in the 
patient’s local area.   
A 
B 
Figure 3.13 continued. 
  
C 
D 
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Section B: Field Work 
3.7 Study population 
Six hundred and six patients were identified that were treated for VL from January 1st 
2006 to December 31st 2010 at the PHC of Mahudin Nagar (Figure 3.12). One hundred 
and thirty four (22%) of them were treated with SSG. The rest (n=472) were excluded 
from the study as they received miltefosine or amphotericin B (n=470) or were 
duplicate entries (n=2). Twenty-five additional VL patients treated with SSG from 2006 
to 2010 were identified at the time of the fieldwork visits. Out of the 159 patients 
identified who had been treated with SSG, the houses of 113 (71%) of them were 
located. The reasons for being unable to locate patients included incomplete/inaccurate 
information (n=43) and distance from Mahudin Nagar block (n=3). From the 113 
patients, 69 (61%) of them were present for interview. Twenty one (19%) of the 
subjects were dead and 23 (20%) were living outside the study area at the time of the 
visit. Relatives from the 44 missing subjects were interviewed. Based on the 
information gathered, 3 patients were excluded as they had their SSG treatment 
terminated due to unavailability of the drug. A cohort of 110 VL patients treated with 
SSG was finally included in the analyses.  
3.8 VL cases and treatment  
The 110 patients were aged between 3 and 60 years old, with a median age of 14 and a 
ratio of males to females of 3:2. Twenty percent of subjects lived within the area of 
Mahudin Nagar town (Figure 3.13). Twenty-three (21%) of patients had experienced 
other illnesses prior to their VL episode including the infectious diseases of malaria 
(n=2), tuberculosis (n=2), hepatitis/jaundice (n=4), cholera (n=1) and polio (n=1). Non-
infectious illnesses included asthma (n=7), diabetes (n=1), arthritis (n=1), eczema (n=1) 
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and neurological complaints (n=3). All study subjects reported similar symptoms from 
their VL episode of fever, anorexia and weight loss (100%, 91%, 90% respectively) 
with malaise, abdominal distension and skin pigmentation being less common (72%, 
44% and 7% respectively). Confirmation of the diagnosis of VL was available in the 
form of record of a positive rapid diagnostic test for VL (e.g. rK39 dipstick) in 26 
subjects (24%). Parasitological confirmation was not available for any patient.  
Seventy-one patients (65%) were only treated with SSG; 52 received one 
treatment, 18 received two and 1 patient received three SSG courses. Fourteen out of the 
52 patients who received one treatment reported SSG treatment courses of 60 and 90 
days duration which are 2 and 3 times the recommended duration. Thirty-nine patients 
(35%) were treated with miltefosine or amphotericin B before (n=3) or after (n=34) 
SSG treatment or both (n=2). The mean number of treatments (using any drug) received 
per person was 1.6 (±0.6).  
 
The number of clinical documents confirming the treatments administered was 
limited. For example, only 16 treatment records were available for review out of the 85 
patients treated at the PHC. According to those records, the treatment of 7 out of 16 
patients (44%) did not conform to WHO recommendations – either by dose (only 
10mg/kg) or duration (20 vs 30d). However, the treatment duration reported by the 
patient in the questionnaire matched the PHC treatment card only in 10 out of these 16 
patients (63%). Information on doses was not available from the patients’ interviews.  
3.9 Outcomes of antimonial treatment  
Sixty two (56%) of the study subjects were classified as “treatment failure” (Figure 
3.13B): 10 (9%) died due to VL within 6 months, 40 (36%) patients experienced no 
Table 3.7 Bivariate logistic regression analysis of risk factors for SSG treatment 
failure  
Variable Treatment 
failure  
n=62* (%) 
Treatment 
success 
n= 48 (%) 
OR (95% C.I.) p-value  
Sex  
Female 
Male 
 
26 (41.9) 
36 (58.1) 
 
17 (35.4) 
31 (64.6) 
 
0.76 (0.35-1.65) 
 
0.488 
Age 
0-5 
6-15 
>15 
 
9 (14.5) 
25 (40.3) 
28 (45.2) 
 
6 (12.5) 
16 (33.3) 
26 (54.2) 
 
1 
1.04 (0.31-3.49) 
0.72 (0.22-2.30) 
 
 
0.947 
0.576 
Location 
Outside MHD town 
MHD town 
 
49 (79.0) 
13 (21.0) 
 
40 (83.3) 
8 (16.7) 
 
1.32 (0.50-3.52) 
 
 
0.570 
Caste 
General upper class 
Backward class 
Schedule lower class 
 
8 (12.9) 
37 (59.7) 
17 (27.4) 
 
4 (8.3) 
29 (60.4) 
15 (31.3) 
 
1 
0.64 (0.17-2.33) 
0.57 (0.14-2.27) 
 
 
0.496 
0.422 
Previous VL treatment with 
SSG in family 
No  
Yes 
 
 
49 (80.3) 
12 (19.7) 
 
 
44 (91.7) 
3 (8.3) 
 
 
2.70 (0.81-8.97) 
 
 
0.106 
Time to treatment, weeks 
0-12  
>12 
 
48 (77.4) 
14 (22.6) 
 
39 (81.3) 
9 (18.8) 
 
1.26 (0.49-3.23) 
 
0.625 
Place of treatment 
Private 
Government 
 
8 (12.9) 
54 (87.1) 
 
8 (16.7) 
40 (83 
 
1.35 (0.47-3.90) 
 
0.580 
Full duration of treatment with 
SSG (30d) 
No  
Yes 
 
 
33 (53.2) 
29 (46.8) 
 
 
14 (29.2) 
34 (70.8) 
 
 
0.36 (0.16-0.80) 
 
 
0.012 
Mean local arsenic level  
(tube wells, n=5) 
<10 µg/L 
≥10 µg/L 
 
 
45 (72.6) 
17 (27.4) 
 
 
39 (81.3) 
9 (18.7) 
 
 
1.64 (0.66-4.09) 
 
 
0.291 
Note: *This number includes 10 deaths  
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clinical improvement, 8 (7%) patients relapsed and 4 (4%) terminated their treatment 
due to toxicity. There was a high death rate in our cohort: 21 (19 %) of 110 patients had 
died by the date of the interview (Figure 3.13C). Sixteen (15%) of these patients died 
from VL (Figure 3.13D), 6 of these deaths occurred after the 6 month follow up period 
for SSG treatment failure so they are not included in the primary outcome. One of these 
deaths was directly due to treatment toxicity. Five patients died from non-VL causes 
including HIV (n=1), asthma (n=1), liver failure (n=1), paralysis (n=1) and a road traffic 
accident (n=1). Treatment outcomes were not recorded in the PHC register, PHC 
treatment cards or seldom in patient’s hand held documents.  
3.10 Arsenic exposure 
3.10.1 Tube well water 
The arsenic concentration in the wells tested ranged from < 3 µg L-1 up to 1050 µg L-
1 arsenic. Fifty (44%) of the study subjects had at least one arsenic contaminated tube 
well in their home or surrounding area and 26 (24%) of them had a mean local arsenic 
level ≥ 10 µg L-1 (Table 3.7) and (Figure 3.13A). Five (4.5%) patients had a mean local 
arsenic level of >50 µg L-1, the previous Indian Government limit. Only 11 (10%) 
patients were aware of the issue of arsenic contamination and 8 of these lived in an area 
with local arsenic contamination. The remaining 18 out of the 26 patients living with 
local arsenic contamination had no knowledge of the issue. 
For the cut off ≥10 µg L-1 arsenic the areas under the ROC curves were (1) 0.54 
for treatment outcome, (2) 0.69 for all-cause mortality and (3) 0.65 for VL mortality. 
The sum of sensitivity and specificity was greater than 100% for all outcomes. The 
quality control assays showed a good agreement (Kappa=90%, p<0.001) between the 
analysis performed at SOES and the University of Aberdeen laboratories. 
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3.10.2 Urine samples 
Of the 69 patients where biological samples were available, only 66 were in the final 
cohort of 110 and one sample was unable to be analysed, therefore arsenic exposure in 
urine was only able to be assessed on an individual basis in 65 (59%) study subjects.   
The correlation between arsenic in urine and in the water in the study subject’s 
local environment gives an R-squared value of 0.60 (P < 0.0001). From this relationship 
45 urinary values were imputed to allow analysis of the full cohort. All the results for 
urinary arsenic analysis will be presented for 2 datasets: biological samples only (n=65) 
and with the imputed values (n=110). 
For the cut off >40 µg L-1 urinary arsenic the areas under the ROC curves were 
0.53 and 0.49 for the two datasets respectively. The sum of sensitivity and specificity 
was ≥100 % for both datasets. The quality control assays showed a moderate agreement 
(Kappa=72%, p=0.012) between the analysis performed at SOES and the University of 
Aberdeen laboratories. 
 
3.11 Treatment failure 
3.11.1 Tube well water  
Although the median arsenic water exposure level was higher in patients with treatment 
failure (Fig 3.14, panel A), this difference was not statistically significant (Mann 
Whitney U p = 0.42).  
Only one covariate had a weak association with treatment failure (p<0.2) in the 
bivariate analysis: previous SSG treatment in the family (p=0.11)(Table 3.7). This 
variable was not retained in the final multivariate model for lack of significance. 
Although the association between treatment duration and outcome was statistically 
Figure 3.15  Dot plots of urinary arsenic exposure and SSG treatment outcome 
Panels A and B show the log of the urinary arsenic level plotted against SSG 
treatment outcome: Urine biological samples (Panel A, MWU p=0.81), urine with 
imputed values (Panel B, MWU p = 0.80). MWU= Mann Whitney U. 
Table 3.8 Multivariate logistic regression analysis using urinary arsenic data 
 
Urine biological samples  
n=65 
Urine with imputed values 
n=110 
Variable OR (95% C.I.) p value OR (95% C.I.) p value 
Urine arsenic level 
> 40 µg/L 2.06 (0.57-7.47) 0.269 1.29 (0.53-3.19) 0.575 
Possible confounding 
factors     
Age (years) 
    0-5 Ref. cat 
 
Ref. cat 
 6-15 9.57 (1.36-67.2) 0.023 1.17 (0.34-4.10) 0.798 
> 15 6.95 (1.03-46.9) 0.047 0.86 (0.25-2.94) 0.808 
Sex  
Female vs male 0.62 (0.20-1.96) 0.419 0.8 (0.36-1.81) 0.595 
Location  
Outside of or within  
Mahudin Nagar town 0.97 (0.23-4.14) 0.964 1.32 (0.49-3.57) 0.582 
OR = Odds Ratio, CI = Confidence Interval. Ref. cat = Reference category 
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significant (p=0.01) this variable was not included in the final model as in the majority 
of cases the treatment duration is dependent on the outcome. The final logistic 
regression model only included the forced variables age, sex and location and shows a 
trend: patients with high mean local arsenic level have a higher risk of treatment failure 
(OR=1.78) than patients using wells with arsenic concentration <10 µg L-1, however 
this association is not statistically significant (95% CI: 0.7 – 4.6, p=0.23).   
3.11.2 Urine samples 
The median urine arsenic exposure values were similar in patients who failed and had a 
successful treatment with SSG (Figure 3.15, A and B). The covariate of previous SSG 
treatment in the family with a weak association with treatment failure (p=0.103) was 
initially included in a multivariate model.  The final logistic regression model only 
included the forced variables age, sex and location. When analysing the biological 
samples only a trend was observed: patients with elevated urinary arsenic have a higher 
risk of treatment failure (OR 2.06) than those with an arsenic level within the normal 
range, however this association is not statistically significant (95% CI: 0.57-7.47, 
p=0.269). When using the data set that includes imputed values, the risk of treatment 
failure with elevated urinary arsenic was markedly attenuated (OR 1.29) and the 
association became less significant (95% CI: 0.53-3.19, p=0.575) (Table 3.8). 
In the multivariate analysis using biological samples only, being of an older age carried 
a significant risk when adjusted for urine arsenic exposure level, location and sex.  This 
risk disappears when the imputed data is also used in the analysis: all the patients who 
were not available for biological sample collection due to relocation were older than 5 
years old at their time of treatment and 66.7% of this group had a successful 1st 
treatment with SSG (compared with a 43.6% success rate in the full cohort). 
Figure 3.16 Kaplan Meier curves for all-cause and VL mortality 
Panels A and B are survival curves comparing arsenic exposed (dotted line, => 10 µg 
L-1 As) and non-arsenic exposed (solid line, <10 µg L-1 As) patients in the outcomes 
of all-cause mortality (log rank p=0.004) and VL mortality (log rank p = 0.044). 
Table 3.9 Multivariate Cox regression analysis of effect elevated arsenic water levels 
(>= 10 µg L-1) on risk of the outcomes of all-cause and VL related mortality in a 
cohort of SSG treated patients  
Variable All-cause mortality VL mortality 
HR (95% CI) p value HR (95% CI) p value 
Effect of arsenic exposure*     
- during first 3 months from 
onset of VL symptoms 0.90 (0.19- 4.37) 0.896 0.92 (0.19 - 4.53) 0.921 
- after 3 months from onset of 
VL symptoms 8.56 (2.52-29.1) 0.001 9.27 (1.75-49.0) 0.009 
Possible Confounding 
Factors     
Age 
  0-5 
  5-15 
  >15 
 Ref. cat.  
0.14 (0.04-0.47) 
0.19 (0.06-0.56) 
0.001 
0.003 
Ref. cat. 
0.11 (0.03-0.45) 
0.17 ( 0.05-0.56) 
  
0.002 
0.003 
Sex – female vs male 1.4 (0.53-3.67) 0.498 1.22 (0.41-3.61) 0.725 
Location –outside of or 
within Mahudin Nagar town 1.04 (0.33-3.25) 0.951 1.30 (0.40-4.28) 0.662 
HR = Hazard Ratio, CI = Confidence Interval. Ref. cat = Reference category 
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3.12 Mortality 
As shown in the dot plots (Fig 3.14, panels B and C) the median arsenic concentrations 
in water are significantly higher in the patients who died (group “all-cause mortality” ( p 
= 0.005) and those who died due to VL (group “VL mortality” p = 0.048) compared to 
the patients that were still alive at the time of the field visits.  
The KM curves (Fig 3.16, panels A and B) confirmed increased mortality in 
subjects exposed to elevated arsenic water levels (p=0.004 and p=0.044 for “all-cause” 
and “VL mortality” respectively). Age was the only covariate to show a significant 
association with mortality and thus the final models only included the forced variables 
of age, sex and location. The multivariate Cox regression model showed that arsenic 
levels ≥ 10 µg L-1 increased significantly the risk of all-cause (HR 3.27; 95% CI: 1.4- 
8.1) and VL related (HR 2.65; 95% CI: 0.96 – 7.65) mortalities. However, the effect of 
arsenic exposure on all-cause mortality was found to vary with time. On the KM plots, 
the two survival lines representing arsenic exposed and non-exposed populations 
separate at 3 months where the effect of arsenic exposure becomes apparent. This was 
confirmed by a modified Cox regression model which allowed the effect of arsenic 
exposure to vary over time. No increased risk of mortality was detected with arsenic 
exposure during the first 3 months after start of VL symptoms. However, after 3 
months, the effect of arsenic exposure significantly increased the risk of all-cause 
mortality (HR 8.56; 95% CI: 2.5 – 29.1) and of VL related mortality (HR 9.27; 95% CI: 
1.8 – 49.0)(Table 3.9).  Characteristics of the individuals who died from VL are 
summarised in Table 3.10. 
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Chapter 4 - 
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4.1 Introduction 
The development of drug resistance in pathogens is a dreaded complication in any 
infectious disease.  This is particularly true in diseases without an established vaccine.  
Antibiotic resistance is a topical issue in the UK currently with David Cameron warning 
that “medicine could soon be cast back into the dark ages” if infections that were 
previously treatable become incurable due to multi-resistant pathogens17.  In response 
the UK government has recently established a working committee to try and reduce 
antibiotic resistance, develop new antibiotics and reduce un-necessary antibiotic use. 
This current situation in the UK has parallels with the situation in Bihar in the 
mid-1990s when antimonial treatment failure rates for visceral leishmaniasis fell to 
around 50 % and resistance in the Leishmania parasite was demonstrated.  The progress 
in developing effective pentavalent antimonial compounds made by Bramachari and 
Leonard Goodwin (Section 1.2.2) had been undone and new drugs were urgently 
needed to treat an otherwise fatal disease. Some of the measures currently outlined for 
the UK came to pass in India with the development of amphotericin B, miltefosine and 
paromomycin as alternative treatments (Section 1.1.7) and the improvement in 
diagnostics, and thus reduction of misprescribing, with the advent of the rK39 rapid 
antigen test (Chappuis et al., 2006)(Section 1.1.6). Why antimonial resistance had 
developed so rapidly in India when antimonial compounds remained remarkably 
effective in the treatment of VL in Africa and South America was not fully addressed. 
Current theories include the unrestricted use in India through private prescriptions and 
over the counter procurement. 
                                                          
17 http://www.bbc.co.uk/news/health-28098838 
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The development of multi-resistant pathogens in the UK is being blamed on 
overprescribing, the unregulated use of antibiotics in countries such as China and India 
(Van Boeckel et al., 2014) and the heavy use of antibiotics in livestock (Alcorn, 2012). 
In the study of resistant micro-organisms a clear picture emerges – the more antibiotic 
use, the more resistance (Albrich et al., 2004; Malhotra-Kumar et al., 2007). With less 
antibiotic use, resistance decreases (Monnet, 2000). However with antimonial resistance 
in Leishmania, not least as it is not part of natural carriage in humans, the situation is 
more complicated.  There are differing reservoirs between countries, some with 
antimonial exposure, e.g. treatment of dogs in Spain and South America.  There are 
differing levels of unregulated treatment access between affected countries – a vial of 
antimony can be bought with a bull in Sudan (personal communication Margriet Den 
Boer) – making useful epidemiological data collection difficult.  In the Indian 
subcontinent, although antimonial use has decreased since it was no longer 
recommended for routine use, both high levels of treatment failure and resistance 
remain. Other factors must be in play which may be related to host susceptibility, the 
parasite itself or the environment – for example exposure to arsenic, the topic of this 
thesis. 
It is important to look into the ecosystem of an organism to establish the reasons 
for resistance development (Ait-Oudhia et al., 2011). In looking further than human 
antibiotic use, one hypothesis being investigated is how the livestock industry’s 
antibiotic practices, particularly the use of growth promoting antibiotics in animal feed, 
are leading to human drug resistant pathogens.  It has been difficult to strongly establish 
the links, as there are many aspects to the food chain. However, in 2012 whole genome 
analysis has demonstrated that the CC398 life stock associated MRSA was originally 
MSSA in humans and acquired methicillin and tetracycline resistance from antibiotics 
in animal feed after it was introduced to livestock from humans (Price et al., 2012). 
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Although this is just one strain of one bacteria it demonstrates the potential of the sub-
therapeutic use of antibiotics in animals can lead to drug resistant pathogens in humans 
and the importance of looking at the whole picture.  
This work looks at the ecosystem of Leishmania in the Indian subcontinent and 
has aimed to look at the study of Leishmania resistance and Leishmania resistance 
selection at different levels. It asks whether sub-therapeutic exposure of Leishmania to 
arsenic within the exposed population could have contributed to the development of 
antimonial resistant parasites and the high rates of treatment failure observed. The key 
findings are summarised below: 
• The method of resistance selection has an effect on speed of resistance 
development and resistance phenotypes of Leishmania life cycle.  This has 
important implications for laboratory study of resistance. 
• Cross resistance between the metalloids arsenic and antimony can be selected 
for in axenic amastigotes, but this resistance is accompanied by phenotypic 
changes that diminish the value of the generated resistant line for mechanistic 
studies. 
• Resistance that was selected for, in vitro or in vivo, intra-macrophage in the 
amastigote form, leads to amastigote stage-specific resistance which may be 
related to antimony reductase and is not solely thiol dependent. 
• Oral arsenic exposure of mice at environmentally relevant levels can induce 
cross resistance to antimony that is relevant in vivo and in vitro. 
• A strong association between arsenic exposure and antimonial treatment failure 
was not detected in a field setting. 
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• There was an unexpectedly high mortality rate in the cohort of SSG treated 
patients and a secondary analysis of mortality showed that arsenic exposure 
strongly increased the risk of both all-cause mortality and VL mortality. 
• Arsenic exposure strongly increases the risk of death from VL particularly if 
there is a delay to treatment. 
4.2 Selection of antimonial resistance  
Antimonial resistance has been selected for at three levels in this work, in axenic 
amastigotes, in intra-macrophage amastigotes and an in vivo model. Each method has 
revealed interesting findings relating to the study of antimonial resistance. 
4.2.1 Antimonial resistance selection in axenic amastigotes 
Axenic amastigotes were developed as a tool to study the amastigote form without the 
complication of the macrophage. As previously described by Ouellette it is possible to 
generate axenic amastigotes cross resistant to antimony and arsenic through progressive 
exposure to increasing concentrations of trivalent antimony (Brochu et al., 2003; El 
Fadili et al., 2009; El Fadili et al., 2005).  However, in the current study, we found that 
maintaining the Leishmania parasite in axenic form for prolonged duration led to an 
unstable phenotype, with promastigote features despite growing in amastigote culture 
conditions. The tolerance developed to the metalloids at high concentrations was not 
maintained through the cloning process for the lines exposed to Sb species and the 
arsenic resistant line required prolonged passage at high arsenic concentrations for the 
metalloid resistance to be retained. Of note Ouellette’s group did not clone their Sb 
resistant generated parasites. Additionally no documentation is made of the phenotypic 
appearance or the duration of exposure prior to removal of the drug for 20 passages to 
create partial revertants. In my work prolonged exposed of > 150 days was required for 
selection of stable resistance. 
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Although extensively studied in L.tarentolae promastigotes, arsenic has not 
previously been used to select for resistance in axenic amastigotes. In my study, it 
would have been useful to compare the arsenic and antimonial - selected resistant lines 
to identify any key mechanistic differences to help to answer the question of how 
antimony resistance had become so prevalent in Bihar. Unfortunately, the phenotypic 
changes, the low baseline susceptibility to antimony naturally present in the clone 
LdSu3 and the decreased virulence of LdBob prevented in vivo work with these strains 
and significantly devalued the use of axenic amastigotes for any kind of comparative 
work.  Additionally it would have been ideal to be expose multiple lines of the same 
original clone to the different metalloids to allow for more robust comparison of any 
mechanistic changes identified. Dramatic differences in resistance mechanisms can be 
found in strains from clones selected using the same resistance method (Lin et al., 
2008). 
The development of axenic amastigotes as a biological tool was initially 
heralded with great excitement within the parasitological world as it would facilitate 
study of amastigote function (Debrabant et al., 2004), resistance development (El Fadili 
et al., 2009; El Fadili et al., 2005; Goyard et al., 2003)  and had potential use for drug 
screening programmes (Callahan et al., 1997). Axenic lines were found to be able to 
infect animals and have many similarities to intracellular amastigotes including acid 
phosphatase production and the presence of the A2 marker (Debrabant et al., 2004).  
However more recent work has identified significant differences between axenic and 
intracellular amastigotes including changes in the key enzyme tryparedoxin peroxidase 
and in enzymes involved in protein and amino acid metabolism (Pescher et al., 2011).  
Keith Gull’s group performed RNA sequencing on L.mexicana and found that while 
1665 annotated genes were differentially expressed between promastigotes and 
amastigotes, axenic amastigotes appeared to be an intermediate phenotype with 143 
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genes differentially expressed between intracellular amastigotes and axenic amastigotes 
and 576 between axenic amastigotes and promastigotes18. Another RNA study 
comparing axenic amastigotes and intracellular amastigotes showed that the groups only 
shared 12% of differentially upregulated genes (Rochette et al., 2009).  A protein screen 
comparing antimonial sensitive and resistant axenic amastigotes should be interpreted in 
light of the recent findings with axenic amastigotes (El Fadili et al., 2009; Pescher et al., 
2011; Rochette et al., 2009)2. Additionally drug screening programmes have found a 
high false positive hit rate with axenic screening assays versus intracellular assays (De 
Rycker et al., 2013).   
An interesting question relating to the axenic amastigote model is -what is the 
relevance of the late log axenic amastigotes in a culture flask when the natural 
environment of an amastigote is resident in a macrophage?  The differences in 
sensitivity to arsenic between mid-log and stationary phase amastigotes observed is 
likely related to depletion of nutrients. Do amastigotes reach this point within 
macrophages in the body and is this the trigger for amastigotes to escape and infect new 
macrophages?  It is not known whether this disruption occurs prior to a ‘stationary 
phase’ within the macrophage being reached. Macrophages within tissue have the 
ability to live for many months (Gonzalez-Mejia and Doseff, 2009)  – so it is possible 
that a saturation point of amastigotes within a macrophage could be reached.  This may 
have implications on the sensitivity to arsenic or antimony in a patient with very heavily 
parasitized organs. 
The use of any laboratory derived strain is a compromise. Laboratory strains 
lose their in vivo virulence with as little as 20 passages (Ali et al., 2013). This work has 
                                                          
18 Eva Gluenz, Michael Fiebig, Steve Kelly and Keith Gull.  
Insights into the missing biology of Leishmania Mexicana from RNA sequencing.  
Abstract A101. British Society of Parasitology 52nd Annual Spring Meeting. April 2014 
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demonstrated that even the correct laboratory handling of LdBob significantly changed 
its sensitivity to SbV in the amastigote form. Although the use of laboratory strains is 
helpful as they can be well characterised and their handling history is known, 
confirmation of any findings within clinical isolates is imperative.   
4.2.2 Selecting for resistance in macrophage through SbV exposure 
To evaluate resistance selection in the intracellular amastigote rather than the axenic 
amastigote an intracellular macrophage method was used (Hendrickx et al., 2012).  This 
approach generated 10-fold resistance rapidly in LV9 amastigotes with only 3 passages 
of 5 day exposures to SbV. The resulting drug-exposed parasites displayed an 
amastigote stage-specific resistance to antimony up to levels of 4.1 mM with no 
difference found in promastigote susceptibility to trivalent antimony. 
This stage-specific susceptibility may be related to loss of the activation step of 
SbV to SbIII via one of the putative reductases TDR1 or LmACR2 or an as yet 
unidentified reductase. Further work will include the analysis of the genomic sequence 
of the 6 lines A-F to look for specific differences between the sensitive and resistant 
isolates particularly in reference to antimony reductases. Another possible explanation 
for this stage-specific resistance would be loss of SbV transport into the cell. 
The speed of resistance development in the macrophage was interesting. In total 
15 day of drug exposure is much shorter than the 108 days required using axenic 
amastigotes to induce 10 fold resistance.  It is also half the length of the recommended 
30 day treatment course implying that sub-therapeutic antimony in dose or duration 
could easily lead to resistance.  
This method has previously been used in antimony-resistant clinical isolates to 
select resistance to paromomycin and miltefosine (Hendrickx et al., 2014; Hendrickx et 
al., 2012) but not to induce resistance to antimony. Paromomycin-resistant isolates were 
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developed rapidly in just two 5–day cycles and displayed a similar pattern of amastigote 
stage-specific resistance.  Conversely, miltefosine did not demonstrate a difference in 
intracellular amastigote EC50 but over 7 successive passages backtransformation of 
promastigotes occurred at higher concentrations of miltefosine (Hendrickx et al., 2014). 
These backtransformed promastigotes however did not display resistance to miltefosine 
in an axenic EC50 assay. These findings highlight the importance of the method of 
resistance selection and that both phenotypes should be tested in assessing parasite 
susceptibility to a given compound. 
It is important to remember though that the type of macrophage used may have 
an effect on results.  This was evident in the different amastigote infection levels that we 
observed with between peritoneal derived mouse macrophages and THP-1 cells in our 
study. Another group demonstrated up to a 3- fold difference in the EC50 between THP-
1 and peritoneal derived mouse macrophages and when using human peripheral blood 
monocytes a 10 fold decrease in SbV EC50 was observed when compared to peritoneal 
derived mouse macrophages (Seifert et al., 2010). 
4.2.3 Leishmania SbV resistance selected for by environmental arsenic exposure 
The in vivo work in this study demonstrates that it is biochemically and physiologically 
plausible that arsenic exposure in the environment could have contributed to the 
development of antimonial resistance in Leishmania in Bihar (Perry et al., 2013).  
As discussed previously, arsenic has long been known to generate cross resistance to 
antimony although this has not previously been demonstrated in an in vivo model.  The 
speed of resistance development was positively correlated to the level of exposure: at 
the level of hepatic arsenic of 0.4 to 1.5 mg kg-1 seen in the 100 ppm group, the exposed 
parasites had become resistant to 4.1 mM SbV in vitro within 3 months. At the lower 
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exposure level of 10 ppm, which is equivalent to a 60 kg man drinking 3L of 1200 µg L-
1, resistance at this level took up to 5 months to develop.  
This work was performed using the WHO reference strain LV9 originally obtained from 
an Ethiopian patient in 1967.  The line used had been passaged through hamsters since 
2002 and through BALB/c mice for one year before use in the arsenic model. It is 
difficult to say how this handling history has affected our results including the speed at 
which the LV9 parasites gained resistance.  Ideally, it would be interesting to repeat this 
resistance selection using clinical isolates from Bihar to see whether the parasites from 
the area in which arsenic exposure occurs behave in the same way as LV9. 
4.2.3.1 Arsenic exposure in Bihar 
This level is in the upper bracket of arsenic contamination in tube wells detected so far 
in Bihar. Only 2.1% of all the wells tested by SOES19 had levels greater than 500 µg L-
1. There have been 2 main surveys performed in Bihar: UNICEF who surveyed 66,623 
wells, 28.9% were > 10 µg L-1 and 10.8% > 50 µg L-1 (Nickson et al., 2007); and SOES 
who measured 19,961 wells, 32.7% were > 10 µg L-1 and 17.8% > 50 µg L-1. Neither of 
the surveys were exhaustive and there was potential inaccuracies in the UNICEF field 
kits and sampling bias in the SOES study towards villages where patients were 
suspected (Ravenscroft et al., 2009).  However, the geographical bias towards areas 
within 10 km of the Ganges River (Nickson et al., 2007) is the main concern and more 
widespread testing is required.  
4.2.3.2 Arsenic exposure model 
The relevance of this hypothesis to Bihar is defined by how closely our model relates to 
the development of antimonial resistance in the leishmania parasite through arsenic 
exposure in patients. The model of arsenic exposure that we used employed high 
                                                          
19 http://www.soesju.org/arsenic/arsenicContents.htm?f=groundwater_bihar.htm 
109 
 
 
concentrations of arsenic to recreate in weeks hepatic arsenic levels that will have built 
up over years in arsenic exposed populations.  This was confirmed by ICP-MS 
measurements.  There have been criticisms of utilising the Reagan Shaw body surface 
area dose conversion equation (Reagan-Shaw et al., 2008; States et al., 2011)(Section 
2.10) between humans and mice as mice methylate arsenic more efficiently than 
humans (Vahter, 1999).  Additionally, there has been a call to use phenotypic anchors 
such as arsenic levels in body tissues as we have done by matching hepatic arsenic 
levels (States et al., 2011)  
Furthermore, as methylation helps to eliminate arsenic from the body and mice 
are efficient methylators (Vahter, 1999), using the high levels of arsenic in murine 
drinking water may have helped to ensure hepatic levels were reached. Although we did 
not perform arsenic speciation, it has been performed on pregnant C3H mice exposed to 
85 ppm arsenic for 10 d. A hepatic level of total arsenic of 1.6 mg (kg wet weight)-1 was 
obtained, of which 37.6% ± 10.4 was inorganic As, 18.9% ± 2.9 MMA species and 43.6 
± 13.2 % DMA species (Devesa et al., 2006).  
In another study where C3H mice were orally dosed with high doses of 50, 100 
and 150 µg As day-1, 6 days a week for a year, hepatic arsenic levels continued to rise 
(Das et al., 2005). At 10 ppm exposure in drinking water, where our BALB/c mice 
where consuming on average 20 µg day-1, reaching hepatic arsenic levels of 0.12 ± 0.02 
mg (kg wet weight)-1 at 56 d, SbV resistance was selected for following 5 months of 
exposure. Over time it is possible that even at lower levels of exposure this level of 
hepatic arsenic levels would be reached in mice.  Furthermore, the incubation period of 
VL is weeks to months and it is possible that with a longer exposure period resistance 
could be selected for in the leishmania parasite at lower hepatic arsenic levels. 
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It is worth noting that recent work has shown that the gut microbiome affects 
both methylation and thiolation of ingested arsenic (Lu et al., 2014; Rubin SS et al., 
2014) which will in turn affect the concentrations of arsenic in internal organs.  The gut 
microbiome is affected by host genetics (Lu et al., 2014) and diet.  This is another 
important difference between the mouse model and chronic exposure to arsenic in 
humans. 
4.2.3.3 In vivo assessment of arsenic generated antimonial resistance 
The assessment of Leishmania SbV resistance in the in macrophage assay is an 
imperfect tool for predicting clinical failure with antimonial treatment (Rijal et al., 
2007).  One reason for this may be related to the dual action of SbV because, as well as 
the toxic effects of SbIII, SbV itself stimulates the production of reactive oxygen species 
and nitrosative stress in mice via the stimulation of production of IL-12 and IFN-γ 
(Murray et al., 2000).  Importantly, the results of the in vivo treatment with SbV show 
that the resistance developed in the arsenic exposed Leishmania is relevant in the in vivo 
setting of our arsenic exposure model. Additionally it showed that this resistance did not 
affect response to miltefosine treatment which is relevant to the VL elimination 
programme. 
The mice continued to be exposed to arsenic during the antimony treatment.  
The reported effects of arsenic on the human immune system include decreased 
expression of inflammatory genes (Andrew et al., 2008), depressed macrophage 
function and nitric oxide production (Banerjee et al., 2009) and decreased production of 
inflammatory cytokines including IFN-γ (Biswas et al., 2008).  If antimony treatment 
cannot overcome this immunosuppressive state then the immune arm of its function 
would be disabled, which, along with the demonstrated antimonial resistance, could 
have contributed to the treatment failure of antimony in this in vivo model.  
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4.2.3.4 Hepatic concentrations of arsenic and antimony 
An intracellular concentration of hepatic arsenic and antimony was calculated, taking 
the hepatocytes per gram of liver to be 135 x 106 (Sohlenius-Sternbeck, 2006) and the 
volume of a hepatocyte to be 3.4 x 10-9 ml (Alberts et al., 1983). It is not known 
whether hepatocytes and Kupffer cells take up arsenic at the same rate but that has been 
assumed in this calculation. In the mice exposed to arsenic at 10 and 100 ppm the 
concentration of arsenic in hepatocytes is estimated to be 3.5 µM and 11.8 µM, 
respectively and the corresponding antimony concentration 72h post treatment is 
estimated to be 35.8 µM.  The arsenic concentration represents a near steady state 
whereas the antimony concentration at 72 hours post treatment reflects an approximate 
10-fold decrease from 1 hour post treatment, with an initial rapid decline in the first 8 
hours, followed by a slow elimination phase (Berman et al., 1988).  This decrease 
correlates well with an in macrophage EC50 of 316 µM (36.5 µg ml-1) at the point of 
treatment.  
The real question is what is the concentration in the phagolysosome where the 
parasite resides? It is possible that an average concentration over all the cells in the liver 
is an underestimate of the concentrations the parasites experience in the Kupffer cell. 
An ultrastructural study of infected macrophages incubated with sodium stibogluconate 
suggests that SbV concentrates in the phagolysosomes (Abok et al., 1988). This built on 
work showing delivery of antimony into the phagolysosomes by liposomes (Heath et 
al., 1984).  Due to the similarities between arsenic and antimony it is possible that with 
arsenic also accumulates in the secondary lysosomes of the macrophage and thus the 
calculated concentrations are lower than the concentrations the amastigotes were 
exposed to in this in vivo model.  
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There was no difference seen in hepatic antimony levels between non-arsenic 
exposed and arsenic exposed groups implying that the presence of arsenic did not 
interfere with the metabolism of SbV and that altered antimony metabolism was not 
responsible for the decreased efficacy of SbV in the arsenic-exposed groups. This 
observation is confirmed by uptake studies where the presence of AsIII did not interfere 
with the uptake of SbV (Brochu et al., 2003). 
4.2.3.5 Effect of arsenic exposure on parasite growth 
The parasite burden in the 3 groups over the 5 passages shows that in the first passages 
the parasite load in the 10 ppm, but particularly in the 100 ppm group was depressed.  
This may be due to a treatment effect of the arsenic which was overcome as the arsenic-
exposed parasites became resistant. This is a trend and not statistically significant. 
However this trend raises the question of whether the arsenic accumulation, in a heavily 
exposed patient, could be protective against clinical infection with a sensitive strain of 
Leishmania.   
In the 10 ppm the parasite load at the 5th passage has risen to greater levels than the 
control group, although, again, this is not statistically significant.  This rise could be 
interpreted in two ways: first, that the resistant parasites are fitter and stronger as 
previously demonstrated by Jean Claude Dujardin’s group (Vanaerschot et al., 2011) or 
secondly that the dampening effect of arsenic on the immune system (Dangleben et al., 
2013) led to an increased in vivo parasite burden now the parasites were not 
experiencing a treatment effect. 
4.2.3.6 Analysis of in vivo generated resistance 
When tested for their susceptibility to the trivalent metalloids SbIII and AsIII, it was 
surprising that promastigotes derived from the arsenic exposed groups of mice (10 ppm 
and 100 ppm) remained as susceptible as the baseline group (0 ppm).  It must be taken 
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into account that the promastigotes tested were passaged through non-exposed mice for 
a total of 8 months, due to issues finding the right conditions for promastigote 
differentiation, prior to susceptibility testing.  Therefore these parasites may be partial 
revertants. 
However, when the promastigotes were used to infect macrophages, the 
amastigote forms of the exposed groups, 10 and 100 ppm, remained resistant to up to 
4.1 mM SbV.  This stage-specific resistance, together with the similarity in thiol levels 
between all 3 groups (Table 3.5) allows for speculation that the mechanism of 
antimonial resistance generated is either through loss of the ability of SbV to enter the 
parasite or through loss of the activation step of SbV to SbIII within the leishmania 
parasite.  
Although the exposure of the mice was to trivalent arsenic, this species is 
rapidly metabolised in the liver to MMAV which is reduced to MMAIII.  In view of the 
sensitivity of the promastigotes to AsIII we hypothesised that the loss of a pentavalent 
reductase may be responsible for the resistance of the 10 and 100 ppm arsenic exposed 
parasites and went on to determine the susceptibility of the 0, 10 and 100 ppm parasite 
groups to MMAV. The 10 and 100 ppm intracellular amastigotes were insensitive to 
MMAV at levels up to 1.5 mM compared to the 0 ppm group which had an EC50 of 0.38 
mM implying that the enzyme required to activate MMAV to the more toxic MMAIII 
was absent or reduced in the arsenic exposed groups. Interestingly, wild type LV9 
promastigotes, which have an EC50 for AsV of 0.05 mM and are thought to express 
TDR1 at significantly lower levels than amastigotes (Denton et al., 2004), were 
refractory to MMAV at concentrations up to 15.4 mM. It is worth noting though that the 
TriTrypDB database20 shows that RNA levels are in fact1.4 fold down-regulated in 
amastigotes versus promastigotes. However this data is less robust as it is well 
                                                          
20 http://www.tritrypdb.org/tritrypdb/ 
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established that the levels of RNA are not necessarily a reflection of the levels of 
protein in Leishmania (Rosenzweig et al., 2008).  
The putative Leishmania antimony reductase TDR1 has a reported specific 
activity for MMAV of 18.6 ± 6.9 µM min-1 (mg of protein)-1 (Denton et al., 2004) which 
is in fact greater than its activity for sodium stibogluconate of 6.3 ± 2.4 µM min-1 (mg 
of protein)-1.  The enzyme is similar to glutathione-S transferase omega which is the 
enzyme thought to be responsible for MMAV reduction in humans (Xu et al., 2009).  
Unfortunately the antibody against TDR1 used to try to detect a difference in TDR1 
levels between our arsenic exposed and non-exposed groups did not detect the presence 
of TDR1 in any group. This may be because the original experiment performed to 
identify the presence of TDR1 in amastigotes performed by (Denton et al., 2004) used a 
thiol-enriched lysate.  The cell numbers that were available to us from our in vivo 
passage were not large enough to perform the Western Blot using a thiol-enriched 
lysate. Further work will include generating our own anti-TDR1 antibody.  It is not 
known whether the other putative reductase LmACR2 can reduce MMAV.  
One important question is why was no resistance built up to the trivalent 
metalloids in promastigotes if the proportion of MMA species (18.9%) previously 
detected in the livers of mice exposed to 85 ppm, with 37.6% inorganic As (iAs) 
(Devesa et al., 2006), is similar to the proportions found in the macrophage/amastigote? 
One answer may be that resistance to the trivalent metalloids was present, but was 
subsequently lost in the long cycles without drug exposure.  Another answer may be 
that the iAs measured is protein bound and not pharmacologically active. 
It is not known whether Leishmania have the capacity to methylate arsenic. A 
BLAST search21 (performed by Alan Fairlamb), for an equivalent enzyme to the 
AS3MT in humans (Section 1.3.2) (Hu and Colman, 1995) detected a number of methyl 
                                                          
21 http://blast.ncbi.nlm.nih.gov/Blast.cgi 
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transferases, including a number of hypothetical proteins with low identity (<21%) and 
low E values (<2e-24). Only one protein had an e-value <e-15, the generally accepted cut-
off for significance. This was 3 –dimethyl ubiquinone 9 3-methyltransferase, putative 
(CoQ3) involved in the biosynthesis of obiquinine.  A reciprocal Blast search against 
the human genome identified CoQ3 as the top hit. If the leishmania parasite can 
methylate arsenic it is likely to be with a different enzyme to AS3MT. 
 In the mammalian cell MMAIII forms an adduct with 2 glutathione molecules 
and can be transported by effluxed via MRP1 in a similar detoxification mechanism as 
SbIII with trypanothione in Leishmania (Carew et al., 2011). Antimony itself is known 
to be methylated to a lesser extent than arsenic and although antimony methylated 
species have been found in the environment (Filella et al., 2002) methylation is not 
thought to be part of the detoxification in humans (Gebel, 1997). 
The transporter for pentavalent antimony to enter the amastigote is unknown. It 
is established to be a different uptake transporter to AsIII which is an aquaglyceroporin. 
The metabolite MMAV is likely to be able to diffuse into the cell and may also be able 
to enter the phosphate transporters used by AsV.  Although SbV can form a similar 
molecule to phosphate in aqueous solution and therefore could also enter by the 
phosphate transporters, loss or the reduction of the phosphate transporter is unlikely to 
be a resistance mechanism due to the essentiality of phosphate for the cell. 
4.2.3.7 Stability of resistant strains 
The stability of resistance is important to this hypothesis as stability allows for spread of 
resistant parasites to areas where there is no arsenic contamination. There are areas of 
Bihar, for example Muzaffarpur, where no significant arsenic contamination has been 
detected (although extensive testing has not yet been performed) and high levels of 
antimonial resistance are reported (Sundar et al., 2000). 
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The stability of the 10 and 100 ppm amastigote resistance to SbV over 8 months 
passage in vivo with no arsenic exposure, and 3 months grown as promastigotes in vitro 
implies that the resistance mechanisms acquired are likely to have occurred on a genetic 
rather than an epigenetic level.  Mutations occur frequently and as the lines 0, 10 and 
100 ppm were not generated in triplicate, sequencing would not be able to correctly 
identify relevant single nucleotide polymorphisms. 
This stability and an increased fitness has been demonstrated in clinical isolates  
with resistant clinical isolates generating a higher in vivo parasite burden, a higher 
proportion of metacyclic promastigotes in stationary phase and more efficient infection 
of macrophages (although this advantage was lost by 96 h post infection) (Vanaerschot 
et al., 2010)(Vanaerschot et al., 2011). This fitness work has only been performed 
handling promastigotes in vitro and needs to be confirmed using sand fly colonies. In 
my study, an increased parasite burden was potentially visible in the 10 and 100 ppm 
parasites at the end of the fifth passage as discussed above (Section 4.2.3.4). We did not 
see any difference in infection levels between the three groups 0, 10 and 100 ppm but 
our slides were only read at 72 h so any difference may not be visible by this time point. 
Amastigotes harvested from BALB/c mice were in general less efficient at 
entering the macrophage and required a different medium of supplemented RPMI rather 
than Grace’s medium to differentiate as compared to ex vivo amastigotes from the 
Syrian hamster.  This implies that although BALB/c mice do function as an animal 
reservoir for Leishmania donovani the harvested parasites have undergone changes 
within the BALB/c mice and appear less fit than those passaged through the hamster. 
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4.3 Pharmacokinetics of antimony related to resistance 
The proposed pharmacokinetics of antimony proffer some interesting questions 
in relation to antimonial resistance. Following injection, SbV follows a 2 compartment 
model with a rapid elimination phase of half-life 2 h and a slow terminal elimination 
phase with a half-life of 76 h (Chulay et al., 1988). A recent study where rhesus 
monkeys received a 21 day course of meglumine antimonite showed a significant 
accumulation over the treatment course of antimony in the liver, spleen and bone 
marrow. Speciation of plasma showed it was the SbIII that was being excreted in the 
longer terminal elimination phase, indicated that the conversion of SbV to SbIII occurs in 
the peripheral organs (Friedrich et al., 2012). 
The ability of organs to convert SbV to SbIII, as suggested in this study (Friedrich 
et al., 2012), could contradict our argument that SbV is reduced to SbIII within the 
amastigote rather than the macrophage.  However it is possible that the hepatocytes, as 
the major metabolising cells of the body, have more of a facility to reduce pentavalent 
antimony than macrophages. 
This marked accumulation in the liver and spleen that reached similar levels to 
the peak blood levels during treatment of the rhesus monkeys (Friedrich et al., 2012) is 
likely to be protective against the development of resistance as it is heterogeneity of 
drug concentration within a 2 compartment model that facilitates the evolution of drug 
resistance (Kepler and Perelson, 1998). The probable importance of the accumulation in 
liver, spleen and bone marrow does indicate, as concluded in 4.2.2, that shorter 
prescribed or unfinished courses would be very risky for the development of resistance. 
The results are interesting if one applies the theory behind the “sanctuary” 2- 
compartment model (Kepler and Perelson, 1998) to the results obtained from the 
BALB/c arsenic exposure model used in this work.  Without the large peak of an 
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applied dose of drug, the constant ingestion of low level arsenic in drinking water 
creates a heterogeneity between blood and plasma levels and the organs of liver and 
spleen, creating an ideal environment for resistance to develop in a step-wise fashion. 
4.4 The clinical relevance of stage-specific resistance 
In both in vitro and in vivo methods of inducing antimonial resistance used in this work 
a stage specific resistance was obtained in the resulting parasite where the promastigote 
form remained sensitive to trivalent metalloids. 
Stage-specific resistance to antimony has been observed in clinical isolates from both 
VL and CL patients and attempts have been made to correlate this with clinical outcome 
in 3 studies. Observations that patients can have a successful outcome with antimony 
treatment but their clinical isolates are resistant to SbV in macrophage assays have led to 
a questioning of the validity of the macrophage assay as a drug susceptibility screen. 
Clinical isolates of L.donovani, L.guyanensis and L.braziliensis were tested for their 
susceptibility to both SbV and SbIII and assessed for resistance using an activity index in 
relation to a sensitive reference strain.  Out of 16 isolates, the two isolates that were 
resistant to both SbV and SbIII (R/R) had a clinical outcome of treatment failure whereas 
the patients from which 4 isolates that were resistant to SbV but sensitive to SbIII (R/S) 
experienced definitive cure (da Luz et al., 2009).  In another study in Peru on CL, out of 
10 isolates with SbV resistance and SbIII sensitivity (R/S) 7 patients were cured and 3 
experienced treatment failure. No statistical correlation between SbIII and clinical 
outcome could be drawn (Yardley et al., 2006). Rijal in Nepal found that out of 11 
isolates from VL patients with paired SbV and SbIII data, stage-specific resistance was 
present but there was no statistical correlation with clinical outcome on this small 
sample size (Rijal et al., 2007).  To further explore the hypothesis that SbV resistance 
with SbIII sensitivity could be an intermediary phase of resistance further studies on 
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larger numbers of clinical isolates are required together with mechanistic studies as the 
above studies do not provide any concrete evidence (Maes et al., 2013). However 
gathering paired data on sensitivity to SbV and SbIII is now recommended. 
In the context of the above stage-specific resistance hypothesis it would be 
interesting to extend the exposure of the SbV exposed lines A-C to determine whether 
promastigotes would eventually develop resistance to SbIII.  If the resistance mechanism 
in lines A-C is the loss of the activation of SbV to SbIII then, if SbV reduction occurs 
solely in the amastigote, the parasite would not be required to develop SbIII resistance 
mechanisms.  However if SbV reduction also occurs in the macrophage then resistance 
to SbIII could develop.   
Why patients with sole SbV resistance in macrophage (R/S) are able to 
experience clinical cure may be related to the action of SbV on the arm of SbV that 
stimulates the immune system.  If the mechanism of R/S resistance is loss of the 
activation step to SbIII- could it be that R/S patients fail if they have a suppressed 
immune system whereas with a fairly intact immune system, i.e. not too far into their 
VL disease and with no co-morbidities, the immunostimulatory effect of SbV is enough 
to kill the parasite without the toxic effect of SbIII. It would make sense drawing from 
the studies of trivalent metalloid generated resistance that R/R resistant parasites are 
more likely to have built up the resistance mechanisms and changes in the thiol system 
of the amastigote that would protect against an activated immune system than R/S 
parasites. 
4.4 Antimonial resistance mechanisms, arsenic and clinical isolates 
The antimonial resistance mechanisms depicted in Figure 1.12 have all been 
demonstrated in Leishmania parasites selected for resistance to AsIII: downregulation of 
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AQP1 (Lin et al., 2008), upregulation of MRPA (Dey et al., 1996), upregulation of 
tryparedoxin peroxidase (Lin et al., 2005) and the enzymes of trypanothione 
biosynthesis, ODC (Haimeur et al., 1999) and γ-GCS (Grondin et al., 1997) with the 
resulting elevation in intracellular thiols (Mukhopadhyay et al., 1996). Subsequently, 
these same mechanisms have been established in Leishmania selected for resistance to 
SbIII (Al Olayan et al., 2002; Brotherton et al., 2013; Haimeur et al., 2000; Wyllie et al., 
2008). This is added evidence of the similarity between arsenic and antimony as, from 
published work, there is no particular resistance mechanism that is unique to one or 
other metalloid. It is unfortunate that the selection of resistance in axenic amastigotes 
performed in this work did not provide samples of a quality that would allow a direct 
comparison to be made between resistance mechanisms to be made. 
In the attempt to ask the question of whether arsenic exposure has helped to fuel 
antimonial resistance in the Indian Subcontinent we run into the same difficulty.  What 
is interesting though is that the resistance patterns demonstrated in clinical isolates from 
this region are heterogenous and although all of the above resistance mechanisms have 
been demonstrated there is not one marker that is present in all isolates (Mandal et al., 
2007; Mandal et al., 2010; Mukherjee et al., 2007; Rai et al., 2013b; Wyllie et al., 
2010).  One important caveat is the heterogeneity of macrophage models used to assess 
resistance, so one isolate could be classified as sensitive in one laboratory and as 
resistant in another. Assay standardisation may be a solution to this problem (Maes et 
al., 2013) including the use of an activity index based on reference strains in all clinical 
isolate susceptibility testing (Yardley et al., 2006). 
It is worth discussing the relevance of the trivalent uptake transporter AQP1 in 
antimonial resistance if, as hypothesised in Section 1.2.4.1 and Section 4.2.3.5, the 
reduction of SbV takes place in the leishmania parasite.  Once MRPA has effluxed the 
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reduced SbIII thiol conjugate from the parasite into the phagolysosome dissociation 
could occur in the acidic oxidising conditions. This could results in the release of SbIII 
to become available to be pumped into the parasite again via AQP1. Hence the detection 
of its downregulation in some antimonial resistant clinical isolates. 
One would hypothesise that once a drug-resistant strain emerged through 
mutation it would spread clonally through anthropogenic transmission. However the 
range of resistance mechanisms identified in clinical isolates contradicts this.  A 
genotyping study of Nepalese isolates confirmed polyclonal populations of resistant and 
sensitive parasites, demonstrated acquired resistance occurring within a patient and 
hypothesised a pleiotropic method of resistance development (Decuypere et al., 2005). 
This results of this work were confirmed in a latter study that looked at resistant 
parasites at 5 levels: DNA sequence, gene expression, protein expression, thiols and 
stress tests. Two distinct populations were analysed and differences seen between their 
mechanisms was dependent on the population group from which they arose (Decuypere 
et al., 2012).  Interestingly there were parallels from this report and the resistant 
parasites selected for in this thesis in that no significant difference in thiols was noted 
between resistant and sensitive pathogens and stage-specific resistance was detected 
(Section 4.5) 
Downregulation or loss of the putative reductases, TDR1 and LmACR2 has not 
been looked for in clinical isolates to the same extent as the mechanisms mentioned 
above. This is not surprising as almost all of the in vitro data on resistance published 
thus far has been generated using strains selected for resistance by trivalent metalloids.  
There are contradictory results on the possible reductases in clinical isolates from the 
Indian subcontinent with one group looking at Nepalese isolates seeing no change in 
expression of TDR1 or LmACR2 and another looking at isolates from Bihar seeing a 26 
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fold over expression of TDR1 in resistant vs sensitive isolates (Mukhopadhyay et al., 
2011).  If TDR1 is upregulated and it is the main antimonial reductase one would expect 
to see parasites that are hypersensitive to SbV not resistant. These contradictions may be 
due the polyclonal nature of antimonial resistance as described above and it would be 
interesting to know if either groups displayed stage-specific resistance. An absence of 
change in TDR1 regulation in Brazilian isolates between patients who succeeded or 
failed with antimonial treatment has also been observed (Torres et al., 2010). There may 
be other antimonial reductases not yet identified. 
Thus, there are many ways in the Indian Subcontinent that antimonial resistance 
could be selected for: through sub therapeutic exposure to arsenic in exposed patients: 
through inadequate dose of antimonials; through pentavalent antimonial preparations 
contaminated with trivalent forms (although this should be improved since the IDA 
regulations (Section 1.2.2)); through inadequate length of regime; and through 
incomplete cure and selection for resistance in an optimally dosed patient of resistance 
within the patient.  These different ways to reach resistance may arise from mutations or 
from a mixed population of parasites within a patient and may select for different 
resistance mechanisms.   
It is possible that in Africa and South America the increase in antimonial dosing 
to 20 mg kg-1 and longer duration courses occurred faster than in India, partially in 
response to reports of resistance from India, as well as a response to local failure rates. 
This would have decreased the risk of selection of resistant parasites. Although there is 
an additional mechanisms for development of resistance in South America in the often 
non curative treatment of dogs with pentavalent antimonials (Gramiccia et al., 1992) 
this has not resulted in high treatment failure rates in humans and antimonials are still 
recommended as treatment in this region (World Health Organization, 2010).  Another 
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potential reason for the difference in resistance rates are developmental differences 
between the species L.donovani and L.infantum but more work is needed to answer this 
hypothesis. 
There has been a consistent observation that antimonial resistant isolates are 
stable and fitter than antimonial sensitive isolates (Vanaerschot et al., 2011; 
Vanaerschot et al., 2010).  The presence of such parasites allows for the spread of 
resistance through the Indian subcontinent even if only some of the above resistance 
scenarios lead to stable fitter parasites. Mathematical models of resistance demonstrate 
that antimonial resistance alone cannot explain the dramatic spread of resistance in 
Bihar.  The picture favours an increased transmissibility fitness rather than disease 
related fitness and the model, taking into account multiple emergences of resistance, 
predicts that antimonial resistant parasites will replace antimonial sensitive parasites 
within 20 to 40 years after the first occurrence of treatment failure (Stauch et al., 2012). 
4.6 Antimonial treatment outcomes in the field 
4.6.1 Antimonial treatment failure 
The primary objective of my field work was to evaluate if arsenic exposure is related to 
treatment failure in SSG treated patients, thus supporting the finding of the in vivo study 
(Section 3.6) that SSG- resistant Leishmania parasites can be selected for by exposure 
to oral arsenic. The results from the field study, although they indicate a trend towards 
increased treatment failure in arsenic exposed patients, have failed to provide robust 
evidence in support of this mechanism. 
A number of reasons may explain why the field results do not support the 
laboratory results.  Firstly, the numbers of patients available were limited as SSG 
treatment for VL is no longer recommended in Bihar and, consequently, the study was 
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underpowered to detect a low level of risk.  Secondly, the in vivo experiments were 
performed in the upper range of arsenic levels found in Bihar. Only 2 patients in our 
study had arsenic levels in their local water supplies in this range and, interestingly, 
they both had a successful treatment with SSG. Thirdly, treatment failure from SSG is 
thought to be multifactorial and not only due to resistant parasites, particularly in that 
there is low correlation between in vitro resistance tests and clinical outcome (Rijal et 
al., 2007). Additionally, extensive work on SSG-resistant parasites has shown that they 
have increased fitness and virulence when compared to SSG-sensitive strains indicating 
that they would thus be preferentially transmitted in the field (Vanaerschot et al., 2011). 
These latter two reasons could mask any existing relationship between arsenic exposure 
and SSG treatment failure in VL.  
The two patients with high arsenic levels but good response to antimonial 
treatment warrant further discussion. One was a ten year old girl who died 2 years 
following treatment from ‘asthma’ which may also have been arsenic associated lung 
disease/bronchiectasis (Section 1.3.6.3).  Liver disease with associated splenomegaly 
has also been described in arsenic exposed persons (Mazumder, 2005)  which could lead 
to a misdiagnosis of kala azar as rK39 can be falsely positive in an endemic population 
– this would explain the ‘success’ of SSG if the fever wasn’t initially caused by 
Leishmania. This patient only had a 24 day delay to treatment and another explanation 
is that, in view of the faster elimination of arsenic in children (Chowdhury et al., 2003), 
this may not have been long enough for the Leishmania parasite to build resistance.  
The other patient was a 37 year old male who died 3 months prior to the study in a road 
traffic accident and was diagnosed with TB subsequent to his VL episode so it is also 
possible here that there was a misdiagnosis. 
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Although multiple studies have been carried out on the mechanisms of 
antimonial resistance in the Leishmania parasite (Croft et al., 2006), only a few 
epidemiological studies have been performed looking at the clinical and demographic 
risk factors associated with SSG treatment failure in the leishmaniases (Llanos-Cuentas 
et al., 2008; Rijal et al., 2010). The most relevant is a prospective study in Nepal on VL 
patients (Rijal et al., 2010) that identified patients living on the border of Bihar as 
having a markedly increased chance of treatment failure. Additionally, fever over 12 
weeks, interruption of treatment and ambulatory treatment were strong risk factors for 
treatment failure. All of the patients in our study received ambulatory treatment, 
treatment interruption was not specifically assessed and no association was found 
between prolonged fever and treatment failure. As arsenic contamination is an issue also 
in Nepal, it would be interesting to assess retrospectively the arsenic exposure in this 
cohort of patients.  
A study in Peru of SSG treatment failure (Llanos-Cuentas et al., 2008) in CL 
identified age and recent relocation into an endemic area as relevant risk factors.  
Leishmania species, number of lesions and lesion diameter are additional risk factors for 
adverse outcome that are specific to CL alone. Arsenic contamination from mining is a 
significant issue in Peru (Reuer et al., 2012) and as arsenic accumulates in the skin as 
well as liver and spleen the hypothesis of arsenic exposure generating resistance is 
relevant to CL as well as VL. Interestingly the area, La Oroya where arsenic 
contamination from mining is an issue appears to be in a similar geographic location to 
a group of antimonial resistant CL isolates tested in 2006 (Yardley et al., 2006). Further 
work is underway in this area of Peru to establish if there is a link between arsenic 
exposure and antimonial treatment failure. 
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A study on rural VL care in Muzaffarpur district, Bihar (Hasker et al., 2010), 
where no significant arsenic contamination has been detected (Perry et al., 2011) but 
SSG resistance is well established (Sundar et al., 2000), had a SSG failure rate of 40% 
compared with 59% in our study.  The difference in failure rates in these similar 
communities, with comparable district level literacy rates of 61.9% and 63.45% 
respectively (Census Organization of India, 2011) may be, among other factors, 
attributable to arsenic exposure and the increased mortality rate. 
4.6.2 Mortality in the antimonial treated cohort 
The main finding in this study, the strong relationship found between arsenic exposure 
and all-cause and VL mortality, agrees with a population-based cohort study performed 
in Bangladesh (Sohel et al., 2009) that demonstrated an increased risk for both all-cause 
mortality and infectious disease deaths with increasing arsenic exposure. The risk of 
death from VL in arsenic-exposed persons in our cohort is predominantly present 
greater than 3 months after the commencement of symptoms. This could be explained 
by 3 disease mechanisms: 1) the longer incubation time in arsenic-exposed tissues 
would allow the parasites to develop arsenic tolerance and thus SSG resistance leading 
to ineffective treatment; 2) patients being infected with SSG-resistant parasites (Sundar, 
2001); and 3) the risk of mortality increases with the progressive dampening effect of 
VL on the immune system (Kaye and Aebischer, 2011) combined with the 
immunotoxicity of arsenic exposure (Dangleben et al., 2013). An alternative 
explanation is with arsenic exposure combined with antimonial treatment increases the 
risk of toxicity from antimonial compounds. The opinion of the experienced VL 
clinician Shyam Sundar is that deaths that occur early in a treatment course are usually 
related to disease and not to antimonial toxicity (personal communication Shyam 
Sundar).  The timing of death from toxicity may be different in arsenic contaminated 
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patients but there is no experimental evidence for this. The characteristics of the 16 
patients who died from VL are shown in Table 3.10 and demonstrate that the deaths 
occurred at varying points in the treatment course and there is no particular difference in 
timing between the exposed and unexposed groups. 
The rural VL study in Muzaffarpur referred to above (Hasker et al., 2010) only 
reported one death (0.7%) of undefined cause in a cohort of 138 (68 of whom were 
treated with SSG) compared with 21 deaths (19%) in our 110 cohort with 16 directly as 
a result of VL (14.5%). This could be explained by a number of factors as well as 
arsenic exposure such as: a different quality of primary health care between districts; a 
more virulent parasite population; or a general lower immune status, for example due to 
malnutrition, in our Samastipur study cohort. However, if the immunotoxicity of arsenic 
and VL combined is responsible for the increased death rate in our study then arsenic 
exposure may increase mortality from VL with treatments other than SSG.  This 
warrants further research. 
Previous studies on mortality in VL have identified the extremes of age, (<5 and 
> 45 years old), long duration of symptoms, co-infections and laboratory abnormalities 
such as severe anaemia and jaundice as risk factors for death (Madalosso et al., 2012; 
Mueller et al., 2009; Sampaio et al., 2010; van den Bogaart et al., 2013). Due to the 
retrospective design of our study, and the rural management of the VL cases, 
information on the above clinical risk factors is mainly not available. Our data does 
agree with age-associated risk at the extremes of age but no increased mortality risk was 
seen with delay to first SSG treatment.   
Could arsenic be silently changing the epidemiology of VL in exposed regions? 
This work shows it may have an effect on mortality. It would require a very large study 
to answer the question of whether arsenic contamination affects the incidence of VL and 
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the proportion of asymptomatic to clinical cases. This would be particularly difficult to 
answer as VL epidemiology is migratory (Malaviya et al., 2011) and the reasons for 
progression to clinical infection are poorly understood (Singh et al., 2014). From an 
immunological perspective cell mediated immunity is thought to be integral to 
developing clinical infection (Bern et al., 2010), a defence which is significantly 
reduced in arsenic-exposed persons (Ahmed et al., 2014).  
4.6.3 Limitations of field work study 
The retrospective design of this study had some limitations in ascertaining VL cases and 
treatments used. There was generally poor documentation of diagnostic methods, 
treatment duration and dosing. No parasitological confirmation was available, however, 
most of the patients were diagnosed with VL by the rK39 rapid diagnostic test which 
shows a good specificity (90.6%) in the context of clinically suspected disease 
(Chappuis et al., 2006). Relying on patient’s and relatives’ responses increased the risk 
of recall bias (Hassan, 2005). Therefore, the definition of treatment failure included the 
requirement for another treatment course which is more concrete that a subjective 
analysis of symptoms. As SSG treatment is prolonged and painful with a dramatic 
economic impact on the patient’s family, the recall bias for treatment may be limited. 
However, it is possible that administered doses were too low, or treatments were given 
with unrecalled interruptions that could have impacted on treatment outcome. 
Unfortunately, there was generally poor documentation of diagnostic methods, 
treatment duration and dosing. 
Finally, VL as a cause of death was confirmed by verbal autopsy only carried 
out by one physician. For this reason VL mortality is always presented with all-cause 
mortality. Verbal autopsy has been criticised as a method of ascertaining cause of death 
(Butler, 2010; Soleman et al., 2006) due to broad generalisation and over-diagnosis of 
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infectious conditions with non-specific symptoms eg. malaria.  However in this setting, 
these issues are less prevalent, as many of our patients were on a register as having VL 
and for all patients we had at least verbal communication that a physician had diagnosed 
VL. 
  A substantial design difficulty in this study is the timing of the assessment of 
arsenic exposure. Forty percent of the patients had their tube well inserted in the years 
following their treatment episode and therefore a proxy of their arsenic exposure had to 
be created from the average of 5 wells surrounding their living area. Additionally, the 
level of arsenic contamination in a tube well water sample can vary according to prior 
usage that day, depth of well and age of well (Erickson and Barnes, 2006; Ravenscroft 
et al., 2009) adding further factors into the difficulty of building up an accurate picture 
of arsenic exposure at a historic time point. Although water arsenic levels were being 
collected on average 5 (± 1.3) years post treatment, it is generally assumed that arsenic 
in tube wells in the Bengal basin is either stable over time (BGS and DPHE, 2011; 
Cheng et al., 2005; Rahman et al., 2007; Sohel et al., 2009) or may rise gradually 
(Erickson and Barnes, 2006; Ravenscroft et al., 2009). 
Measurement of arsenic levels in urine is usually an excellent biomarker of 
arsenic exposure (Concha et al., 2006) and allows for a direct individual assessment 
which includes any exposure from foods and other sources.  However in the context of 
this study it has many disadvantages.  Urine represents arsenic exposure in the 
preceding 24 h (Vahter, 1994) whereas we are interested in representing arsenic 
exposure at the time of the patient’s VL episode up to 6 years prior to the study. This, 
coupled with the need to impute 41% (n=45) of these values to be able to analyse the 
full cohort, due to the unavailability of these VL patients, decreases the value of urine as 
an exposure variable. 
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Additionally there is controversy on how to present urine measurements. The 
ideal way to measure arsenic in urine is through a 24 h collection but this is often 
impractical in field study settings. Some studies use µg g-1 of creatinine to address this, 
however arsenic exposure has been shown to increase creatinine clearance which would 
distort results (Gamble and Liu, 2005). There is no definitive cut off for elevated arsenic 
in urine.  In 2001, D.N.G. Mazumder recommended a level of > 50 µg L-1 urinary 
arsenic (Mazumder, 2001), but this was to diagnose ‘arsenicosis’ and is coupled with 
drinking water at >50 µg L-1.  However, drinking water contaminated with arsenic at 
levels between 10-50 µg L-1 in my study and in the literature is associated with 
pathology (Sohel et al., 2009).  In view of this, a cut off of urinary arsenic levels above 
the normal range of 5- 40 µg l-1 (Mandal and Suzuki, 2002; Ravenscroft et al., 2009) 
was utilized in this study. 
It would have been ideal to perform a prospective study where the parasites’ 
sensitivity to pentavalent antimony in vitro in macrophages was correlated with current 
arsenic exposure and the clinical outcome of SSG treatment.  However, due to the high 
rate of treatment failure with antimony and the recommendation of discontinuation of 
use, this type of prospective study was not possible.  The retrospective nature of the 
study meant that parasite isolates from antimony-treated cases were not available.  The 
presence of SSG-resistant parasites was reported earlier in the Samastipur District 
(Thakur et al., 2004). Determining if antimonial resistant parasites are still circulating in 
the study area today may have helped to interpret the findings of our study, provided 
that stably resistant parasites had not extensively displaced SSG-sensitive isolates due to 
their increased fitness (Vanaerschot et al., 2010).     
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4.6.4 Rural management of VL 
This cohort study was performed in an area where research on VL has not been 
undertaken previously and gives a view of practice in an area without any special 
intervention. It highlights the issue, previously identified in Muzaffarpur (Hasker et al., 
2010), that SSG was still being used in just under a quarter of patients treated between 
2006 and 2010, with no record of its generally poor outcome, despite recommendations 
for its discontinuation since 2005 (Chappuis et al., 2007). In the registers available at 
the PHC there was no indication of any treatment failure or relapse and on interview the 
staff were only aware of one death during the study period. The majority of patients 
(57%) felt the need to change health care provider to obtain an effective treatment. The 
doctors at the PHC knew of the issue of SSG resistance and have been aware of a drive 
to mainly use miltefosine or amphotericin but, worryingly, were unaware of the VL 
elimination programme. They were aware of the issue of arsenic contamination but 
unaware of its wide-ranging health effects.  
Two further issues identified during the field work were firstly that there is a 
substantial delay between the patient initially seeking care with a village health worker 
or unqualified ‘doctor’ and finally receiving treatment. In our study the median delay 
was 30 d. Prompt treatment reduces morbidity and mortality and work is ongoing to 
empower the village health workers to be able to identify kala azar and refer patients 
promptly and appropriately to the right health care facility. 
Secondly, in India is that it is very easy to obtain a private tube well even for those 
below the poverty line and the Public Health and Education department have mainly 
focussed their surveys on governmental wells. Shallower wells are cheaper to obtain but 
unfortunately run a higher risk of arsenic contamination and their insertion is 
undocumented. In India, water supply is a state level responsibility but the provision of 
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clean water is not being matched by an adequate surveillance system. This work shows 
the urgent need for improved record keeping, education and intervention in both VL and 
arsenic contamination within these vulnerable communities (Boelaert et al., 2009; Sohel 
et al., 2009). 
4.7 Arsenic hypothesis and summary 
This study on arsenic, antimony and visceral leishmaniasis has looked in depth at the 
relationship between these 2 metalloids and this potentially fatal parasitic disease 
particularly in relation to the four steps of the hypothesis depicted in Figure 1.22. 
In step 1, humans drink arsenic-contaminated water.  Through our murine 
arsenic exposure model we have demonstrated that, as well as the established 
accumulation in skin, hair, nails and liver, arsenic also is detected at significant levels in 
the other organs related to Leishmania, namely the spleen and the bone marrow.  This 
accumulation is related to dose and duration.  At a cellular level we demonstrated that 
arsenic accumulates in macrophages, the cell in which the leishmania parasite resides. 
We demonstrated in the field in Bihar that arsenic contamination is present in 
areas of VL endemicity.  Twenty four percent of the VL patients in our cohort had a 
mean local arsenic contamination level of greater than the WHO limit of 10 µg L-1 and 
4.5% a level greater than the Indian Bureau of National Standards limit22 of 50 µg L-1.  
However previous arsenic surveys have shown that levels vary considerably between 
regions23. 
It is important to note that humans are exposed to arsenic from many sources 
other than drinking water: food grown in arsenic contaminated soil can accumulate 
arsenic, arsenic in cosmetics can be absorbed through the skin, chicken feed can contain 
                                                          
22 http://bis.org.in/sf/fad/FAD25(2047)C.pdf 
23 http://www.soesju.org/arsenic/arsenicContents.htm?f=groundwater_bihar.htm 
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high levels of organoarsenicals (although this is less relevant in the vegetarian Hindu 
communities of Bihar) (Mukhopadhyay et al., 2002) and arsenic has even been found in 
counterfeit drugs including miltefosine (personal communication Thomas Dorlo). 
In step 2, the leishmania parasite is selected for resistance to arsenic in the 
human body.  
We demonstrated the selection of cross resistance to antimony through exposure 
to arsenic in vitro and in vivo. The in vivo oral exposure led to levels of arsenic in liver, 
spleen and bone marrow that were capable of inducing resistance in the leishmania 
parasite. This in vivo generated resistance was demonstrated using ex vivo amastigotes 
in an in vitro in macrophage assay but was found to be stage-specific as the 
corresponding promastigotes were sensitive to trivalent metalloids. 
It is unlikely that the leishmania parasite would have been exposed to arsenic 
within the sand fly stages of the life cycle. Sand flies eat aphid honey dew as their sugar 
source and the female takes blood meals.  Aphid honey dew is unlikely to contain 
arsenic. If the sand fly is taking blood meals from arsenic exposed patients then there 
will be arsenic in the gut.  In mammals arsenic is rapidly absorbed from the gut and 
should the same apply in sand flies, then exposure of a growing promastigote 
population in the gut would be minimal. A sand fly larva’s main food source is thought 
to be rat faeces (Section 1.1.8.1) and even if rats are drinking arsenic contaminated 
water it would be excreted in the urine and not the faeces. 
In step 3, treatment failure with antimony occurs secondary to selection of 
resistance through exposure to arsenic. This was demonstrated in our in vivo model 
through a minimal suppression of parasite growth (<20%) following a 5 day SbV 
treatment course in the arsenic exposed groups compared with a > 75% suppression in 
the non-exposed group. Hepatic levels of arsenic and antimony measured post treatment 
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indicated that arsenic interfering with the metabolism of antimony was unlikely to have 
contributed to the treatment failure in the in vivo model.  The immunosuppressive effect 
of arsenic however may have decreased the effect of the immunostimulatory effect of 
antimony but we have no experimental data to support this. 
In the field there was a trend of increased risk of treatment failure in arsenic-
exposed patients.  However this trend was not significant. It is not clear whether the 
levels of arsenic exposure in this community were not high enough to induce resistance 
or the shortcomings in study timing and design meant that we were unable to detect a 
link that may be present (Section 4.6.3).   
In step 4, the selected resistant parasite population is propagated through the 
leishmania vulnerable community due to stability of resistance and increased fitness 
over sensitive parasites.  We demonstrated stability of resistance in the amastigotes of 
our arsenic in vivo generated resistant line over >8 months.  Apart from a slightly higher 
parasite load at the end of the 5th passage in the 10 ppm exposed group there was no 
experimental evidence of increased fitness in our parasite lines.  However, this has been 
demonstrated in clinical isolates (Vanaerschot et al., 2011; Vanaerschot et al., 2010). 
4.8 Further work 
The work presented here in this thesis provides many questions for future research: 
Firstly, the presence of a leishmania antimony reductase that is lost in antimonial 
resistant parasites has not yet been established. Using the resistant leishmania parasites 
selected for by the in-macrophage exposure assay and the in vivo arsenic exposure 
model and a combination of genomic sequencing and western blot analysis with newly 
generated antibodies this may be possible.  However even if a reductase was identified 
that was also common to all antimonial resistant clinical isolates it still may not be able 
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to provide a universal test for antimonial treatment failure as resistant parasites can be 
isolated from patients who experience clinical cure. 
Secondly, is there an association with antimonial treatment failure and arsenic in 
cutaneous leishmaniasis patients? Arsenic is known to accumulate to the skin and 
therefore leishmania parasites in CL lesions could be exposed to high levels of arsenic.  
In Peru a prospective study of CL looking at reasons for antimonial treatment failure is 
now gathering information on arsenic exposure of recruited patients. 
Thirdly, does the increased risk of death from VL with arsenic exposure hold for 
patients not treated with antimonials? The increased risk of death from VL in arsenic 
exposed patients may be secondary to arsenic’s immunosuppressive effects. It may 
therefore hold that arsenic exposure increases the risk of death in patients treated with 
any anti-leishmanial agent. 
Fourthly, how does arsenic exposure affect outcome in other infectious diseases? 
The immunosuppressive actions and toxic effect of arsenic on the macrophage may 
mean that exposure has an adverse effect on treatment outcome and mortality for other 
pathogens, particularly those which are obligate intracellular pathogens.  Analysis of 
large scale data sets of mortality from Bangladesh is underway to begin to address this 
question. 
4.9 Conclusions 
Nepal and Bihar are the only places worldwide where arsenic contamination has been 
detected, VL is endemic and there are such high levels of resistance that antimonial 
compounds are no longer recommended for use. This work demonstrates that it is 
biochemically and epidemiologically plausible that treatment failure could be linked to 
arsenic exposure.  However, it also shows that antimonial resistance is easily selected 
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for by SbV in macrophage. The Indian health care system is under-regulated in both the 
public and private sectors and it is likely that the number of sub-therapeutic or 
incomplete courses are higher in this continent than in Africa where the majority of VL 
treatment is administered by aid organisations such as MSF and in Brazil where VL 
care is free and given at hospital level (Alvar et al., 2012).  Additionally the cost of 
treatment in India is the highest per gross national income which is a significant barrier 
to completion of a full treatment course (Thornton et al., 2010).  Thus, in conclusion, 
although there are many routes to antimonial resistance and treatment failure in Bihar, it 
is possible that exposure of the population to arsenic through contamination of the 
groundwater has been contributory. 
A recent global review of the epidemiology of the leishmaniases gave an overall 
case fatality rate for VL of 10 % (Alvar et al., 2012) which is considerably lower than 
the VL mortality rate of 14.5 % in the field work presented here. The field study 
demonstrates that arsenic exposure is strongly associated with VL mortality in this 
antimony treated cohort and may be responsible for the elevated mortality rate. Arsenic 
contamination is a significant issue in Bihar and effort needs to be made to improve 
coordination of the mitigation programmes with a push for the Bureau of Indian 
Standards to bring down its acceptable limit to < 10 µg L-1 in accordance with the WHO 
guidelines. 
This research into antimonial resistance and treatment failure has important 
implications for the leishmaniases worldwide and is a reminder to consider the 
environment in which an organism is propagating when assessing reasons for treatment 
failure and mortality.  
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4.10 Lessons learned 
The work presented in this thesis attempted to answer the question of how 
arsenic may have contributed to the emergence of antimonial treatment failure in Bihar 
using many different methods.  Looking back on 3-4 years of work there will always be 
areas that you wish you could change or plans that would have been different if you had 
been able to make them with the knowledge and experience that you have at the end of 
that time period. 
Presenting this work together highlights the issues of translating between the 
basic science laboratory and the field, particularly those of dose equivalence between 
mice and men.  It would have been more helpful in answering the hypothesis underlying 
this work to have included a lower dose of arsenic exposure in the mouse model that is 
more representative of levels commonly found in Bihar rather than the lowest level of 
murine exposure only being at the very upper range of arsenic levels in the field. 
Additionally, in this in vivo work, selecting for resistance in triplicate at each arsenic 
exposure level would have given us parasite isolates that would be able to sequenced, 
allowing for more detailed analysis for resistance mechanisms. 
The field study performed had many limitations which are addressed at length in 
the discussion and demonstrated the issues of trying to answer a question about an event 
that has happened maybe 20 years ago or more. This type of field study would not be 
able to distinguish between resistance driven by arsenic exposure and resistance by 
antimony therapy but instead aimed to look for whether arsenic exposure and 
antimonial treatment failure were linked.  With the small numbers in the cohort it would 
only have been able to detect a very strong association between arsenic exposure and 
treatment failure with the hypothesis that the presence of arsenic has a high probability 
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to select for mutations that lead to antimonial resistance, as demonstrated in the murine 
model.  
Epidemiological studies generally only show associations and it is a difficult 
task to ever ‘prove’ causality.   As it was, although no significant association between 
arsenic exposure and treatment failure was found, our study detected an unexpectedly 
strong relationship between increased mortality from VL in those exposed to arsenic. A 
more optimum design could have been to have had 2 study sites – one with arsenic 
exposure and the other without and compare treatment failure and mortality.  Additional 
data collected on nutritional status and socioeconomic status of patients would have 
strengthened the analysis of confounding factors. 
As discussed above, I hope that the field study will act as a pilot for further 
investigation into the relationship between arsenic exposure, treatment failure and 
mortality in both VL and other infectious pathogens. 
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